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The ovary, or female gonad, plays a central role in the production of the female gam-
etes, the oocytes, and is the major organ where sex steroid hormones are produced 
in females. In humans, the oocytes are produced from a limiting primordial follicle 
pool, which is established before birth (1). From the primordial follicle pool follicles 
are continuously recruited to develop through primary and secondary stages to be-
come antral follicles. After puberty, when menstrual cycling has commenced, at each 
cycle, follicles will be recruited from this growing follicle pool under the influence of 
Follicle Stimulating Hormone (FSH), and ultimately only one of those follicles will 
reach the preovulatory stage (dominant follicle) (Figure 1). The remaining follicles 
that are not rescued by FSH will become atretic (2).
Under the influence of Gonadotropin Releasing Hormone (GnRH) from the 
hypothalamus, Luteinizing Hormone (LH) and FSH are secreted by the pituitary (3). 
During a menstrual cycle, which has an average length of 28 days, two phases can 
be recognized before and after ovulation: the follicular and the luteal phase (4-5). In 
normal cycling women, FSH levels are highest when the dominant follicle emerges. 
This leads to the production of estrogens by the granulosa cells of the preovulatory 
follicle. After estrogen levels peak, the LH surge occurs and ovulation will follow. Af-
ter ovulation, the follicle remnant without the oocyte forms the corpus luteum, which 
marks the beginning of the luteal phase. The corpus luteum produces progesterone 
and estrogens which synergistically stimulate the endometrium. When pregnancy 
does not occur, progesteron and estrogen levels drop and menses start (Figure 1).
1.2 Polycystic Ovary Syndrome
Since the menstrual cycle is the result of the strict interplay of hormones produced 
by the hypothalamus, pituitary and ovaries, cycle irregularities are an indication 
of a disbalance and may be an indication of infertility. The most common cause of 
female infertility is Polycystic Ovary Syndrome (PCOS), which affects about 6-8% 
of women worldwide (6). Based on the Rotterdam Criteria, PCOS is characterized 
by two of the following three criteria: clinical or biochemical hyperandrogenism, 
oligo- or amenorrhea, and polycystic ovaries (PCO) (7). The various combinations of 
the criteria which emerged due to the introduction of the Rotterdam criteria, intro-
duced three different PCOS phenotypes. (i) The classic phenotype is characterized by 
hyperandrogenism and oligo-or amenorrhea, with or without PCO morphology. (ii) 
The ovulatory phenotype is characterized by hyperandrogenism and PCO. Finally, 
(iii) the normoandrogenic phenotype is characterized by oligo- or amenorrhea and 
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PCO (8). Although the etiology of PCOS is unknown, the failure in dominant fol-
licle selection leading to an accumulation of small antral follicles suggests that FSH 
sensitivity is altered in PCOS ovaries. This is further discussed in §1.2.1.
Treatment of women with PCOS focuses on infertility and the metabolic charac-
teristics which are often present, such as obesity and insulin resistance (discussed 
in §1.2.2). For the treatment of infertility usually pharmacological ovulation induc-
tion is used. Clomiphene citrate is the most commonly used agent. It is a selective 
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Figure 1. Menstrual cycle. Hormonal, ovarian and endometrial stages throughout the menstrual 
cycle.
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estrogen receptor modulator and inhibits the binding of estradiol in the pituitary and 
hypothalamus by competitive receptor antagonism, thereby stimulating the release 
of FSH and LH, which lead to stimulation of follicular growth, eventually leading 
to ovulation (9). Metformin is used as an oral antihyperglycaemic reagent in the 
treatment of diabetes. However, in PCOS metformin has been suggested to improve 
fertility by lowering insulin levels and thereby restoring the hormonal milieu in the 
ovary and thus restoring ovulation (10). In addition, treatment of insulin resistance 
and obesity also often indirectly leads to the treatment of infertility.
There are multiple methods to treat obesity within PCOS: lifestyle changes, phar-
maceutical interventions and bariatric surgery. Lifestyle changes usually encompass 
exercise and calorie restriction, which lead to changes in body composition, improve-
ment of insulin sensitivity and improvement of hyperandrogenism (11). Regarding 
pharmaceutical interventions, metformin (see above) is most often used. Besides 
lowering the insulin levels, it has also been associated with weight loss (12). Especially 
the use of metformin in combination with a hypocaloric diet leads to weight reduc-
tion, improvement of the ovulatory function and fertility rates (13). Finally bariatric 
surgery, which is increasingly used, has proven to result in very positive effects on 
the metabolic, hyperandrogenic and reproductive manifestations and can even lead 
to complete resolution of PCOS (14). However, this procedure remains drastic. Al-
though positive effects are reached with these interventions, treatment is palliative 
rather than curative and focuses on symptomatic approaches. Nevertheless palliative 
treatment may become increasingly important since over the years it has become 
evident that PCOS is associated with long-term health consequences beyond the 
reproductive system. Around 7.5% of the affected women will develop type 2 diabetes 
(15). Furthermore, women with PCOS have more extensive cardiovascular diseases 
(16). Also, it has been assumed that PCOS predisposes to endometrial cancer (17).
1.2.1 The reproductive phenotype in PCOS
Approximately 85% of PCOS patients have clinically evident menstrual dysfunc-
tion (18), although occasional ovulations have been reported (19). Interestingly, the 
greater the menstrual irregularity is, the more severe the metabolic alterations are, 
such as BMI and fasting insulin (20). Besides menstrual dysfunction there are other 
reproductive manifestations, including hyperandrogenism, referring to high levels of 
circulating endogenous androgens, including testosterone, dehydroepiandrosterone 
(DHEA), dehydroepiandrosteronesulfate (DHEAS) and androstenedione. Similar to 
the number of ovulations and its correlation to phenotype severity, there is also a 
correlation between hyperandrogenism and the metabolic phenotype severity. Nor-
moandrogenic PCOS patients have milder metabolic phenotypes (21).
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The characteristic morphological feature of ovaries in anovulatory PCOS women 
is an accumulation of small antral follicles and the polycystic appearance of the ova-
ries as a result of the arrest in follicle growth (22). This suggest an intrinsic abnormal 
ovarian environment which contributes to the follicular arrest (22), as exemplified by 
the higher FSH threshold in PCOS patients. (23). This has been confirmed by studies 
in which granulosa cells from PCOS women, cultured in vitro, were hyperresponsive 
to FSH, producing 6- to 10-fold more estrogens in response to FSH than normal cells 
(24-25). The origin of the decreased FSH sensitivity and follicular arrest may be due 
to a combination of factors. A neuroendocrine hallmark of PCOS is the increased 
GnRH pulse frequency leading to excess luteinizing hormone (LH) secretion (26). 
Combined with the premature acquisition of LH receptor expression by growing fol-
licles at too early stages, this in turn causes increased ovarian androgen production, 
leading to a premature maturation of follicles (26). Eventually, there is a block in 
folliculogenesis leading to an accumulation of small antral follicles and thereby an 
increased Antral Follicle Count (AFC).
1.2.2 The metabolic phenotype in PCOS
Besides having a reproductive phenotype, PCOS patients also frequently display 
metabolic derangements, which closely resemble the metabolic syndrome. The 
metabolic syndrome is a cluster of risk factors for the development of cardiovascu-
lar diseases and according to the National Cholesterol Education Adult Treatment 
Program (27) comprises: diabetes and prediabetes, abdominal adiposity, high cho-
lesterol and high blood pressure. Indeed, 38-88% (depending on the study) of the 
PCOS women are obese (28-29) and 50-70% are insulin resistant (30-32). Women 
with PCOS predominantly show abdominal obesity (33). This central or visceral 
adiposity is highly associated with insulin resistance (34). Also, a positive correla-
tion is present between adiposity and hyperandrogenism. The androgen receptor is 
present in pre- and mature adipocytes of subcutaneous and abdominal fat of both 
men and women (35). Furthermore, the expression of androgen receptors is higher 
in intra-abdominal preadipocytes compared to other fat depots (36). Thus the high 
androgen levels present in PCOS women can have a direct effect on abdominal fat 
tissue, leading to abdominal adiposity. Furthermore, in vitro experiments using 
adipocytes from healthy premenopausal women revealed impaired insulin-mediated 
glucose uptake when adipocytes were exposed to testosterone (37). The link between 
obesity and hyperandrogenism can also partly be explained by hyperinsulinism, 
which is often present in PCOS. Although other metabolic tissues become insulin 
resistant in PCOS, the theca cells of the ovary partly remain insulin sensitive (38). 
As a result, high insulin levels stimulate the theca cells of the ovary to produce an-
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drogens in synergy with LH (39). Furthermore, insulin inhibits the expression of Sex 
Hormone Binding Globulin (SHBG), a protein produced by the liver that binds sex 
steroid hormones. When SHBG levels decrease, more unbound or free testosterone 
is present in the circulation, which further contributes to hyperandrogenism. Also, 
high insulin levels can lead to an arrest of follicular development in ovaries of PCOS 
women (40). As a consequence, a detrimental vicious circle between high insulin lev-
els, hyperandrogenism, abdominal adiposity and the ovaries is established, leading 
to a worsening of the PCOS phenotype (Figure 2), possibly explaining the beneficial 
effect of an insulin-sensitizing drug such as metformin. Weight loss in combination 
with metformin not only induces a decrease in serum insulin levels, but also of tes-
tosterone levels and an increase in serum SHBG levels and as a result significantly 
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Figure 2. Schematic model of the pathophysiology in PCOS. GnRH pulse frequency is often in-
creased in women with PCOS, leading to an increased LH secretion. LH stimulation of the ovary 
results in increased androgen production, which in turn has an effect on adipose tissue, causing 
obesity, insulin resistance and high leptin levels. Insulin resistance in turn leads to compensatory 
high insulin levels. These high insulin levels cause further elevation of androgen levels, since insulin 
in synergy with LH stimulates the theca cells in the ovary. High insulin and leptin levels can lead to 
hypothalamic resistance. Hyperandrogenism and hyperinsulinemia thereby create a vicious circle 
in PCOS.
Adapted from Escobar-Morreale, Trends in endocrinology and metabolism 18(7): 266-72, 2007 & 
Franks, Fertility and Sterility 97(1): 2-6, 2012.
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1.3 Animal models for PCOS
So far the etiology of PCOS is still unknown because PCOS is a complex genetic 
disease (41-42) and has a heterogeneous presentation as discussed above. Therefore, 
animal models of PCOS may help to better understand the development of PCOS-
related pathologies. Furthermore, they may contribute to our knowledge about the 
long term health consequences of PCOS. An ideal animal model should replicate 
most common clinical features of PCOS, i.e. the reproductive and metabolic abnor-
malities. Naturally occurring animal models for PCOS are unknown. However, in 
the past decade several animal models of PCOS have been developed. Most of these 
models are based on hyperandrogenism induced pre- or postnatally or during adult-
hood, because it is generally agreed that elevated androgens are the main culprit of 
PCOS. Although hyperinsulinemia is known to be of importance in the etiology of 
PCOS, previous studies in rats showed that experimentally high insulin levels are not 
sufficient to induce PCOS (43). Possibly, the application of insulin to induce PCOS in 
animal models has therefore not been further explored.
Prenatally induced hyperandrogenism in non-human primates and sheep has 
resulted in the most suitable animal model, displaying many of the characteristics 
of PCOS, such as cystic ovaries, enhanced androgen production by theca cells, 
increased visceral fat mass, and insulin resistance (44-48). In both sheep and non-
human primate models of PCOS, androgens have most often been administered in 
utero, varying from early prenatal androgenization to late prenatal androgenization. 
In sheep androgenization during early gestation has been induced by either testos-
terone or dihydrotestosterone (DHT). After 60 days of in utero treatment, ovaries 
of the ewes contained a significantly lower proportion of primordial follicles and 
more growing follicles (49-50), due to an increased follicular recruitment. Andro-
genization during mid gestation did not alter ovarian morphology. However, there 
was evidence for an enhanced androgen production by theca cells, proving that a 
thecal defect can be induced during fetal life (46). Recabarren and colleagues (51) 
showed that sheep prenatally treated with testosterone had a reduced body weight 
and alterations in their insulin sensitivity, but these effects disappeared in later life. In 
contrast, Padmanabhan et al. showed that insulin resistance was still evident in adult 
life at 22 months (48), nevertheless dosages where higher in the latter study (100 mg 
vs 60 mg). Other studies using the 100 mg dosage of prenatal testosterone showed 
that sheep were hypertensive, had hyperglycaemia and were insulin resistant (47).
In non-human primates androgenization during early gestation resulted in both 
the reproductive as well as the metabolic phenotype of PCOS (44) with traits like 
PCO, insulin resistance and abdominal adiposity. Also in non-human primates, the 
difference between androgenization during early and late gestation was studied. Both 
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groups developed a metabolic phenotype, with an impaired insulin response. How-
ever, androgenization during early gestation led to an impaired insulin response due 
to impaired beta-cell function, whereas androgenization during late gestation caused 
an impaired insulin response due to an increase in the amount of visceral fat (45). 
This may suggest that the timing of androgen treatment is very important in order to 
create a permanent metabolic phenotype later in life in both sheep and non-human 
primate models of PCOS.
Although prenatally androgenization of non-human primates and sheep closely 
resembles PCOS, these models have the disadvantage that they are quite expensive 
and have a relatively long reproductive lifespan and gestational cycle. Therefore, 
many researchers, including ourselves, use rodents as a model of PCOS, since ro-
dents have the advantage of being affordable, having a shorter reproductive lifespan, 
easier handling, and having stable genetic backgrounds. Particularly, the use of mice 
provides the possibility of genetic manipulation and availability of various transgenic 
lines already generated.
1.3.1 Induced hyperandrogenism in mouse models of PCOS
The excess of androgens is considered the main cause of PCOS. Therefore, not sur-
prisingly, most PCOS animal models have been induced with androgens. Most com-
monly used androgens in mouse models of PCOS are testosterone, DHEA and DHT. 
However, also estrogen treatment has been applied. The timing of androgen exposure 
varies widely, starting as early as prenatal exposure. But also neonatal, prepubertal 
and adult androgenization of mice has been applied. Since clinical symptoms of 
PCOS often start during puberty (52), treatment of mice before adulthood will likely 
more closely resemble PCOS in human.
Dihydrotestosterone
Treatment with DHT is the most frequently used approach to induce a PCOS-like 
phenotype in rodents. This can be explained by the fact that DHT is a non-aromatiz-
able androgen and therefore, in contrast to testosterone, is not converted into estra-
diol. Therefore, results obtained with DHT treatment can be fully attributed to DHT. 
However, data show that DHT can be metabolized to 5α-androstane-3β,17β-diol, 
which can bind to the estrogen receptor β (53). Nevertheless, DHT has a higher affin-
ity for the androgen receptor than testosterone, making it a more potent androgen.
Prenatal treatment of female mice with 250 µg DHT per day on days 16-18 of 
pregnancy resulted in reproductive abnormalities in their female offspring (54-57). At 
an adult age, these prenatally DHT-exposed mice had a disrupted estrous cycle, and 
their ovaries contained fewer corpora lutea and an increased number of small antral 
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follicles. Follicles had a thinner granulosa cell layer and a slightly thickened theca cell 
layer (54, 57). However, the formation of cyst-like follicles was not reported. Serum LH 
and testosterone levels were elevated compared to vehicle-treated mice (57). Interest-
ingly, in this neonatally-induced model of PCOS, the authors investigated the effect of 
androgens on GnRH pulsatility. In PCOS, GnRH pulse frequency is increased, which 
has prompted researchers to suggest that androgens may reprogram the steroidal 
feedback on GnRH neurons, resulting in GnRH neuron hyperactivity (58). Using 
transgenic mice with GFP targeted to GnRH neurons, allowing easy identification 
of these neurons, it was shown that prenatal DHT treatment resulted in increased 
GABAergic drive to GnRH neurons and increased GnRH neuron activity (55, 57). 
Importantly, treatment of these DHT-exposed mice with metformin, an insulin sen-
sitizing agent frequently used to treat women with PCOS, during adulthood restored 
GnRH firing activity (55). These results suggest that metformin may have beneficial 
effects in PCOS at multiple sites. Prenatal DHT-treatment also induces several meta-
bolic disturbances. Although the body weight and percentage fat mass did not differ 
between 5-month-old prenatally androgenized and control mice, visceral adipocytes 
of DHT-treated mice were increased in size. Serum adipokine levels were not differ-
ent between treated and control mice. Nevertheless, prenatally DHT-treated mice had 
increased fasting glucose levels and reduced glucose tolerance, which may result from 
an impaired pancreatic β cell function or peripheral insulin resistance (56).
In contrast to human, formation of individual murine primordial follicles and 
initiation of follicular growth occurs after birth (59). Studies have shown that single 
oocyte formation is regulated by sex steroids (60). Hence we reasoned that androgen 
exposure either prenatally or neonatally might disrupt this process. Therefore, in our 
studies, we have chosen to develop a mouse model of PCOS, in which DHT treat-
ment is initiated during puberty when all stages of follicle growth have been initiated. 
The results of this study are described in chapter 2 of this thesis.
Testosterone
Although testosterone has often been used in rat models of PCOS (61-64), it has 
been less frequently administered to mice. In mice, only models in which testos-
terone was administered neonatally have been described. Treatment of female mice 
with 100 µg testosterone or testosterone propionate during the first three days of 
life resulted in anovulation and polyfollicular ovaries (65). However, the ovarian and 
metabolic phenotype of this model was not studied in detail, since the focus was on 
the behavioral effects of steroids. A study in which a single injection of a very high 
dose of testosterone propionate (1 mg) was given to 5-day-old female mice reported 
the presence of cyst-like follicles and the absence of corpora lutea at 9 weeks of age 
(66). Furthermore, in vitro culture of tertiary follicles showed that follicles from 
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these testosterone-treated mice failed to show a dose-dependent increase in follicular 
diameter in response to hCG, whereas progesterone production was significantly 
increased (67). These results suggest that neonatal testosterone treatment of mice 
induces changes in follicular function later in life.
Dihydroepiandrosterone
DHEA, an androgen of mainly adrenal origin, is often increased in women with PCOS 
(68). Therefore, not surprisingly, DHEA has been used to induce PCOS in different 
rodent models. Interestingly, prenatal DHEA androgenization of mice has not been 
reported, probably because prenatal DHEA treatment during early pregnancy (up 
to day 7 of pregnancy) causes embryonic resorption (69). Whether prenatal admin-
istration of lower dosages of DHEA or administration at a later stage of pregnancy 
would prevent embryonic resorption and could induce PCOS has not been studied. 
Therefore, in most studies, prepubertal treatment with DHEA was applied. In the de-
scribed studies, DHEA treatment was initiated during puberty. Motta and colleagues 
have treated 25-day-old mice for 20 days with daily injections of 6 mg/100 g body 
weight DHEA (70-72). Treated mice are infertile and their ovaries contained more 
atretic follicles and follicular cysts, although not more than two per ovary. These 
cysts had a thin theca layer and a compact layer of granulosa cells. Serum estradiol 
and progesterone levels were increased by at least 3-fold (71, 73). Subsequent studies 
showed that these DHEA-treated mice had a normal body weight and normal fasting 
glucose levels; however, fasting insulin levels were increased (71). Treatment with a 
10-fold lower concentration of DHEA did induce an increase in body weight, and 
also increased fasting insulin and glucose levels (72). This suggests that the dosage of 
DHEA used may differentially affect metabolic parameters. These studies also showed 
that DHEA treatment resulted in an increased number of T lymphocytes infiltrating 
the ovary (71-72). Although this observation requires further analysis, it may suggest 
that an altered immunoregulatory response may contribute to the ovarian pathology 
in PCOS. A possible role for the immune system in PCOS has been implicated by 
human studies in which altered T lymphocyte and leukocyte profiles were observed 
in theca cells and in follicular fluid of women with PCOS (74). Combined treatment 
of DHEA and the insulin sensitizing drug metformin prevented the development of 
endocrine and immune phenotypes (71), although it would be more interesting to 
study whether metformin can alleviate the phenotypes after being induced.
In conclusion, postnatal treatment of mice with DHEA induced some of the 
phenotypes of PCOS, such as anovulation and follicular cysts. However, whereas in 
women with PCOS cysts have a thickened theca cell layer, cysts from DHEA-treated 
ovaries have a thin layer. This suggests that DHEA treatment may not be an ideal 
approach to mimic PCOS.
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Estrogens
Daily subcutaneous injections of 20 µg estradiol in neonatal mice at 5-7 days of age 
have been applied to develop a PCOS model (75). Analysis of the ovaries of 100-day 
old mice revealed that this short term estradiol treatment resulted in the presence of 
follicular cysts and a complete lack of corpora lutea (75). Interestingly, thymectomy 
prior to estradiol injection prevented the formation of cystic follicles and restored 
ovulation in nearly 50% of the animals, while in the other 50% of the animals the 
ovaries became dysgenic. This might indeed indicate that an altered immunoregula-
tory balance may contribute to the ovarian pathology, as was observed upon DHEA 
treatment of mice. Estrogens may have a stimulatory role in autoimmune disease, 
which is mediated through altered function of the thymus (76). The presence of auto-
antibodies in serum of women with PCOS suggests that autoimmune processes may 
contribute to PCOS (77). Although the results of Chapman et al. (75) suggest that an 
altered thymus function may play a role in ovarian cyst formation, further studies 
are necessary to confirm whether this is also true in women with PCOS. Particularly, 
since elevated estrogen levels are not a hallmark of PCOS. Therefore, an estrogen-
induced mouse model of PCOS may also not be an ideal model to study PCOS.
1.3.2 Transgenic mouse models of PCOS
To date, several genetically modified mouse models have been described that exhibit 
features of the PCOS phenotype. Most of these models have been linked with PCOS 
because their ovaries had a polycystic appearance. In some of the described models 
these cysts had a hemorrhagic appearance, different from the follicles found in PCOS 
women. Particularly in various transgenic mice with chronically elevated gonadotro-
pin levels, hemorrhagic cyst formation appears to be common. Besides cyst forma-
tion, ovaries of mice overexpressing human chorionic gonadotropin (hCG) or the 
LHβ subunit display a thickened theca cell layer and luteinization of stroma cells 
(78-80). Indeed, enhanced ovarian steroidogenesis is observed in these mice, with in-
creased hCG/LH action, resulting in elevated testosterone levels, but also in elevated 
estradiol levels. Elevated circulating LH levels are also observed in mice lacking 
estrogen receptor α (Esr1) or aromatase (Cyp19), due to a lack of negative feedback by 
oestradiol on the hypothalamic-pituitary-gonadal axis (81-82). The ovarian pheno-
type of both Esr1 and Cyp19 knockout mice displays strong similarities with the hCG/
LHβ overexpressing mice, including the presence of hemorrhagic cysts. Combined, 
these transgenic mice clearly indicate a crucial role for LH action in follicular growth 
beyond the antral stage. This is in agreement with the phenotype observed in women 
with PCOS, where the increased serum LH/FSH ratio resulting from the increased 
GnRH pulsatility has been suggested to result in follicular arrest. However, in the 
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transgenic mice with increased hCG/LH action additional pathological phenotypes 
were observed, which included pituitary adenomas, mammary gland tumors in mice 
at older ages, or even ovarian teratomas (80, 83). Depending on the promoter used 
to chronically overexpress hCG or LHβ, serum levels of hCG and LH were 5-fold to 
even 1000-fold increased (78, 80, 83). In contrast, women with PCOS only show a 
3-fold increase in LH levels, which is observed in about 60% of the patients (7). Thus, 
the extent of LH elevation may explain the difference in phenotype observed in the 
transgenic mice and women with PCOS. Interestingly, female hCG overexpressing 
mice, that carry the transgene in low copy numbers, do not develop any ovarian 
histological abnormalities, although they do become infertile by 6-7 months (78). 
Thus, elevated LH action alone may not be the primary cause of PCOS. LHβ overex-
pressing mice become obese and are hyperphagic. The significantly increased white 
adipose tissue mass is reflected by increased leptin levels. Furthermore, insulin levels 
are increased but insulin tolerance appears to be normal (84). The authors concluded 
that the elevated androgens are responsible for the obese phenotype, however a 
contribution of adrenal steroids could not be ruled out since these mice also have 
high corticosterone levels (84). Also in women with PCOS, an adrenal contribution 
to the phenotype has been suggested (85). Thus, LHβ overexpressing mice may be an 
interesting model to gain insight into the metabolic alterations in PCOS.
Another model that may provide insight into the etiology of PCOS are transgenic 
mice overexpressing human plasminogen activator inhibitor-1 (PAI-1) under the 
control of murine preproendothelin 1 promoter, which targets gene expression to 
vasculature and epithelial surfaces (86). These mice fail to ovulate, and more than half 
of the animals develop ovarian cysts. In addition, overexpression of PAI-1 resulted in 
a hypertrophied theca cell layer and in a nearly two-fold increase in testosterone 
levels (86). PAI-1 is a member of the serine protease inhibitors (serpin) family and 
has been implicated in various diseases, including diabetes (87-88). Furthermore, 
PAI-1 levels have been proposed as a marker for metabolic and cardiovascular 
risk (87, 89). In women with PCOS increased levels of PAI-1 have been reported, 
although this may not be independent of the obesity status (90-92). Since PAI-1 plays 
a role in vascular integrity, PAI-1 may be one of the factors involved in the vascular 
endothelial dysfunction in PCOS, in addition to its role in the ovary. Interestingly, 
fibrillin-3, another factor involved in vascular matrix remodeling, and extracellular 
matrix (EMC) remodeling in general, has been implicated in the etiology of PCOS 
through genetic studies (93). This may suggest that changes in ECM elasticity may be 
involved in various aspects of PCOS.
Ovarian nerve growth factor (NGF) has also been implicated to play a role in the 
ovarian pathology of PCOS. It has been proposed that many of the features of PCOS 
are the result of sympathetic overactivity (94). The neurotropin NGF is a marker of 
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sympathetic nerve activity. Indeed, increased levels of NGF were measured in follicu-
lar fluid and granulosa cell cultures of PCOS women (95). In mice, overexpression 
of NGF under the control of the Cyp17 promoter, which leads to overexpression in 
androgen producing cells, causes follicular arrest at the antral stage, leading to an 
accumulation of small growing follicles. NGF overexpressing mice have normal LH 
levels, and ovaries of these mice do not contain follicular cysts. However, ovaries of 
NGF-overexpressing mice are hyperresponsive to gonadotropins. A challenge with a 
single dose of pregnant mare serum gonadotropin significantly increased the steroidal 
output, and treatment with a low dose of hCG for seven days led to significantly more 
cysts in immature NGF-overexpressing mice than in wild type animals (95). These 
findings suggest that increased innervation of the ovary, as observed in the NGF 
transgenic mice, may contribute to the ovarian and possibly metabolic phenotype 
in PCOS. Whether NGF is a causative factor in PCOS remains to be determined. 
Since increased ovarian expression of NGF is also observed in the estradiol valerate-
induced rat PCOS model (96), changes in NGF expression may be a secondary effect. 
However, a role for NGF in follicular arrest is evident because immunoneutralization 
of NGF partially restored follicular growth in this rat model (96).
In PCOS, both hyperandrogenism and hyperinsulinemia contribute to the ovarian 
and metabolic phenotypes. A role for the metabolic pathway in the development of 
the ovarian phenotype in PCOS was elegantly shown in mice lacking leptin receptors 
and insulin receptors selectively in pro-opiomelanocortin (POMC) neurons of the 
hypothalamus (IR/LepRPOMC) (97). These mice were generated to study the hypotha-
lamic contribution of leptin and insulin signaling in glucose homeostasis. As may 
have been expected, these mice develop a clear metabolic phenotype, with increased 
basal insulin levels, glucose intolerance, and insulin resistance. At 6 months of age, 
these IR/LepRPOMC mice had an increased body weight, reflected by increased white 
adipose tissue mass with hypertrophied adipocytes (98). Although the penetrance 
was incomplete, in mice older than 4 months 45% of the animals were anovulatory 
and histological analysis of their ovaries revealed the presence of occasional cysts 
(97-98). LH levels were increased by two-fold, and also testosterone levels were sig-
nificantly increased (97). Previous studies have already shown that both leptin and 
insulin signaling are important for reproduction by regulating GnRH release. Indeed, 
POMC neurons directly project to GnRH neurons (reviewed in (99)). Furthermore, 
it was shown that in obese patients resistance of leptin and insulin can develop (100). 
The results from the IR/LepRPOMC mice suggest that hypothalamic resistance to leptin 
and insulin may contribute to the multiple phenotypes of PCOS.
Animal models may be useful to study the association between the reproductive 
and metabolic phenotype observed in PCOS, and to gain more insight into the 
pathophysiology of this syndrome. However, PCOS is a heterogeneous disorder 
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making it difficult to generate a model that reflects all phenotypes. Indeed, the vari-
ous mouse models reflect the PCOS phenotypes only to a certain degree. The current 
models also reveal that PCOS can be induced at various levels, as schematically 
shown by the light grey boxes in Figure 2. This may suggest that several etiologies are 
involved in PCOS. Development of both reproductive and metabolic disturbances 
is predominantly seen upon androgen treatment. However, it is unknown whether 
besides androgens other factors secreted by the increased follicle pool contribute to 
the reproductive and metabolic phenotypes of PCOS.
1.4  Transforming Growth Factor β super 
family
The Transforming Growth factor β (TGFβ) superfamily plays an important role in 
the ovary, regulating various stages of folliculogenesis (101) and, therefore, will be 
discussed in more detail. TGFβ family members signal through a receptor complex 
consisting of type I and type II serine/threonine kinase receptors. Upon ligand bind-
ing, the type II receptor activates the type I receptor through phosphorylation, which 
in turn phosphorylates and activates the downstream Smad proteins. Based upon the 
downstream Smad family members involved, two main signaling pathways can be 
identified: the TGFβ/activin-like signaling pathway, signaling through Smad2 and -3; 
and the BMP-like signaling pathway, signaling through Smad1, -5 and -8 (102).
1.4.2 Bone Morphogenetic Proteins
The Bone Morphogenetic Proteins (BMPs) and Growth Differentiation Factors 
(GDFs) form the largest group within the TGFβ family. In the ovary, GDF9 and 
BMP15, also known as GDF9B, are specifically expressed by oocytes of all follicular 
stages (103-107) and inhibit FSH receptor expression and stimulate granulosa cell 
mitosis (108). Furthermore, GDF9 and BMP15 are fundamental for the activation of 
primordial follicles and subsequently participate in all stages of follicular develop-
ment (109). In sheep, naturally occurring inactivating BMP15 mutations have been 
identified which demonstrated a role for BMP15 in the regulation of ovulation rate. 
Sheep heterozygous for the BMP15 mutation have an increased ovulation rate, while 
sheep with a homozygous mutation are infertile, due to the absence of follicular de-
velopment, in spite of the apparently normal activation of the oocyte and expression 
of a number of oocytes specific genes (110). In addition, likewise to the BMP15 muta-
tion, sheep which carry a heterozygous mutation in GDF9 have increased ovulation 
rates and sheep with a homozygous mutation are infertile due to streak ovaries (111). 
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BMP6 has an oocyte/granulosa cells expression pattern in various species and inhib-
its FSH-induced progesterone synthesis by granulosa cells (112). BMP2 and BMP5 
are expressed by granulosa cells and BMP4 and BMP7 are expressed by theca cells in 
rats. The first report of the existence of a functional BMP system in the ovary showed 
that BMP4 and BMP7 regulate FSH-induced estradiol and progesterone production 
in granulosa cells (113). Rats injected with BMP7 had increased numbers of primary, 
preantral, and antral follicles but significantly fewer ovulated oocytes compared to 
control rats (114). Furthermore, it was found that BMP7 is involved in the selection of 
bovine follicles (115). Thus, BMP7 promotes the recruitment of primordial follicles into 
the growing follicle pool, while inhibiting ovulation and progesterone production. It 
has also been reported that BMP2 and BMP4 regulate FSH-induced steroidogenesis 
by stimulating estradiol production and reducing progesterone synthesis (116).
Little is known about the expression of BMPs in ovaries of PCOS women. Interest-
ingly, BMP6 expression levels in granulosa cells of women with PCOS are higher 
compared with granulosa cells from normal healthy women, possibly adding to the 
FSH insensitivity of PCOS follicles (117). Furthermore, decreased GDF9 expression 
has been observed in developing PCOS oocytes compared to normal oocytes (118). 
These findings indicate that TGFβ superfamily members may contribute to an altered 
intra-ovarian environment in PCOS, however, whether they play a role in the patho-
physiology of PCOS, has not been investigated in detail.
1.4.3 Anti-Müllerian Hormone
Anti-Müllerian hormone (AMH), or Müllerian inhibiting substance (MIS), has long 
been known for its involvement in the sexual differentiation of the male embryo. 
AMH is secreted by the Sertoli cells of the fetal testis and induces regression of the 
Müllerian duct, the anlagen of the female reproductive tract (119-120). Although 
initially not expressed in the ovary, ovarian AMH expression starts after birth in mice 
and from the 36th week of gestation onwards in human (121-122). In the human ovary, 
AMH is expressed in granulosa cells as soon as follicles are recruited from the pri-
mordial follicle pool. Expression is highest in follicles smaller than 4mm (preantral 
and small antral follicles) and is nearly lost in follicles larger than 8mm (123). Also 
in rodents, maximum expression is reached during the preantral and small antral 
stage. AMH expression decreases once FSH-dependent follicular growth has been 
initiated (121). Thus, AMH is expressed by those growing follicles in between initial 
recruitment and cyclic selection (Figure 3). The similarity of expression pattern in 
human and mice suggests that AMH may have a comparable role in both species.
AMH, signaling through its specific type II receptor (AMHRII), was shown to 
activate a BMP-like pathway (reviewed in (124)). Furthermore, in studies focusing 
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initially on Müllerian duct regression, the BMP type I receptors ALK2 and ALK3 
were identified as AMH type I receptors. Antisense ALK2 treatment of urogenital 
ridge organ cultures resulted in inhibition of AMH-induced Müllerian duct regres-
sion (125). Targeted disruption of ALK3 signaling in the Müllerian duct also abolished 
regression (126). Interestingly, this phenotype could be rescued in the presence of 
increased AMH levels (127), suggesting the involvement of an additional type I recep-
tor, such as ALK2. Finally, based on the AMH-induced interaction between AMHRII 
and ALK6, also ALK6 has been implicated as an AMH type I receptor (128). In rats, 
the AMHRII has a similar expression pattern to AMH (129). The three AMH/BMP 
type I receptors are also expressed in the ovary (130).
Insight into the role of AMH in folliculogenesis came from studies performed in 
the AMH knockout (AMHKO) mice. In these studies, the complete follicle population 
was determined in AMHKO and wild-type mice. At 4 months of age, ovaries of AM-
HKO mice contained more growing follicles and less primordial follicles compared to 
wild-type mice. The increased recruitment in the absence of AMH resulted in a much 
faster depletion of the primordial follicle pool, evident at 13 months of age when ova-
ries of AMHKO mice were nearly devoid of primordial follicles whereas wild-type 
ovaries still contained primordial follicles (131). These results strongly suggested that 
AMH has an inhibitory role in primordial follicle pool recruitment. This conclusion 
was confirmed in a neonatal ovary culture system in which ovaries of 2-day-old mice 
were cultured in the presence or absence of AMH. In the presence of AMH, cultured 
ovaries contained 40-50% less growing follicles compared with control ovaries (132). 
Initial recruitment Cyclic recruitment 
primordial 
follicle pool 
Selection for dominance 
AMH 
small growing follicles large antral 
preovulatory 
FSH FSH 
Figure 3. Follicular development and the role of AMH. During folliculogenesis, follicles progress 
through various developmental stages. AMH is expressed by the small growing follicles and has an 
inhibitory effect on primordial follicle recruitment and FSH sensitivity.
Modified from Visser et al, Reproduction 131(1): 1-9, 2006.
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Similarly, grafting of mouse neonatal ovaries beneath the chorioallantoic membrane 
of chick embryos, which results in exposure to high levels of AMH secreted by 
the chick gonads, suppressed primordial follicle recruitment. Interestingly, follicle 
recruitment was not suppressed when neonatal ovaries of AMHRII null mice were 
grafted (133). Similar results were obtained using bovine ovarian cortical strips. In 
vitro culture of cortical strips in the presence of AMH inhibited follicle recruitment, 
whereas recruitment occurred in bovine ovarian cortex grafted in gonadoectomized 
chicks (133). Likewise, treatment of human ovarian cortical strips with AMH for 7 
days in vitro suppressed the initiation of primordial follicle growth (134). In contrast, 
Schmidt et al. (135) reported that follicle growth was more advanced in the presence 
of AMH in cryopreserved human ovarian cortical tissue cultured for 4 weeks. The 
difference in material (fresh vs. frozen-thawed) and the duration of culture (7 days 
vs. 4 weeks) perhaps explains these conflicting results.
The specific window of AMH expression, i.e. in between the two major regulatory 
steps of folliculogenesis, suggests that in addition to primordial follicle recruitment, 
AMH may also regulate FSH-dependent cyclic selection. The increase in FSH during 
each cycle results in the selection of a limited number of follicles from the cohort 
of small growing follicles. For this cyclic selection of follicles, FSH levels need to 
rise to a certain threshold concentration to prevent follicles becoming atretic (2). 
Studies in mice and human suggest that AMH is one of the intra-ovarian growth 
factors contributing to the establishment of this threshold. In the AMHKO mice, 
more growing follicles were observed despite lower FSH levels (131). Detailed analysis 
throughout the estrous cycle revealed that the FSH surge was blunted in AMHKO 
mice. Nevertheless, the FSH-dependent selection of small antral follicles was more 
pronounced in the absence of AMH. In addition, recruitment of large preantral fol-
licles was observed in AMHKO mice at estrous, whereas in wild-type mice these 
follicles are not sensitive to FSH (136). Thus, in the absence of AMH follicles display 
an enhanced and premature sensitivity to FSH.
In mice serum AMH levels declined gradually with increasing age, whereas the 
expression of AMH in individual growing follicles did not change. This decline in 
serum AMH correlated strongly with the decreasing number of growing follicles, and 
more importantly, with the decline in number of primordial follicles (137). Similarly, 
in adult women serum AMH levels declined with increasing age to undetectable 
levels after menopause (138-139). AMH levels correlated strongly with antral follicle 
count (AFC), but also with other markers for ovarian aging such as FSH and inhibin 
B on cycle day 3 (138). Interestingly, AMH levels remained relatively stable during 
the menstrual cycle and also do not vary significantly between cycles (140-141), sug-
gesting that AMH expression is not regulated by gonadotropins. This may explain 
why AMH is considered one of the earliest markers for ovarian reserve. In young 
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normo-ovulatory women AMH levels decreased over a 3-years interval, whereas 
serum levels of FSH and inhibin B and AFC did not change. In agreement, analysis 
of normal women at an on average 4-years interval revealed that of these markers, 
serum AMH level is the best predictor for the occurrence of menopausal transition 
(142). Furthermore, in a study by van Disseldorp et al. (143), in which AMH levels of 
a cohort of normal women were related to the observed age at menopause distribu-
tion of a prospective cohort, it was observed that AMH is a much better marker to 
predict a woman’s reproductive age than chronological age.
1.5 Anti-Müllerian Hormone and PCOS
Besides the effect of androgens on the etiology of PCOS, a role of ovarian growth fac-
tors, such as AMH and BMPs, on the pathophysiology of PCOS cannot be ruled out.
As mentioned above, serum AMH levels correlate with AFC. Several studies 
showed that serum AMH levels are 2-3 fold increased in PCOS women, and cor-
relate with the increased follicle number (144-147). In addition, serum AMH levels 
are positively correlated with androgen levels. Increased AMH levels were also 
observed in follicular fluid of PCOS women (144, 148). This suggests that not only 
the increased number of follicles contribute to the elevated serum AMH levels, but 
also that the production per granulosa cell is increased. Indeed, Pellatt et al. (148) 
observed that AMH expression in granulosa cells of PCOS patients was nearly 75-
fold higher than in those of control women. Interestingly, AMH levels are highest in 
those PCOS patients with the more severe phenotype. PCOS women with PCO had 
higher AMH levels than those without (146). Likewise, subdividing PCOS women 
in ovulatory and anovulatory women showed that anovulatory PCOS women had 
increased AMH levels (149). Women with both PCO and hyperandrogenism had 
higher AMH levels than women with PCO only, although the number of small antral 
follicles was not different between the two groups (150). A relationship with insulin 
resistance is less clear. A lack of correlation between serum AMH levels and insulin 
levels or BMI has been reported (146-147), whereas other studies did observe a posi-
tive correlation between the Homeostasis Model Assessment (HOMA) index and 
higher AMH levels in insulin-resistant PCOS women than in PCOS women with 
normal insulin sensitivity (151-152). Nevertheless, treatment with insulin lowering 
drugs such as metformin, only weakly lowers AMH levels and only after a prolonged 
treatment period (153-154), suggesting that insulin does not directly regulate AMH 
production.
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1.6 Aim and scope of this thesis
In PCOS, androgens are seen as the main culprit of the syndrome, exerting an ef-
fect on both the ovary as well as on the metabolic tissues. Besides androgens, other 
growth factors are also secreted by the ovary. We postulated that ovarian growth 
factors contribute to the PCOS phenotype, especially since there are ovarian growth 
factors which are increased in PCOS, like AMH. In this thesis, we describe studies on 
the role of ovarian growth factors in the regulation of metabolism in PCOS. In chap-
ter 2 of this thesis we describe the development of a mouse model of PCOS, which 
exhibited both the ovarian as well as the metabolic characteristics seen in PCOS 
women in order to learn more about the pathophysiology of PCOS. In chapter 3 we 
examined the contribution of ovarian growth factors on the metabolism in PCOS by 
removing the ovaries of PCOS mice. In chapter 4 we studied the contribution of an 
increase in ovarian growth factors on the metabolic phenotype, using anti-Müllerian 
hormone knock out (AMHKO) and anti-Müllerian hormone type II receptor knock 
out (MRKI) mice as models of an increased number of growing follicles. In chapter 
5 we investigated whether serum BMP levels could be used as a marker of ovar-
ian function in women with PCOS. In chapter 6 we examined the relationship of 
serum AMH with the metabolic syndrome in a large cohort of women with PCOS. 
Finally, in the general discussion, the findings of this thesis are discussed in a general 
perspective and some directions for future research are given.
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Polycystic ovary syndrome (PCOS), the most common endocrine disorder in women 
in their reproductive age, is characterized by both reproductive and metabolic fea-
tures. Recent studies in human, nonhuman primates and sheep suggest that hyper-
androgenism plays an important role in the development of PCOS. We investigated 
whether chronic DHT exposure in mice reproduces both features of PCOS. Such a 
model would allow us to study the mechanism of association between the reproduc-
tive and metabolic features in transgenic mice.
In this study, prepubertal female mice received a 90 days continuous release pellet 
containing the non-aromatizable androgen dihydrotestosterone (DHT) or vehicle.
At the end of the treatment period, DHT-treated mice were in continuous an-
estrous, their ovaries contained an increased number of atretic follicles, with the 
majority of atretic antral follicles having a cyst-like structure. Chronic DHT-exposed 
mice had significantly higher body weights (21%) than vehicle-treated mice. In ad-
dition, fat depots of DHT-treated mice displayed an increased number of enlarged 
adipocytes (P<0.003). Leptin levels were elevated (P<0.013), adiponectin levels were 
diminished (P<0.001), and DHT-treated mice were glucose intolerant (P<0.001).
In conclusion, a mouse model of PCOS has been developed showing reproductive 
and metabolic characteristics associated with PCOS in women.
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Introduction
PCOS is the most common endocrine disorder in women in their reproductive age 
and affects about 6-8% of women worldwide (1). Based on the Rotterdam criteria, 
PCOS is diagnosed by the presence of at least two of the following three criteria: 
clinical or biochemical hyperandrogenism, oligo- or amenorrhea, and the presence 
of polycystic ovaries (PCO) by ultrasound (2).
Although PCOS is a complex and multifactorial disorder, the failure in domi-
nant follicle selection leading to an accumulation of small antral follicles suggests 
an altered FSH sensitivity in PCOS ovaries. Furthermore it is generally agreed 
that elevated androgens are the main culprit of the syndrome. Indeed, prenatal 
exposure of female rhesus monkeys to testosterone induces PCOS (3). Similarly, 
in sheep in utero exposure to testosterone resulted in increased LH secretion and 
cycle disturbances, resembling PCOS (4). Clinical evidence of the effects of early 
androgen exposure was observed in daughters of PCOS women. These girls are at 
high-risk for reproductive and metabolic abnormalities. The percentage of girls with 
increased ovarian volume and elevated androgen and insulin levels was significantly 
higher in Tanner IV and V stages for breast development for daughters of PCOS 
women compared to daughters of normo-ovulatory women (5). In addition to the 
ovarian phenotype, PCOS is also associated with a metabolic phenotype. A large 
proportion of PCOS women are obese (38-88%, depending on the study (5-6)), with 
predominantly abdominal adiposity, which is considered a risk factor for metabolic 
disease (7-8). Indeed, 50-70% of women with PCOS are insulin resistant resembling 
type 2 Diabetes Mellitus (8-10). Interestingly, the presence of hyperinsulinemia in 
women with PCOS appears to be independent of obesity, although only obese PCOS 
women are at risk of becoming glucose intolerant. A role for metabolic features in 
the pathogenesis and/or severity of PCOS is emphasized by studies showing that 
weight loss in combination with an insulin-sensitizing drug such as metformin not 
only induces a decrease in serum insulin but also in testosterone and significantly 
normalizes the menstrual cycle (9). The beneficial effect of lowered insulin levels on 
ovarian function is explained by the synergistic effect of insulin with LH on theca 
cells to produce androgens (10). In addition, hyperinsulinemia in the ovary can 
directly lead to an arrest of follicular development in women (11), which improves 
after metformin treatment. Consequently, the interplay between high insulin levels, 
hyperandrogenism, and abdominal adiposity may lead to an exaggerated PCOS 
phenotype (12-13).
Since naturally occurring animal models for PCOS are not known, several models 
have been generated. Prenatal or neonatal androgen exposure or treatment with an 
aromatase inhibitor was most often used to induce a polycystic phenotype (14-16). 
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In most of these studies the emphasis has been on the ovarian phenotype rather 
than the metabolic consequences of androgen treatment, although lately also the 
metabolic phenotype is receiving increased attention. Recently, a rat model has been 
described in which prepuburtal administration of dihydrotestosterone (DHT), the 
active metabolite of testosterone, induced both the ovarian and metabolic phenotype 
of PCOS (17). Besides acyclicity and the presence of cyst-like follicles, increased body 
weight and reduced insulin sensitivity were observed in DHT-treated rats (17). Since 
the use of mice has the advantage of the availability of the plethora of transgenic 
lines, we have used a prepubertal DHT-treatment approach to develop a mouse 
PCOS model.
Our data demonstrate that chronic exposure of mice to DHT for 90 days leads to 
acyclicity, large cyst-like follicles, and hormonal and metabolic disturbances resem-
bling the features found in women with PCOS.
Materials and Methods
Animals
C57BL/6J wild-type female mice were obtained from the Animal Facility of the 
Erasmus MC (Rotterdam, The Netherlands) and were kept under standard animal 
housing conditions in accordance with the National Institutes of Health guidelines 
for the Care and Use of Experimental Animals. The experiments were performed 
with permission of the local ethics committee.
At postnatal day 19, mice of comparable body weight were randomly divided over 
two treatment groups (DHT and control; n = 9-10 per group), and were implanted 
subcutaneously with a 90-day continuous DHT release pellet (Innovative Research 
of America, Sarasota, FL, USA). These pellets contained 2.5 mg DHT (daily dose 
27.5 μg). Control mice received a placebo pellet. Mice were sacrificed at the end of 
the treatment period (90 days). To determine the stage of the estrous cycle, daily 
vaginal smears were taken ten days before the animals were sacrificed, and examined 
as described previously (18). Body weight was determined at the start and end of 
treatment. In addition, at the end of the 90-day treatment period blood samples and 
tissues were isolated. Blood samples were collected by orbital puncture after mice 
were anesthetized with isoflurane. Ovaries and uterus were isolated, weighed, and 
fixed overnight in Bouin’s fluid. Inguinal, retroperitoneal and gonadal fat depots 
were isolated and fixed overnight in 4% paraformaldehyde. The inguinal fat depot is 
located anterior to the upper segment of the hind limbs, and represents subcutaneous 
adipose tissue in mice. The gonadal fat depot is located at the level of the ovaries, and 
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is considered to represent visceral fat. The retroperitoneal fat depot is located to the 
dorsal wall of the back (19). In addition, isolated tissues were snap frozen in liquid 
nitrogen and stored at −80°C until further processing.
Ovarian histology and follicle counting
For histological examination of ovarian morphology, one fixed ovary was embedded 
in paraffin. After routine histological procedures, 8 μm sections were mounted on 
glass slides and stained with hematoxylin and eosin. Follicle count was performed as 
described previously (18). In brief, based on the mean diameter of the follicle, growing 
follicles were divided into four classes: small preantral (20-170 μm), large preantral 
(171-220 μm), small antral (221-310 μm), and large antral (>311 μm). Nonatretic and 
atretic growing follicles were counted in every fifth section. Primordial follicles were 
counted in every second section. In addition, the presence of recent corpora lutea 
was determined.
Immunohistochemistry
Immunohistochemistry was performed as described previously (20). Briefly, sec-
tions were mounted, deparaffinized, blocked for endogenous peroxidase activity, 
washed with water and transferred to PBS. After antigen retrieval was performed on 
the sections, they were cooled down, rinsed in PBS and incubated with a biotinyl-
ated anti-Müllerian Hormone (AMH) mouse monoclonal antibody (antibody 5/6A, 
MCS2246; Serotec; (21)). Sections were diluted 1:100 at 4°C overnight and washed 
with PBS. Then the sections were incubated for 30 min at room temperature with 
streptavidin-biotinperoxidase complex (ABC; diluted 1:200 in PBS; Dako, Glostrup, 
Denmark), washed with PBS three times and the peroxidase activity was developed 
with 0.07% 3,3-diaminobenzidine tetrahydrochloride (Sigma-Aldrich). Finally, all 
sections were counterstained with hematoxylin.
Real time PCR
Total RNA was isolated per whole ovary using TriPure Isolation Reagent (Roche 
Applied Sciences, Almere, The Netherlands) according to the manufacturer’s in-
structions. After DNase treatment (Promega Benelux BV, Leiden, The Netherlands), 
samples were reverse transcribed using a cDNA Synthesis Kit (Roche Applied Sci-
ences, Almere, The Netherlands). Real-time PCR (RT-PCR) was performed with 
SYBR Green (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) using 
an ABI PRISM® 7900HT Sequence Detection System. The expression of the target 
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gene was normalized according to the average expression level of three housekeeping 
genes (β2-microglobulin, HPRT, and cyclophilin A) using the 2-ΔΔCt-method (22).
IPGTT
At the end of the treatment period mice were fasted overnight (16h) prior to an ip 
glucose tolerance test (IPGTT). Glucose levels were measured by tail vein blood 
sampling using a Freestyle mini glucometer and test strips (Abbot, Alameda, CA, 
USA). Following a baseline (fasted) measurement, mice were injected intraperitone-
ally with glucose (2 g/kg as a 20% glucose solution) and tail sampling was performed 
at 15, 30, 60, and 120 minutes. In addition, at baseline a 50 μl sample was drawn into 
EDTA microvettes (Sarstedt, Nümbrecht, Germany) for insulin measurements. After 
centrifugation at 3000 rpm, 4°C, plasma was removed and stored at −20°C.
Hormone measurements
AMH levels were measured with an in-house AMH ELISA assay (commercially 
available through Beckman Coulter, Woerden, The Netherlands) (20). Plasma in-
sulin levels were determined using an ultrasensitive mouse insulin ELISA (Alpco 
Diagnostics, Salem, NH, USA). Total adiponectin serum levels were measured with 
an Adiponectin (Mouse) Total, HMW ELISA (Alpco Diagnostics). Leptin levels were 
measured with a Leptin (Mouse/Rat) ELISA (Alpco Diagnostics). All samples were 
measured in one assay. DHT levels were measured with a DHT ELISA (Diagnostics 
Biochem Canada Inc. Ontario, Canada). Serum LH levels were measured with a 
rodent LH+ ELISA (Endocrine Technologies, Newark, CA, USA).
Measurement of adipocyte size
Four mice per treatment group were randomly selected and fixed white adipose tis-
sue was processed and analyzed. In brief, adipose depots were embedded in paraffin, 
and after routine histological preparation sectioned at 8 μm. Mounted sections were 
stained with hematoxylin and eosin. For each fat depot, micrographs were taken at 
100x magnification. In three randomly selected micrographs the diameter of at least 
130 adipocytes was measured using Image J software (version 2.0, http://imagejdev.
org), and subsequently the number of adipocytes per similar size class with intervals 
of 2 µm was calculated.
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Statistics
Data were statistically analyzed by Student’s t-test, repeated measures ANOVA (IP-
GTT, body weight), or two-way ANOVA (adipocyte size distribution) using SPSS 
15.0 (SPSS Inc., Chicago, IL). Data were expressed as mean ± SEM and differences 
were considered significant at P<0.05.
Results
DHT levels
To confirm that implantation of the DHT-releasing pellets resulted in elevated DHT 
levels, serum DHT was determined. Indeed, DHT levels in DHT-treated animals 
were significantly increased 6-fold compared to placebo-treated animals (2.82 ± 0.30 
nmol/l vs. 0.44 ± 0.13 nmol/l, respectively, P<0.001).
Cyclicity and ovarian morphology
Cycle irregularity and the presence of polycystic ovaries are hallmarks of the repro-
ductive abnormalities in PCOS. All placebo-treated mice had a regular cycle of 3-5 
days and their ovaries contained fresh corpora lutea, indicative of recent ovulations. 
Vaginal smears of DHT-treated mice revealed that all mice were in continuous 
anestrous, suggesting that DHT-treated mice were acyclic. In agreement with the 
disrupted estrous cycle, none of the ovaries of DHT-treated mice showed signs of 
Table 1. Hormone levels and ovarian weight in placebo- and DHT-treated mice
Placebo DHT
Ovarian weight (mg) 7.59 ± 0.27 8.73 ± 1.05
LH (ng/ml) 0.19 ± 0.05 0.09 ± 0.02
AMH (ng/ml) 6.01 ± 1.44 8.16 ± 1.26
Leptin (ng/ml) 2.14 ± 0.35 5.17 ± 1.09a
Adiponectin (μg/ml) 22.51 ± 2.28 12.75 ± 2.28b
Insulin (ng/ml) 0.49 ± 0.06 0.43 ± 0.07
Ovaries and serum samples were collected at the end of the 90-day treatment period. Serum sam-
ples were used for hormone measurements. For fasting insulin levels, plasma samples were col-
lected at the start of the ip glucose tolerance test, performed at the end of the 90-day treatment 
period. Values represent mean ± SEM (n = 9-10 mice per group, except for LH: n = 6 mice per 
group). a P<0.05, b P<0.01 (placebo vs. DHT).Values represent mean ovarian weight of both ovaries 
± SEM (n = 9-10 mice per group).
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ovulations, i.e. corpora lutea. Serum LH levels did not differ significantly between 
the two groups, although LH levels tended to be decreased in the DHT-treated mice 
(Table 1). Particularly, in the placebo-treated mice LH levels showed a wide variation, 
which could be explained by sampling exactly on day 90 of the experiment, irrespec-
tive of their estrous cycle, whereas all DHT-treated mice were anestrous. Ovaries of 
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Figure 1. Effect of DHT-treatment on follicle numbers. Mice were treated for 90 days with vehicle 
(open bars) or DHT (closed bars) and ovaries were isolated at the end of the treatment period (90 
days). The number of follicles in different size classes was determined per ovary. A) Number of 
primordial follicles; B) Number of healthy growing follicles; C) Number of atretic follicles. Data 
represent mean ± SEM (n = 9-10 mice), ** P<0.01, and *** P<0.001.
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DHT-treated mice tended to have an increased weight, although this failed to reach 
significance (data not shown). Ovaries of DHT-exposed mice contained a similar 
number of primordial and healthy growing follicles to placebo-treated mice (Figure 
1A and B). However, the number of atretic follicles, in particular the number of 
atretic small antral and large antral follicles was increased by 2-4 fold (Figure 1C). 
The majority of these atretic follicles had a cyst-like appearance, which was never 
observed in the placebo-treated mice (Figure 2A and D). Compared to atretic fol-
licles in placebo-treated mice (Figure 2B), these cystic follicles were larger and had a 
larger fluid-filled antrum with a thin granulosa cell layer containing several detached 
pyknotic granulosa cells (Figure 2E). Atretic follicles in placebo-treated mice had a 
compact theca cell layer (Figure 2C), whereas in DHT-treated mice the theca cell 
layer of the cystic ovaries was dispersed and contained cells that resemble interstitial 
tissue, giving the theca cell layer a hyperplastic appearance. For several of these 
cyst-like follicles the difference between theca cell layer and stroma was not distinct 
(Figure 2F). Immunohistochemistry showed that DHT did not have an effect on the 
expression pattern of the important ovarian regulator AMH (Supplemental Fig.1). In 
agreement, serum AMH levels did not differ between placebo- or DHT-treated mice 
(Table 1). Aromatase mRNA expression was not significantly different between the 
two groups (Supplemental Fig. 2)
Body weight of DHT-treated mice
In addition to the ovarian morphology, we also analyzed several metabolic charac-
teristics. At the start of treatment, there were no differences in body weight present 
between the placebo- and DHT-treated mice (Figure 3). However, DHT-treated mice 
gained significantly more weight than placebo-treated mice (P<0.0001). As a result, 
DHT-treated mice had a 21% higher body weight at the end of the treatment period, 
compared to the placebo treated mice (P<0.0001) (Figure 3).
Adipocyte size in DHT-treated mice
Although body composition or weight of the adipose depots were not analyzed, gross 
morphological analysis of the mice suggested that adipose depots of DHT-treated 
mice were enlarged. Histological analysis of retroperitoneal, inguinal, and gonadal 
white adipose tissue (WAT) revealed the presence of enlarged adipocytes in DHT-
treated mice (Figure 4A). Detailed analysis of the adipocyte size revealed that all 
adipose depots of DHT-treated mice contained a significantly increased number 
of enlarged adipocytes, reflected by the right-sided shift in the size distribution 











Figure 2. Ovarian morphology of placebo- and DHT-treated mice. Ovaries were isolated at the 
end of the 90-day treatment period. A) HE-stained ovarian section of a normal cycling placebo-
treated mouse with healthy growing follicles and a corpora luteum (*) Magnification 40x. B) Higher 
magnification (200x) of the boxed area in A, showing an atretic antral follicle. C) Higher magnifi-
cation (400x) of the boxed area in B, showing a compact theca cell layer (double-sided arrow). D) 
HE-stained ovarian section of an acyclic DHT-treated mouse with several cyst-like follicles (#). E) 
Higher magnification (200x) of the boxed area in D, showing an atretic cyst-like follicle with a large 
fluid filled antrum and detached pycnotic granulasa cells. F) Higher magnification (400x) of the 
boxed area in E, showing a dispersed theca cell layer containing cells that resemble interstitial tissue 
(double-sided arrow). Scale bar = 100 µm.
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was significantly increased in all WAT depots analyzed compared to placebo-treated 
mice (P<0.01) (Table 2).
Adipokine levels and glucose tolerance in DHT-treated mice
Obesity has been shown to be associated with changes in serum adipokine levels 
(23). DHT treatment resulted in 2.5-fold higher leptin (P=0.013) and 1.5-fold lower 
adiponectin (P=0.001) levels in DHT-treated compared to placebo-treated mice 
(Table 1). When corrected for body weight, the difference in leptin levels just failed to 
reach significance (P=0.05), whereas adiponectin levels remained highly significantly 
different between placebo- and DHT-exposed mice (P=0.004).
To investigate whether the DHT-treated mice showed an altered glucose tolerance, 
an ip glucose tolerance test was performed at the end of the treatment period. While 
fasting glucose levels were unchanged, DHT treatment resulted in significantly 
elevated glucose levels following ip glucose administration at all time points deter-
mined (P<0.001) (Figure 5A) and a significantly increased 0-120 min AUC value 
(P<0.001) (Figure 5B). Fasted insulin plasma levels did not differ between DHT- and 














Figure 3. Effect of DHT-treatment on body weight. Body weight was determined at start (0 days of 
treatment) and at the end of the experiment (90 days of treatment) in mice exposed to vehicle (open 
bars) or DHT (closed bars). Data represent mean ± SEM (n = 9-10), *** P<0.001.
Table 2. Average diameter of adipocytes per fat depot.
Gonadal Retroperitoneal Inguinal
Placebo (μm) 12.83 ± 1.10 13.53 ± 1.28 8.38 ± 0.37
DHT (μm) 23.89 ± 0.67* 29.45 ± 1.71* 23.44 ± 1.83*
Fat depots were isolated at the end of the 90-day treatment period. The diameter of a total of 130 
adipocytes was measured in three randomly selected sections per fat depot per mouse. Values rep-









































Gonadal Retroperitoneal Inguinal 
Figure 4. Increased adiposity upon chronic DHT treatment. Adipose depots were isolated at the 
end of the 90-day treatment period. A) HE-stained section of gonadal, retroperitoneal, and in-
guinal adipose depots in placebo- and DHT-treated mice. Scale bar = 100 µm. B) Adipocyte size 
distribution in placebo- (open circles) and DHT-treated (closed circles) mice. In each group, the 
diameter of a total of 130 adipocytes was measured in three randomly selected sections per fat de-
pot per mouse. Data represent mean ± SEM (n = 4 mice per group), P<0.001.
**  
































Figure 5. DHT treatment induced glucose intolerance. The ip glucose tolerance test was performed 
at the end of the 90-day treatment period. A) Ip glucose tolerance test in placebo- (open circles) and 
DHT-treated (closed circles) mice. B) Corresponding 0-120 minutes AUC for placebo- (open bars) 
and DHT-treated (closed bars) mice. Data represent mean ± SEM (n = 9-10), *** P<0.001.
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Discussion
This study shows that chronic exposure to DHT in prepubertal female mice induces a 
reproductive phenotype resembling features observed in women with PCOS, such as 
acyclicity and large atretic follicles with a cyst-like structure. Furthermore, our results 
show that the mice had an increased body weight and their WAT depots contained 
significantly more enlarged adipocytes. Leptin levels were elevated, adiponectin lev-
els were decreased, and DHT-treated mice were glucose intolerant. Thus, our DHT-
treated mice also display the metabolic disturbances often associated with PCOS.
Women with PCOS suffer from oligo- or anovulation and their ovaries contain 
large cyst-like follicles. In our study, all mice treated with DHT were acyclic and 
their ovaries were devoid of corpora lutea, showing that these mice lacked ovulations. 
Furthermore, the ovaries of DHT-treated mice contained many large follicles with a 
cyst-like appearance. The hyperplastic appearance of the theca cell layer of the cystic 
follicles, which contained cells that resembled interstitial cells, is in agreement with 
previous studies showing that androgen treatment in rats resulted in a pronounced 
thickening of the theca cell layer (17, 24). However, we cannot rule out that the 
phenotype of the granulosa and theca cell layer of the cystic-follicles also represents 
an advanced apoptotic stage, resulting in a degenerating follicular integrity. Interest-
ingly, Manneras et al. (17) reported that DHT-treated rats, which our mouse model 
is based on, had irregular cycles and the ovarian weights of the DHT-treated rats 
were decreased compared to control rats, whereas in our DHT-treated mice ovar-
ian weights tended to be increased (results not shown). A possible explanation of 
this discrepancy may be the dosage of DHT used. The DHT-treated mice showed 
6-fold increased DHT serum levels compared to controls. In normo-ovulatory 
women, mean DHT levels range from 8.1 to 8.5 ng/dL during their cycle (25). In 
women with PCOS this can increase 3-fold to 24 ng/dL (26), which is less high as 
in the DHT-treated mice. Although, unfortunately the DHT levels in the rat model 
were not reported (17), it may be suggested that the more severe hyperandrogenic 
state in the DHT-treated mice may be responsible for the more severe reproductive 
phenotype. Indeed, also in women with PCOS higher androgens levels are associated 
with a worse phenotype (27).
Although the ovaries of DHT-treated mice contained cyst-like follicles, the follicle 
distribution did not completely resemble the one found in ovaries of PCOS women. 
Women with PCOS have an increased antral follicle count with accompanying in-
creased AMH levels, with AMH reflecting the increased number of small antral folli-
cles (28-29), while ovaries of DHT-treated mice had a comparable number of growing 
follicles and AMH levels to control mice. Furthermore, the AMH expression pattern 
as determined by immunohistochemistry was not different from control animals, 
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whereas a reduced AMH expression in transitional primordial follicles accompanied 
with an increased expression in growing follicles has been observed in human poly-
cystic ovaries compared to normal ovaries (30). This suggests that AMH expression, 
at least in mice, is not regulated by 5α-reduced androgens. The unchanged follicle 
distribution was unexpected, since it has been suggested that androgens increase early 
follicle selection and growth in primates (31-32). Also in sheep, in utero exposure to 
testosterone or DHT also resulted in an increased recruitment of primordial follicles 
in the fetal ovary (33-34). However, postnatally, this effect was dependent on whether 
testosterone or DHT was administered prenatally. Only prenatal testosterone-treated 
sheep displayed an increased number of growing follicles, whereas animals treated 
with the non-aromatizable DHT were similar to controls. Smith et al. (33) concluded 
that estrogenic programming affects postpubertal follicular recruitment and growth, 
and androgenic programming only plays a role prenatally. However, in rats postnatal 
exposure to high testosterone levels lead to extensive follicle loss, whereas low doses 
of testosterone had no effect on follicular morphology (24). These results suggest 
that depending on the concentration of androgens used, opposing effects on follicle 
growth can be observed. In our study, mice were exposed to relatively high DHT lev-
els, which might explain the lack of increased follicle growth. In addition, one cannot 
exclude that androgens have a different effect on folliculogenesis in poly-ovulatory 
species, such as rodents, than in species with single birth and twin/triplet births, such 
as human and sheep. We did observe that ovaries of DHT-treated mice contained a 
significantly higher number of atretic small and large antral follicles. Follicular arrest 
and atresia of these follicular stages suggests the presence of an insufficient FSH surge 
or a reduced sensitivity of these follicles to FSH. The latter has been proposed as the 
main cause of the follicular arrest in PCOS, and is explained by the antagonistic effect 
of androgens, particularly 5α-reduced androgens, on FSH-induced follicular growth 
(35-36). DHT administration reduced FSH-induced estradiol production in primates 
and it inhibited FSH-induced granulosa cell proliferation and induced atresia in rats 
(37-38). Although FSH levels were not determined in our mice, a previous study in rats 
suggests that DHT treatment does not alter the FSH surge and that DHT directly acts 
on the follicles by decreasing granulosa cell number and aromatase activity, resulting 
in reduced estrogen production and increased atresia (39). However, in our DHT-
treated mice, aromatase mRNA expression did not differ from placebo-treated mice.
PCOS is often associated with metabolic dysfunction such as abdominal obe-
sity and impaired insulin sensitivity and, similar to the reproductive disturbances, 
androgens have also been implied in the development of metabolic abnormalities 
in PCOS. Indeed, our results showed that prepubertal mice treated with DHT had 
an increased body weight and that their WAT depots contained significantly more 
enlarged adipocytes.
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Increased adiposity with adipocyte hypertrophy is known to cause altered levels of 
adipokines (40). Adipokines, adipose secreted factors that play an important role in 
metabolic disorders, may be involved in both metabolic and reproductive character-
istics of PCOS. Leptin levels have been shown to increase with increasing adiposity, 
whereas adiponectin levels decrease (41-42). The increase of leptin in PCOS women 
is believed to be the result of their obesity. When leptin levels in PCOS women were 
corrected for BMI, levels did not differ from weight matched controls (43). Also in 
our DHT-treated mice, a body weight-dependent increase in leptin was found. In 
addition to the increased adiposity, the decreased adiponectin levels may also reflect 
a direct effect of DHT on adipocytes, since in cultured rat adipocytes, androgens 
have been shown to suppress the secretion of adiponectin (44). Lower adiponectin 
levels, associated with impaired glucose tolerance, were observed in PCOS women 
compared to BMI matched controls (45-46). In agreement, in our DHT-induced 
PCOS model, mice displayed decreased adiponectin levels independent of body 
weight. Furthermore, DHT-treated mice were indeed glucose intolerant. Impaired 
glucose tolerance can be interpreted as a metabolic state intermediate between nor-
mal glucose homeostasis and diabetes, and is referred to as prediabetes (47). Thus, 
DHT-treated mice are in a prediabetic state, similar to women with PCOS.
Surprisingly, basal fasting insulin levels were not affected by DHT treatment, 
whereas previous studies detected an increase in circulating insulin levels in sheep 
(48), rats (15) and rhesus monkeys (49) upon prenatal androgen exposure. The ab-
sence of changed insulin levels in the DHT-treated mice may be due to the timing of 
androgen administration; prenatal androgen treatment may result in an altered pro-
gramming of glucose homeostasis, whereas postnatal treatment may have no effect. 
Since our DHT-treated mice were unable to suppress glucose levels and probably are 
insulin-resistant to a certain degree, it will be of interest for future studies using our 
DHT-treated mouse model to incorporate insulin tolerance tests.
The effects of DHT on adipocytes and glucose tolerance seen in our mouse model 
resemble the androgenic effect seen in other animal models with increased adiposity 
upon in utero or postnatal exposure to testosterone or DHT. The pro-adipogenic and 
metabolic effects of DHT in our mouse model may also be partly explained by the 
absence of estrogen production by the non-cycling ovaries, since it has been shown 
that a lack of estrogens or estrogen receptor-α (ERα) signaling results in adipocyte 
hyperplasia, hypertrophy, insulin resistance and glucose intolerance (50). Also, es-
trogen receptor-β (ERβ) KO mice, fed a high fat diet, showed increased adiposity, 
although these mice where protected against diet-induced glucose intolerance. Thus, 
based on these results the metabolic phenotype in our DHT-treated mice could be 
explained by a direct androgenic effect, reduced estrogen signaling, or a combination 
of both.
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In conclusion, chronic exposure to DHT excess in prepubertal mice induces a 
reproductive and metabolic phenotype with features in common with PCOS. In 
the future, this treatment regimen can be applied to transgenic mice to study the 
contribution of ovarian growth factors to the reproductive and metabolic phenotypes 
of PCOS.
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Supplemental data
A B 
Supplemental Fig. 1. Immunohistochemical analysis of AMH expression in ovaries of placebo- 
and DHT-treated mice. AMH is expressed in granulosa cells of healthy growing follicles. Expres-
sion disappears in small antral atretic follicles and is absent in the large antral atretic follicles. The 
pattern and intensity of AMH expression did not differ between A) placebo-treated mice and B) 

















Supplemental  Fig. 2. Aromatase mRNA expression in ovaries of placebo- and DHT-treated 
mice. Aromatase mRNA expression did not differ between placebo- (open bar) and DHT-treated 



















Ovarian growth factors contribute to 
the metabolic dysregulation in a mouse 
model of Polycystic Ovary Syndrome
E. Leonie A.F. van Houten, Piet Kramer, Anke McLuskey, Bas Karels, 


















Androgens are known to play an important role in the development of polycystic 
ovary syndrome (PCOS). Indeed, dihydrotestosterone (DHT) treatment of prepu-
bertal mice induces reproductive and metabolic characteristics resembling those 
of women with PCOS. However, little is known about the contribution of ovarian 
growth factors to the metabolic phenotype of PCOS. In order to study their contribu-
tion, we ovariectomized DHT-treated mice and compared their metabolic phenotype 
to intact DHT-treated mice.
Prepubertal female mice received a 90 days continuous release pellet containing 
DHT or vehicle. At day 45 of the treatment period, mice were ovariectomized (OVX) 
or received a sham surgery. Mice were analyzed after 90 days of DHT treatment.
DHT treatment and ovariectomy both resulted in an increase in body weight. 
The combined treatment resulted in a further gain in body weight. DHT treatment 
reduced glucose tolerance, while ovariectomy alone had no effect. Interestingly, 
ovariectomy of DHT-treated mice normalized the glucose tolerance. DHT treatment 
and ovariectomy both increased the weight of white adipose tissues, adipocyte size, 
and lipid accumulation in brown adipose tissue (BAT). Ovariectomy did not alter the 
DHT-induced white adipose tissue (WAT) characteristics. However, in BAT of DHT-
OVX mice lipid accumulation was less pronounced than in DHT-sham mice, which 
is also reflected by the decrease in Hormone Sensitive Lipase (HSL) and the increase 
of Lipoprotein Lipase (LPL) mRNA expression levels in BAT after ovariectomy in 
DHT-treated mice.
In conclusion, androgens are a dominant factor in the development of the meta-
bolic phenotype in our DHT-induced PCOS mouse model. However, removal of 
the ovaries results in a normal glucose tolerance and reduced lipid accumulation in 
BAT. These results suggest that, in addition to androgens, ovarian growth factors may 
contribute to the metabolic phenotype of PCOS.
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Introduction
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders 
in women in their reproductive years affecting 6.5-8% of women (1). According to the 
Rotterdam Criteria, two out of the following three criteria diagnose PCOS: ovarian 
dysfunction characterized by oligo- or anovulation, hyperandrogenism, and the pres-
ence of polycystic ovaries on ultrasound (2). In addition to the ovarian phenotype, 
PCOS is associated with a metabolic phenotype: 38-88% of PCOS women are obese 
and 50-70% of women with PCOS are insulin resistant (3-7).
In women with PCOS, there is a failure in the selection of a dominant follicle. 
Combined with an accelerated early follicular growth, this leads to an accumulation 
of small antral follicles. Although the etiology of PCOS is unknown, the failure in 
dominant follicle selection suggests an altered FSH sensitivity in PCOS ovaries. This 
change in FSH sensitivity can partly be explained by an increased LH/FSH-ratio (8). 
As a consequence, growing follicles are prematurely stimulated by LH to produce 
androgens. Hyperandrogenism is considered to play a significant role in the patho-
physiology of PCOS (9), since there is a strong correlation between hyperandrogen-
ism and phenotype severity. Hyperandrogenic PCOS women have a higher body 
weight, BMI, and waist-hip ratio. They have higher blood glucose levels and are more 
frequently insulin resistant compared to normoandrogenic women with PCOS (10). 
Furthermore, many animal models of PCOS demonstrated that administration of 
androgens induces a reproductive PCOS phenotype but also metabolic disturbances 
(11-13). Indeed, recently we showed that prepubertal dihydrotestosterone (DHT) 
exposure in female mice led to both reproductive and metabolic phenotypes, resem-
bling those observed in women with PCOS. Mice treated with DHT for 90 days were 
in continuous anestrous and their ovaries contained an increased number of atretic 
follicles with the majority having a cyst-like structure. In addition, DHT-treated 
mice had increased body weight, increased adiposity, elevated serum leptin levels, 
and decreased serum adiponectin levels. Furthermore, DHT-treated mice were 
glucose intolerant (14). Thus, androgens play an important role in the development 
of the phenotypic appearance of PCOS. However, it is unknown whether, besides 
androgens, also other growth factors or hormones secreted by the increased follicle 
pool contribute to the metabolic phenotype of PCOS. Previous studies have shown 
that serum levels of the transforming growth factor β (TGFβ) family member anti-
Müllerian hormone (AMH) are 2-3 fold elevated in women with PCOS (15-18). These 
increased serum levels are explained by the increased follicle numbers, but also by an 
increased expression per granulosa cell in women with PCOS (19). Although AMH 
is not expected to have a direct effect on metabolism because its receptors are not 
expressed beyond the reproductive system, other ovarian growth factors potentially 
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could. Receptors of the bone morphogenetic proteins are expressed in metabolic 
tissues, such as adipose tissue and pancreas (20-22). BMPs have been shown to play 
a critical role in white and brown adipogenesis (23-25). Furthermore, studies from 
knockout mice revealed that BMP4 signaling is required for insulin secretion (21). 
Interestingly, expression levels of BMP6 are increased in granulosa cells of PCOS 
women compared with normal healthy women (26), whereas the expression of the 
oocyte-specific GDF9 is decreased in PCOS women (27). However, whether this 
altered ovarian expression also leads to altered serum levels of BMPs is yet unknown. 
Unfortunately, the current sensitivity of the BMP assays, does not allow the detection 
of BMP levels in almost all PCOS patients, as we showed recently (28). In contrast, 
it has been shown that serum levels of Vascular Endothelial Growth Factor (VEGF) 
and basic Fibroblast Growth Factor (bFGF) are elevated in PCOS patients (29, 30). 
VEGF not only is secreted by granulosa cells of the ovary, but also is highly expressed 
in adipose tissue and levels are increased in overweight and obese subjects (31). 
Therefore, not surprisingly, a link between VEGF and metabolism has been estab-
lished. Upregulation of VEGF-A in adipocytes improved their vascularization and 
induced the appearance of a metabolically favourable phenotype, i.e. the presence 
of brown adipocytes in white adipose tissue (WAT). In contrast, in a preexisting dis-
turbed metabolic environment, such as in the obese leptin deficient mice, inhibition 
of VEGF-A can also lead to an improved metabolic phenotype (32). These findings 
suggest that the role of VEGF-A may depend on the metabolic environment. FGFs 
are expressed by ovarian granulosa cells (33), and similar to VEGF, play an important 
role in adipocyte differentiation. FGF2 is expressed in preadipocytes and during dif-
ferentiation FGF2 protein levels dropped coincidental with the appearance of lipid 
droplets (34). These results suggest that factors secreted by the ovary also play a role 
in metabolic tissues, such as WAT. We hypothesize that, in addition to androgens, an 
altered production of ovarian growth factors in PCOS may modulate and contribute 
to the metabolic phenotype.
Removal of ovarian growth factors and hormones through ovariectomy results 
in body weight gain, increased fat accumulation, and also in a worsening of glucose 
tolerance. Although it is known that the acute loss of estrogens plays an important 
role in these metabolic changes, it is unknown to which extent the loss of other ovar-
ian hormones and secreted growth factors contribute to these metabolic changes. In 
order to study the contribution of ovarian growth factors to the metabolic phenotype 
in PCOS, we analyzed the metabolic phenotype in our DHT-induced PCOS mouse 
model after ovariectomy.
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Materials and methods
Animals
C57BL/6J wild-type female mice were obtained from the Animal Facility of the 
Erasmus MC (Rotterdam, The Netherlands) and were kept under standard animal 
housing conditions in accordance with the National Institutes of Health guidelines 
for the Care and Use of Experimental Animals. The experiments were performed 
with permission of the local ethics committee.
At postnatal day 19, mice of comparable body weight were randomly divided over 
two treatment groups (DHT and control), and were implanted subcutaneously with 
a 90-day continuous release pellet containing 2.5 mg of DHT or a placebo pellet 
(Innovative Research of America, Sarasota, FL, USA), as described previously (14). 
At day 45 of the treatment period, DHT- and placebo-treated mice were randomly 
divided over two intervention groups (ovariectomy (OVX) or sham surgery; n=6-10 
per group). Mice were anesthetized with isoflurane and an incision was made in both 
flanks to remove the ovaries or as a sham surgery. Mice were sacrificed at the end 
of the treatment period (90 days). Body weight was measured every two weeks. At 
the end of the experiment blood samples were collected. Uteri and ovaries from the 
sham groups were isolated, weighed, and fixed overnight in Bouin’s fluid or snap 
frozen in liquid nitrogen and stored at −80°C until further processing. In addition, 
white and brown adipose depots were isolated, weighed, and fixed overnight in 4% 
paraformaldehyde or stored at −80°C for further analysis.
Ovarian histology
Ovaries of ovariectomized placebo- and DHT-treated mice were fixed overnight 
in Bouin’s fluid and processed as described previously (14). Eight μm sections were 
mounted on glass slides and stained with hematoxylin and eosin for histological 
examination.
Real time PCR
Total RNA was isolated from the different fat depots, using an RNeasy Mini Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s instructions. RNA samples 
were treated with Dnase (Promega Benelux BV, Leiden, The Netherlands) prior to 
cDNA synthesis. cDNA was synthesized using a cDNA synthesis kit (Roche Applied 
Sciences, Almere, the Netherlands). Real-time PCR (RT-PCR) was performed as de-
scribed previously (14). Briefly, RT-PCR was performed with SYBR Green (Applied 
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Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) using an ABI 7900 HT ap-
paratus. The expression of the target genes was normalized to the average expression 
level of three housekeeping genes (β2-microglobulin, hypoxanthine-guanine phos-
phoribosyl transferase (HPRT), and ribosomal protein S29) using the 2-ΔΔCt method 
(35). Primers of target and housekeeping genes are shown in Table 1.
Intraperitoneal glucose tolerance test
Glucose tolerance was measured using an intraperitoneal glucose tolerance test 
(IPGTT) as described previously (14). In short, after an overnight fast (16h), basal 
glucose levels were measured using a Freestyle mini glycometer and test strips (Ab-
bott, Alameda, CA). Next, 2% glucose was injected intraperitoneally and glucose 
levels were measured 15, 30, 60 and 120 minutes after the injection.
Hormone measurements
Plasma insulin levels were determined using an ultrasensitive mouse insulin ELISA. 
C-peptide serum levels were measured using a Mouse C-peptide ELISA. Total 
adiponectin serum levels were measured with an Adiponectin (Mouse) Total, HMW 
ELISA. Leptin levels were measured with a Leptin (Mouse/Rat) ELISA (all assays, 
Alpco Diagnostics, Salem, NH, USA). All samples were measured in one assay. DHT 
levels were measured with a DHT ELISA (Diagnostics Biochem Canada Inc. On-
tario, Canada). Triglycerides were measured with an ABX PENTRA Triglycerides CP 
reagent with associated calibrators (HORIBA ABX, Montpellier, France). Glycerol 
Table 1. Primer sequences
Gene Sequence (5′-3′) Accession number








Rps29 Ribosomal protein S29 F: tgaaggcaagatgggtcac
R: gcacatgttcagcccgtatt
NM_009093.2
HSL Hormone Sensitive Lipase F: cgctacacacaaaggctgctt
R: ggatggcaggtgtgaactg
NM_001039507.2
ATGL Adipose Triglyceride Lipase F: gagccccggggtggaacaagat
R: aaaaggtggtgggcaggagtaagg
NM_001039507.2
LPL Lipoprotein Lipase F: gctggtgggaaatgatgtg
R: tggacgttgtctagggggta
NM_008509.2
CD36 Fatty Acid Translocase F: cctccagaatccagacaacc
R: cacaggctttccttctttgc
NM_008509.2
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and non-esterified fatty acids (NEFA) were measured by enzymatic calorimetric 
procedure using a glycerol or a NEFA-HR kit (both Instruchemie, Delfzijl, The 
Netherlands).
Measurement of adipocyte size and quantification of lipid droplets
To determine the adipocyte size distribution in white adipose tissues (WAT), four 
mice per group were randomly selected. Mounted sections of 8 µm, stained with 
hematoxylin and eosin (HE), were randomly selected per fat depot and three mi-
crographs were taken with a 100x magnification. Next, the diameter of at least 130 
adipocytes per micrograph was measured using ImageJ software (version 2.0; http://
imagejdev.org), followed by the calculation of the number of adipocytes per similar 
size class with intervals of 2 µm.
To determine the lipid droplet content in brown adipose tissue (BAT), three mice 
per group were randomly selected. HE-stained sections of 8 µm were randomly 
chosen and per mouse five micrographs were taken with a 100x magnification. Im-
ageJ software was used to transform the micrographs into 8-bit grayscale images to 
calculate the lipid droplet content.
Immunohistochemistry
Immunohistochemistry was performed as described previously (14). Briefly, sections 
were mounted, deparaffinized, blocked for endogenous peroxidase activity, washed 
with water and transferred to PBS. After antigen retrieval, sections were incubated 
overnight with an Uncoupling Protein 1 (UCP1) rabbit polyclonal antibody (1:1000) 
(Abcam, Cambridge MA, USA). Next, sections were incubated with Brightvision 
poly-HRP-Anti Ms/Rb/Rt IgG kit (Immunologic, Duiven, The Netherlands) and the 
peroxidase activity was developed with 0.07% 3,3-diaminobenzidine tetrahydrochlo-
ride (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Finally, all sections 
were counterstained with hematoxylin.
Statistics
Data were statistically analyzed by two-way ANOVA to measure the effects of treat-
ment (placebo vs. DHT) and procedure (sham vs. OVX) (treatment x procedure). 
When a significant difference was present, Student’s t-test was performed as a post-
hoc test. Body weight gain and IPGTT were analyzed by two-way repeated measures 
(RM) ANOVA (treatment x procedure), followed by a one-way ANOVA analysis as 
a posthoc test. The adipocyte size distribution was analyzed by three-way ANOVA 
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(treatment x procedure x size). All statistical analyses were performed using SPSS, 
version 20.0 (SPSS, Inc., Chicago, IL). Data were expressed as mean ± SEM, and 
differences were considered significant at P<0.05.
Results
Ovarian histology
Analysis of the ovaries removed during the ovariectomy procedure revealed that 45 
days of DHT treatment was sufficient to induce the ovarian PCOS-like phenotype. 
After 45 days of treatment, ovaries of DHT-exposed mice already lacked corpera 
lutea and contained large cyst-like follicles with a hyperplastic theca cell layer and a 
thin granulosa cell layer. This ovarian phenotype was similar to that observed after 90 
days of DHT treatment (Supplemental Figure 1).
Increased body weight but normal glucose tolerance after combined ovariectomy 
and DHT treatment
In our previous study we observed that DHT treatment resulted in increased body 
weight and reduced glucose tolerance (14). To characterize the contribution of 
ovarian hormones and growth factors to this metabolic phenotype, we determined 
the effect of ovariectomy on body weight in placebo- and DHT-treated mice. By 
two-way RM ANOVA analysis, there was a significant effect of both treatment and 
procedure on body weight (both P<0.001) (Figure 1A). DHT treatment resulted in a 
significant increase in body weight compared to placebo-treated mice (P<0.001, by 
post-hoc analysis). This increase in body weight in DHT-treated mice was already 
present prior to ovariectomy, i.e. day 45 of DHT treatment (P<0.001, by post-hoc 
analysis). Ovariectomy at day 45 of treatment resulted in a significant weight gain 
in both placebo- and DHT-treated mice (P=0.006 and P<0.001, respectively, by 
posthoc analysis) (Figure 1A). As a consequence, at the end of the treatment period 
DHT-sham and placebo-OVX mice had a comparable increased body weight, while 
DHT-OVX mice had the highest body weight.
In addition, we determined the glucose tolerance of these mice. Two-way RM 
ANOVA analysis indicated a borderline significant interaction between treatment 
and procedure (P=0.053). In agreement with our previous study, DHT-sham mice 
had an impaired glucose tolerance compared to placebo-sham mice (P=0.012, by 
posthoc analysis) (Figure 1B). Interestingly, DHT-OVX mice had a significantly bet-
ter glucose tolerance than DHT-sham mice (P=0.016, by posthoc analysis), and did 
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Figure 1. Ovariectomy increases body weight but normalizes glucose tolerance in DHT-treated 
mice.
A) Body weight of plc-sham (dotted grey line), plc-OVX (solid grey line), DHT-sham (dotted black 
line) and DHT-OVX (solid black line) mice was measured every 2 weeks, starting at 19 days of age 
(d0 of DHT treatment) until 90 days of DHT treatment. Ovariectomy was performed at day 45 
of DHT treatment, indicated by the arrow. Two-way RM ANOVA revealed a significant effect of 
both treatment (P<0.001) and procedure (P<0.001) on body weight. B) The intraperitoneal glucose 
tolerance test was performed 5 days before sacrifice in plc-sham (dotted grey line), plc-OVX (solid 
grey line), DHT-sham (dotted black line) and DHT-OVX (solid black line) mice. Two-way RM 
ANOVA revealed a borderline significant interaction between treatment and procedure (P=0.053) 
on glucose tolerance. Post-hoc analysis indicated a significant effect of ovariectomy on glucose tol-
erance in the DHT-treated mice (P=0.016). C) Corresponding 0-120 minutes AUC values in sham 
(open bars) and ovariectomized (black bars) placebo- and DHT-treated mice. Two-way ANOVA 
indicated a borderline significant interaction between treatment and procedure (P=0.060). Data 
represent mean ± SEM (n=6-10).
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not differ from plc-sham mice. Ovariectomy had no effect on the glucose tolerance 
of placebo-treated mice (Figure 1B). Similarly, there was a borderline significant 
interaction between treatment and procedure by two-way ANOVA analysis for the 
0-120 min AUC values (P=0.060) (Figure 1C).
Ovariectomy does not alter the adiposity of DHT-treated mice
To understand the normal glucose tolerance combined with the increased body 
weight in DHT-OVX mice, we next analyzed WAT depots. By two-way ANOVA, 
there was a significant interaction between treatment and procedure for the relative 
weight of all WAT depots (Figure 2A). Gonadal, subcutaneous, inguinal, and retro-
peritoneal WAT depots (gWAT, sWAT, iWAT, and rWAT) showed a significant in-
crease in weight after DHT treatment in sham operated mice (P=0.001, 0.003, 0.004, 
and 0.033, respectively, by post-hoc analysis) (Figure 2A). Ovariectomy resulted in a 
significant increased weight of all WAT depots in placebo-treated mice (P<0.001 for 
all WAT depots, by post-hoc analysis) (Figure 2A). Interestingly, ovariectomy did not 
result in a further increase in WAT depot weight in DHT-treated mice, despite the 
increase in body weight in DHT-OVX mice.
Gross morphological analysis of the sWAT depot of DHT-sham mice showed that 
adipocytes were enlarged compared to placebo-treated mice (Figure 2B), which is 
in agreement with our previous study (14). Measurement of the adipocyte cell di-
ameter confirmed that sWAT of DHT-sham mice contained more large adipocytes 
than placebo-sham mice (P<0.001, by posthoc analysis) (Supplemental Figure 2). 
This is also reflected by the increased average adipocyte diameter in DHT-sham 
Figure 2. No effect of ovariectomy on adiposity of DHT-treated mice.
A) Percentage adipose depot weight relative to body weight in sham (open bars) and ovariectomized 
(black bars) placebo- and DHT-treated mice. Two-way ANOVA indicated a significant interaction 
between treatment and procedure for relative weight of gonadal WAT (gWAT) (P=0.047), subcuta-
neous WAT (sWAT) (P=0.040), inguinal WAT (iWAT) (P=0.001) and retroperitoneal WAT (rWAT) 
(P=0.008). Data represent mean ± SEM (n=6-10). Significant differences for the effect of DHT 
treatment in sham-operated mice by posthoc tests: *, P<0.05; **, P<0.01; ***, P<0.001. Significant 
effect of ovariectomy in placebo-treated mice: ###, P<0.001. B) Representative HE-stained section of 
sWAT of plc-sham, plc-OVX, DHT-sham and DHT-OVX mice. C) Adipocyte size distribution of 
sWAT. Upper graph: plc-sham (open circles) vs. plc-OVX (closed black circles) mice. Lower graph: 
DHT-sham (open triangles) vs. DHT-OVX (closed triangles) mice. Two-way ANOVA indicated 
a significant interaction between treatment and procedure (P<0.001). Posthoc analysis indicated 
a significant effect of ovariectomy on the adipocyte size in placebo-treated mice (upper graph) 
(P<0.001), but not in DHT-treated mice (lower graph). In each group the diameter of a total of 130 
adipocytes was measured in three randomly selected sections per mouse. Data represent mean ± 
SEM (n=4 mice per group).




























































































































































































































mice (plc-sham: 46.0 ± 3.3 µm vs. DHT-sham: 80.8 ± 6.8 µm, P=0.004, by posthoc 
analysis). Morphological analysis of the sWAT depot revealed that ovariectomy alone 
increased adipocyte size but did not have an additional effect on adipocyte size in 
the DHT-treated mice (Figure 2B). The increase in adipocyte size in plc-OVX mice 
was confirmed by the right sided shift in the size distribution compared to plc-sham 
mice (P<0.001, by posthoc analysis) (Figure 2C), and by the increase in average 
adipocyte diameter (plc-sham: 46.0 ± 3.3 µm vs. plc-OVX: 74.8 ± 9.3 µm, P=0.027, by 
posthoc analysis). In contrast, ovariectomy did not affect adipocyte size distribution 
in DHT-treated mice (Figure 2C), which is also reflected by the comparable average 
adipocyte diameter in DHT-sham and DHT-OVX mice (DHT-sham: 80.8 ± 6.8 µm 
vs. DHT-OVX: 72.1 ± 5.9 µm, P=0.371, by posthoc analysis).
Ovariectomy does not alter leptin and C-peptide levels in DHT-treated mice
Next, we measured serum hormones, adipokines, and lipid levels to gain insight into 
the normalized glucose tolerance in the presence of unchanged fat depot weights 
upon ovariectomy in DHT-treated mice (Table 2). Two-way ANOVA analysis in-
dicated a significant effect of both treatment (P=0.026) and procedure (P=0.03) on 
Table 2. Hormone levels in sham and ovariectomized placebo- and DHT-treated mice
Plc-sham Plc-OVX DHT-sham DHT-OVX
Basal glucose levels (mM) 3.60 ± 0.57 4.33 ± 0.22 5.05 ± 0.44* 5.01 ± 0.50
Insulin (ng/ml) 0.37 ± 0.10 0.68 ± 0.08 1.37 ± 0.30* 1.41 ± 0.20¶¶
C-peptide 464.77 ± 70.16 807.48 ± 110.27 1087.97 ± 205.14* 1435.94 ± 300.17
Leptin (ng/ml) 1.46 ± 0.18 7.81 ± 2.04## 7.92 ± 1.92** 9.23 ± 1.81
Adiponectin (μg/ml) 29.32 ± 2.52 30.95 ± 2.83 14.71 ± 1.51*** 12.14 ± 0.69¶¶¶
Triglycerides 0.74 ± 0.07 0.88 ± 0.05 1.02 ± 0.12 1.09 ± 0.12
Glycerol 0.42 ± 0.03 0.47 ± 0.02 0.45 ± 0.02 0.47 ± 0.03
NEFA 1.00 ± 0.14 1.04 ± 0.04 1.00 ± 0.08 0.98 ± 0.07
Nineteen-days-old female mice (T0) were treated with a DHT or placebo pellet for 90 days. Ovari-
ectomy or sham surgery was performed on day 45 of the treatment period (T45). Serum samples 
were collected at the end of the 90-day treatment period (T90). For fasting insulin levels, plasma 
samples were collected at the start of the ip glucose tolerance test, which was performed at the end 
of the experiment. Two-way ANOVA indicated a significant effect of treatment on basal glucose, 
insulin, C-peptide, leptin, adiponectin, and triglyceride levels (2WA t: P=0.025, P<0.001, P=0.002, 
P=0.026, P<0.001, and P=0.015, respectively), and a significant effect of procedure on leptin levels 
(2WA p: P=0.03). Values represent mean ± SEM (n = 6-8 mice per group). Significant differences by 
post-hoc test between plc-sham and DHT-sham mice: *, P<0.05; **, P<0.01, ***, P<0.001; between 
plc-OVX and DHT-OVX mice: ¶, P<0.01; ¶, P<0.001; between placebo-sham and placebo-OVX: 
##, P<0.01.
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leptin levels. DHT treatment resulted in a 5.4-fold increase in leptin levels in the 
sham-operated mice (P=0.005, by post-hoc analysis). Ovariectomy significantly 
increased leptin levels in placebo-treated mice (P=0.008, by post-hoc analysis) to 
comparable levels as observed in DHT-sham mice, but did not further elevate leptin 
levels in DHT-treated mice (Table 2). Two-way ANOVA analysis indicated that DHT 
treatment significantly reduced adiponectin levels (P<0.001), while ovariectomy had 
no effect on adiponectin levels. Likewise, DHT treatment significantly increased 
triglyceride levels (P=0.015), while ovariectomy had no effect. There were no sig-
nificant differences present in glycerol and NEFA profiles upon DHT treatment or 
ovariectomy. Two-way ANOVA analysis revealed a significant effect of treatment on 
insulin and C-peptide levels (P<0.001 and P=0.002, respectively), while ovariectomy 
tended to affect only C-peptide levels (P=0.07). C-peptide and insulin levels were 
significantly increased after DHT treatment in sham-operated mice (P=0.016 and 
P=0.012, respectively, by posthoc analysis) (Table 2).
Ovariectomy does not alter the decreased BAT activity upon DHT treatment
Brown adipose tissue (BAT) plays an important role in the regulation of energy 
expenditure and adiposity. Therefore, we determined whether BAT activity was af-
fected in our mice. DHT treatment resulted in a significant increase in weight of 
the intrascapular BAT depot (P<0.001, by posthoc analysis), while ovariectomy had 
no effect on BAT weight in either placebo- or DHT-treated mice (data not shown). 
Morphological analysis of BAT of plc-sham mice showed a compact structure with 
the presence of multilocular lipid droplets (Figure 3A). DHT treatment resulted 
in a profound accumulation of lipids, resulting in the presence of unilocular lipid 
droplets in BAT (Figure 3A). Lipid accumulation also occurred after ovariectomy in 
BAT of placebo-treated mice, although the lipid droplets appeared smaller compared 
to DHT-treated mice (Figure 3A). In the DHT-treated mice, ovariectomy slightly 
decreased the DHT-induced lipid accumulation, since the lipid droplets in BAT of 
DHT-OVX mice appeared smaller compared to those of DHT-sham mice. Two-
way ANOVA analysis of the total lipid content in BAT confirmed that there was a 
significant interaction between treatment and procedure (P<0.001). Indeed, DHT 
treatment induced a significant increase in BAT lipid content (P=0.001, by post-hoc 
analysis) (Figure 3B). Also ovariectomy increased the BAT lipid content of placebo-
treated mice (P=0.001, by post-hoc analysis), but this increase was significantly less 
than in DHT-treated mice (P=0.02, by post-hoc analysis). In DHT-treated mice, 
ovariectomy slightly reduced the BAT lipid content, which was borderline significant 
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In addition, we performed immunohistochemistry for UCP1, a marker for BAT 
activity. UCP1 showed a decrease in staining intensity upon DHT treatment and 
ovariectomy, although the decrease seemed less strong upon ovariectomy. In agree-
ment with the lower lipid accumulation, UCP1 staining intensity appeared to be 
slightly stronger in BAT of DHT-OVX mice compared to DHT-sham mice (Figure 
3A).
DHT-treated ovariectomized mice do not exhibit an increased lipolysis
To determine whether the change in adipocyte size in WAT and lipid accumulation 
in BAT was accompanied by a change in lipolysis and lipogenesis, we determined 
mRNA levels of the lipolytic genes Hormone Sensitive Lipase (HSL) and adipose 
TG lipase (ATGL) and the lipogenic genes lipoprotein lipase (LPL) and CD36, also 
known as fatty acid translocase. In sWAT, DHT treatment, ovariectomy, or the com-
bination, had no effect on mRNA expression of these lipolytic and lipogenic genes 
(data not shown). In BAT, however, analysis by two-way ANOVA revealed a sig-
nificant interaction between treatment and procedure for both HSL and LPL mRNA 
expression (P=0.008 and P=0.010, respectively), while there was no significant effect 
on the mRNA expression of ATGL and CD36. HSL mRNA expression was increased 
in DHT-sham mice compared to plc-sham (P=0.026, by post-hoc analysis). Interest-
ingly, upon ovariectomy HSL mRNA expression in the DHT-treated mice decreased 
to expression levels observed in placebo-sham mice (P=0.028, by post-hoc analy-
sis) (Figure 4). LPL mRNA expression was decreased to a similar extend by DHT 
treatment (P=0.045, by posthoc analysis) and ovariectomy, although the latter only 
reached borderline significance (P=0.057, by posthoc analysis). In contrast, ovariec-
tomy tended to increase LPL mRNA expression in DHT-treated mice (P=0.056, by 
post-hoc analysis) (Figure 4).
Figure 3. Ovariectomy partly protects against lipid accumulation and a decreased UCP activity in 
BAT of DHT-treated mice.
A) HE-stained section and adjacent section with immunohistochemical UCP1 expression in BAT 
of plc-sham, plc-OVX, DHT-sham and DHT-OVX mice. DHT-treatment increased lipid accumu-
lation and decreased UCP1 expression in BAT. With the combined treatment lipid droplets ap-
peared slightly smaller and UCP1 expression seemed stronger than upon DHT treatment alone. 
B) Percentage of lipid droplet content in BAT. Two-way ANOVA indicated a significant interaction 
between treatment and procedure on the lipid droplet content (P<0.001). DHT treatment increased 
the lipid content, while ovariectomy slightly reduced this increase (P<0.001 and P=0.054, respec-
tively, by posthoc analysis). In each group, 3 mice were randomly selected and the lipid content was 
measured in five sections per mice. Data represent mean ± SEM (n=3 mice per group).
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Discussion
In this study, we investigated whether ovarian growth factors contribute to the meta-
bolic phenotype observed in the DHT-induced PCOS mouse model. In agreement 
with our previous study (14), mice treated with DHT became glucose intolerant. 
However, we observed that ovariectomy prevented this DHT-induced glucose intol-
erance. This normalized glucose tolerance in DHT-OVX mice was surprising because 
ovariectomy did not affect the DHT-induced increase in adipose depot weights or 
adipocyte size. Basal glucose and insulin levels were not different between the two 
groups. However, C-peptide levels were increased, although not significantly, in the 
DHT-OVX mice indicating that the endogenous insulin production by the pancreas 
may be elevated, which might partially explain the improved glucose tolerance in 
DHT-OVX mice. In addition, we observed an increase in body weight without a 
further increase in adiposity in DHT-OVX mice, which might suggest an enhance-
2WA t x p 
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Figure 4. Analysis of lypolytic and lypogenic genes in BAT of ovariectomized DHT-treated.
A) mRNA expression of the lipolytic genes HSL and ATGL and the lipogenic genes LPL and CD36 
in BAT of sham and ovariectomized placebo- or DHT-treated mice. Two-way ANOVA indicated a 
significant interaction between treatment and procedure for the expression of HSL (P=0.008) and 
LPL (P=0.01). Significant effect of DHT treatment in sham-operated mice: *, P<0.05. Significant 
effect of ovariectomy in DHT-treated mice: $, P<0.05.
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ment of the anabolic effect of DHT after ovariectomy. This may lead to a stronger 
increase in lean body mass in DHT-OVX mice compared to DHT-sham mice, which 
might contribute to the improved glucose tolerance. However, we did not observe 
a difference in muscle or heart weight relative to body weight between the studied 
groups (data not shown). For future studies, DEXA scans, which were not available 
for the current study, are needed to determine whether indeed a change in lean body 
mass occurred with the combined treatment.
In contrast to our results, McInnes et al (36) showed that DHT treatment com-
bined with ovariectomy in mice did lead to an increase in fat depot weight. However 
in their study, DHT treatment was initiated at the time of ovariectomy at an age of 
one year, when ovaries of mice are already nearly depleted of follicles (37), which 
makes the two models impossible to compare.
Ovariectomy did not appear to alter the function of DHT-exposed WAT. Leptin 
and adiponectin levels were not significantly different between the DHT-sham and 
DHT-OVX mice and also mRNA expression of lipolytic and lipogenic genes in WAT 
did not change between these two groups. In contrast, our results suggest that ovari-
ectomy affects the function of BAT. BAT is specialized in energy expenditure and an 
increase in BAT activity can partially explain an improvement in metabolism. In this 
study, DHT treatment led to an increased BAT depot weight, due to an accumulation 
of unilocular lipid droplets and decreased UCP1 staining in BAT. These results are in 
agreement with results observed in female mice overexpressing LH (38), that have 
increased BAT depot weights combined with reduced thermogenic capacity, due to 
elevated androgens levels in response to the overexpressed LH. Similarly, ovariectomy 
increased lipid accumulation of BAT, although this effect seemed weaker compared 
to DHT treatment. Interestingly, also with the combined treatment, the increase in 
lipid accumulation and reduction in UCP1 expression was less pronounced than with 
DHT treatment alone. The combined treatment also normalized or tended to nor-
malize the DHT-induced changes in HSL and LPL mRNA expression in BAT. These 
findings suggest that removal of the ovaries reduces the negative metabolic effect of 
DHT on BAT. Although ovariectomy only partly counterbalanced the effects of DHT 
on BAT, this improvement may be sufficient to lead to a better energy expenditure, 
and thereby also contribute to the normal glucose tolerance in DHT-sham mice 
compared to DHT treatment alone.
Ovariectomy, and thus the removal of estrogens and ovarian growth factors, 
has been extensively studied in various species like monkeys, rats, mice and sheep 
(39-43). Despite the difference in timing and duration of ovariectomy, most stud-
ies showed a worsening of metabolic parameters upon ovariectomy, such as body 
weight increase, glucose intolerance and higher levels of circulating lipids (44-46). In 
this study, ovariectomy led to metabolic disturbances, such as body weight increase, 
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increased adiposity and increased lipid accumulation in BAT. However, we did not 
observe a worsening in glucose intolerance. This discrepancy has also been reported 
in previous studies, in which glucose intolerance was only observed when ovariec-
tomy was combined with an extra stressor such as a high fat diet (42, 47). It is well 
known that the loss of estrogens upon ovariectomy causes these changes in metabo-
lism. After menopause, women gain body weight (48), but also have elevated plasma 
triglyceride concentrations (49). However, a loss of estrogens alone does not explain 
the difference in metabolic phenotype of DHT-sham and DHT-OVX mice because 
the DHT-treated mice lack preovulatory follicles and thus already have low estrogen 
levels. Indeed, uterine weight, which was measured as readout of estrogen action, 
was decreased to a similar extent in DHT-sham and DHT-OVX mice (results not 
shown). Therefore, we rationalize that, in addition to androgens, also ovarian growth 
factors contribute to the metabolic phenotype of DHT-treated mice. In contrast to 
the ovarian phenotype observed in women with PCOS, ovaries of the DHT-exposed 
mice do not contain more healthy growing follicles, but do have an increased num-
ber of atretic growing follicles (14). Therefore, it remains to be determined whether 
the growth factors influencing metabolism are secreted from the healthy or atretic 
growing follicle pool. Furthermore, it remains to be determined whether follicles of 
women with PCOS secrete the same factors and whether also in women with PCOS 
these factors contribute to the metabolic phenotype.
To conclude, our study demonstrates that androgens are a dominant factor in 
the development of the metabolic phenotype. However, our findings also show that 
removal of the ovary prevents or improves these metabolic alterations, suggesting 
that ovarian growth factors contribute to the metabolic phenotype observed in our 
DHT-induced mouse model. Whether these ovarian growth factors also contribute 
to the metabolic phenotype of women with PCOS will need to be determined in the 
future.
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Supplemental Figure 1. Ovarian morphology of placebo and DHT-treated mice.
HE-stained ovarian sections of A) a normal cycling placebo-treated mouse with healthy growing 
follicles and corpora lutea (CL); B) an acyclic DHT-treated mouse with several cyst-like follicles 
and absence of CL after 45 days of treatment; C) an acyclic DHT-treated mouse with several cyst-
like follicles and absence of CL after 90 days of treatment. Magnification 40x. D, E, and F: Higher 
magnification (100x) of the boxed area in A, B, and C, respectively. Arrows indicate the presence of 
apoptotic granulosa cells in the cyst-like follicles.
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Supplemental Figure 2. Increased number of large adipocytes upon DHT-treatment.
Adipocyte size distribution in sWAT. Upper graph: plc-sham (open circles) vs DHT-sham (open 
triangles) mice. Lower graph: plc-OVX (closed circles) vs DHT-OVX (closed triangles) mice. 
Two-way ANOVA indicated a significant interaction between treatment and procedure (P<0.001). 
Posthoc analysis indicated a significant effect of DHT treatment on the adipocyte size in sham-
operated mice (upper graph) (P<0.001), but not in ovariectomized mice (lower graph). For clarity 
adipocyte size distribution graphs are presented per procedure. In each group the diameter of a to-
tal of 130 adipocytes was measured in three randomly selected sections per mouse. Data represent 
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Polycystic ovary syndrome (PCOS) is a disorder associated with infertility and 
metabolic disturbances. Hyperandrogenism is an important hallmark of PCOS and 
contributes to the metabolic phenotype. An increased number of growing follicles is 
another important feature. However, the contribution of ovarian growth factors to 
the metabolic phenotype of PCOS has not been investigated. To determine the inter-
action between ovarian and metabolic function, we studied the metabolic phenotype 
of mice lacking anti-Müllerian hormone (AMH) signaling as a model for an altered 
profile in ovarian growth factors.
Female mice lacking AMH (AMHKO) or its type II receptor (MRKI) and wildtype 
(WT) littermates were analyzed at 4, 5, and 8 months of age. AMHKO and MRKI mice 
had a normal body weight, but displayed an improved glucose tolerance compared 
to WT mice at 5 months of age (P<0.002). AMHKO and MRKI mice had reduced 
adiposity, with white adipose tissue (WAT) depots containing smaller adipocytes 
(P<0.001). In agreement, leptin levels were 40-80% reduced in AMHKO and MRKI 
mice (P<0.001 and P=0.007, respectively). Interestingly, mice lacking AMH signal-
ing had more active brown adipose tissue (BAT) and displayed increased browning 
of subcutaneous WAT, illustrated by an increased UCP1 staining, compared to WT 
mice. At 8 months of age, AMHKO mice continued to have smaller adipocytes 
(P<0.001), lower leptin levels (P<0.05), and tended to have an improved glucose tol-
erance (P<0.07) combined with lower insulin levels (P<0.05) compared to WT mice.
In conclusion, in the absence of AMH signaling mice are protected against the 
age-related decline in metabolism. This suggests that an altered profile in ovarian 
growth factors may affect metabolism and may modulate the effect of metabolic ag-
ing.
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Introduction
Polycystic Ovary Syndrome (PCOS) is the most common endocrinopathy in 
premenopausal women, with a prevalence of up to 10% in the general population 
(1). PCOS is characterized by two out of the following three criteria being present: 
hyperandrogenism, oligo/anovulation and polycystic ovaries (2). Ovaries of women 
with PCOS show an increased accumulation of small antral follicles and an aberrant 
selection of a dominant follicle, suggesting a decrease in FSH sensitivity (3). Although 
the etiology of PCOS is unknown, the excess in androgen levels is considered the 
main culprit in PCOS.
In addition to a reproductive phenotype, PCOS patients also often display a meta-
bolic phenotype; 38-88% (depending on the study) of the PCOS women are obese and 
50-70% are insulin resistant (4-8). Metabolic aberrations include glucose intolerance 
and type II diabetes mellitus. The excess in androgen levels is considered to induce 
multiple metabolic effects in women with PCOS (9). Indeed non-human primate 
and sheep animal models of PCOS demonstrated that prenatal exposure to testos-
terone resulted in metabolic disturbances (10, 11). In addition, we recently showed 
that prepubertal dihydrotestosterone (DHT) treatment of mice not only resulted in 
a reproductive but also in a metabolic phenotype resembling PCOS (12). However, 
several studies suggest that non-hyperandrogenic PCOS women may have an adverse 
metabolic phenotype compared to non-PCOS women. Non-hyperandrogenic PCOS 
women have an increased waist-hip-ratio compared to BMI-matched non-PCOS 
women (13). Furthermore, when matched for age and BMI, non-hyperandrogenic 
PCOS women remain to have elevated insulin levels and HOMA-IR (14), suggesting 
that androgens are not the sole driver of the metabolic phenotype in PCOS. Since 
ovaries of women with PCOS contain an increased number of small growing follicles, 
a contribution of an altered ovarian growth factor profile to the metabolic phenotype 
of PCOS cannot be ruled out. Studies have already shown that ovarian growth fac-
tors, especially members of the transforming growth factor β (TGFβ) family, may 
play a role in the ovarian pathogenesis of PCOS. For example, the mRNA expression 
level of growth differentiation factor 9 (GDF9) is reduced in PCOS (15), while expres-
sion of anti-Müllerian hormone (AMH) and bone morphogenetic protein 6 (BMP6) 
is increased in granulosa cells of PCOS women (16-18). Furthermore, reflecting the 
increased number of growing follicles and the increased expression per granulosa 
cell, serum levels of AMH are elevated in women with PCOS (19, 20). This may sug-
gest that serum levels of other ovarian growth factors are also altered in women with 
PCOS.
To determine whether an altered profile of ovarian growth factors indeed contrib-
utes to the regulation of metabolism, we have used mice lacking AMH (AMHKO) 
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or its specific type II receptor (MRKI) as a model resembling the increased number 
growing follicles in women with PCOS. AMH is solely expressed in the ovary and 
in the absence of AMH, mice display enhanced recruitment of primordial follicles 
(21). As a result, ovaries of AMHKO mice contain 3- to 4-fold more growing follicles 
compared to wild type mice (22). Mice lacking AMH signaling have a normal ovula-
tion rate and a normal estrous cycle, allowing us to investigate the effect of ovarian 
growth factors secreted by the increased number of growing follicles on metabolism 
independent from cycle irregularities.
Our results revealed that female mice lacking AMH signaling have reduced adi-
posity, with increased browning of white adipose tissues, and an improved glucose 
tolerance with increasing age.
Materials and methods
Animals
AMH knockout mice (AMHKO) and AMH type II receptor, or Müllerian inhibit-
ing substance (MIS) receptor, knockout mice (MRKI) were generated as described 
previously (22,23). The MRKI mice were kindly provided by Dr. R. Behringer. Female 
AMHKO and MRKI mice and wildtype littermates on a C57BL/6J background were 
obtained from the Animal Facility of the Erasmus MC and were group-housed under 
standard animal housing conditions in accordance with the National Institutes of 
Health guidelines for the Care and Use of Experimental Animals. The experiments 
were performed with permission of the local ethics committee. Mice were analyzed 
at 4, 5 and 8 months of age.
To determine the stage of the estrous cycle, daily vaginal smears were taken two 
weeks before the animals were sacrificed and examined as described previously (24). 
Body weight was measured every two weeks. At the end of the experiment ovaries 
and uterus were isolated, weighed, and fixed overnight in Bouin’s fluid or snap frozen 
in liquid nitrogen and stored at −80°C until further processing. In addition, white 
and brown adipose depots were isolated, weighed and either fixed overnight in 4% 
paraformaldehyde or stored at −80°C for further analysis.
Follicle count
After routine histological procedures, 8 µm sections were mounted on glass slides 
and stained with hematoxylin and eosin. Follicle count was performed as described 
previously (24), using one ovary per animal. In brief, follicles were classified based on 
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their mean diameter, which was determined by measuring two perpendicular diam-
eters per section. Primordial, nonatretic and atretic growing follicles were counted in 
every fifth section. The presence of corpora lutea was also determined.
Real-time PCR
Real-time PCR was performed as described previously (12). In short, the qPCR mix-
ture contained 6.25 µl FastStart Universal SYBR Green Master mix (Roche Diagnos-
tics, Almere, The Netherlands), 0.5 µl of forward and reverse primers (1.0 pmol/µl) 
and 4 µl H2O per reaction. The qPCR reaction was performed using an ABI 7900 HT 
apparatus. The expression of the target genes was normalized to the average expres-
sion level of three housekeeping genes (β2-microglobulin, hypoxanthine-guanine 
phosphoribosyl transferase (HPRT), and ribosomal protein S29) using the 2−ΔΔCt 
method (25). Primer sequences of the used target genes are listed in Table 1.
Table 1. Primer sequences
Gene Sequence (5′-3′) Accession number








Rps29 Ribosomal protein S29 F: tgaaggcaagatgggtcac
R: gcacatgttcagcccgtatt
NM_009093.2
Ucp1 Ucoupling protein 1 F: ggcctctacgactcagtcca
R: taagccggctgagatcttgt
NM_009463.3
HSL Hormone Sensitive Lipase F: cgctacacacaaaggctgctt
R: ggatggcaggtgtgaactg
NM_001039507.2
ATGL Adipose Triglyceride Lipase F: gagccccggggtggaacaagat
R: aaaaggtggtgggcaggagtaagg
NM_001039507.2
LPL Lipoprotein Lipase F: gctggtgggaaatgatgtg
R: tggacgttgtctagggggta
NM_008509.2
CD36 Fatty Acid Translocase F: cctccagaatccagacaacc
R: cacaggctttccttctttgc
NM_008509.2





Intraperitoneal glucose tolerance test (IPGTT)
An IPGTT was performed as described previously (12). Glucose levels were measured 
by tail vain blood sampling using a Freestyle mini glycometer and test strips (Abbott, 
Alameda, CA). In brief, mice were fasted overnight (16h) after which a baseline glu-
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cose measurement was performed. Then mice were injected intraperitoneally with 
glucose (2g/kg as a 20% glucose solution) and tail sampling was performed at 15, 30, 
60 and 120 min.
Hormone measurements
Total adiponectin serum levels were determined using an Adiponectin (Mouse) ELI-
SA. Leptin serum levels were measured with a Leptin (Mouse/Rat) ELISA. C-peptide 
serum levels were measured with a Mouse C-peptide ELISA. Plasma insulin levels 
were measured with an ultrasensitive mouse Insulin ELISA (all Alpco Diagnostics, 
Salem, NH). Triglycerides were measured with an ABX PENTRA Triglycerides CP 
reagent with associated calibrators (HORIBA ABX, Montpellier, France). Glycerol 
and non esterified fatty acids (NEFA) were measured by enzymatic calorimetric pro-
cedure using a glycerol or a NEFA-HR kit (both Instruchemie, Delfzijl, The Nether-
lands).
Measurement of adipocyte size
Adipocyte size distribution in white adipose tissue (WAT) was determined as de-
scribed previously (12). Four mice per age and per genotype were randomly chosen, 
and hematoxylin and eosin (HE)-stained sections of 8µm were randomly selected per 
fat depot and three micrographs were taken with a 100x magnification. The diam-
eter of at least 130 adipocytes per micrograph was measured using ImageJ software 
(version 2.0; http://imagejdev.org), followed by the calculation of the number of 
adipocytes per similar size class with intervals of 5 µm.
Immunohistochemistry
Mounted sections of 8µm of both white and brown fat depots were deparaffinized, 
blocked for endogenous peroxidase activity, rinsed with water, and transferred to 
PBS. Following antigen retrieval, sections were incubated overnight with an Uncou-
pling Protein 1 (UCP1) rabbit polyclonal antibody (1:1000) (Abcam, Cambridge MA, 
USA). Next, sections were incubated with Brightvision poly-HRP-Anti Ms/Rb/Rt 
IgG kit (Immunologic, Duiven, The Netherlands) and the peroxidase activity was 
developed with 0.07% 3,3-diaminobenzidine tetrahydrochloride (Sigma-Aldrich 
Chemie BV, Zwijndrecht, The Netherlands). Finally, all sections were counterstained 
with hematoxylin.
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Statistics
SPSS software (version 20.0 SPSS, Inc., Chicago, IL) was used for statistical analysis. 
Two-way ANOVA was used to measure effects of genotype (WT vs. AMHKO vs. 
MRKI) and age (4 vs. 5 months) (genotype x age), followed by post-hoc Tukey’s test 
or Student’s t-test when significant differences were observed. Body weight gain was 
analyzed by two-way repeated measures (RM) ANOVA (genotype x age), followed 
by Bonferroni correction. Three-way RM ANOVA was used to analyzed IPGTT 
(genotype x age x sample time point). The adipocyte size distribution was analyzed 
by three-way ANOVA (genotype x age x size). For analyses at 8 months of age, two-
way RM ANOVA (IPGTT), two-way ANOVA (adipocyte size distribution), and 
Student’s t-test were used. Data were expressed as mean ± SEM, and differences were 
considered significant at P<0.05.
Results
Increased follicle numbers in AMHKO and MRKI mice
Female AMHKO and MRKI mice displayed a regular estrous cycle at 4 and 5 months 
of age. Uterine weight, measured to determine changes in ovarian estrogen produc-
tion, did not differ between the three genotypes at both ages studied (results not 
shown). Ovarian weight of AMHKO and MRKI mice was significantly increased 
compared to WT mice at both 4 and 5 months of age (P<0.001, results not shown). 
Two-way ANOVA revealed that genotype significantly affected the number of 
primordial follicles (P=0.002), number of healthy growing follicles (P<0.001), and 
number of atretic follicles (P<0.001). AMHKO and MRKI mice both displayed a 
2- to 3-fold increase in healthy growing follicles (P<0.001 by post-hoc analysis) and a 
2-fold lower number of primordial follicles (P<0.05 by post-hoc analysis) compared 
to WT mice at 4 and 5 months of age (Supplemental Figure 1A). Furthermore, ovaries 
of AMHKO and MRKI mice contained significantly more atretic follicles compared 
to WT mice at 4 and 5 months of age (P<0.001 by post-hoc analysis) (Supplemental 
Figure 1A).
Normal body weight but improved glucose tolerance in AMHKO and MRKI mice
To characterize the effect of a loss in AMH signaling and the concomitant change 
in follicle number on metabolism we compared body weights of WT, AMHKO and 
MRKI mice up to an age of 5 months. Genotype did not affect body weight (Figure 
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Figure 1. Normal body weight but improved glucose tolerance with increasing age in AMHKO 
and MRKI mice.
A) Body weight was measured for WT mice (open circles), AMHKO mice (closed grey circles) and 
MRKI mice (closed black circles) every 2 weeks, starting at 2 weeks of age until 5 months of age. 
Two-way RM ANOVA revealed no significant effect of genotype on body weight. n = 8-17 mice per 
group. B) The ip glucose tolerance test was performed 5 days before sacrifice at 4 and 5 months of 
age (WT mice, open circles; AMHKO mice, closed grey circles; MRKI mice, open black circles). For 
clarity IPGTT graphs are presented per age. Three-way RM ANOVA indicated a significant interac-
tion between genotype, age, and sample time point (P=0.006). RM ANOVA indicated a significant 
difference between genotypes at 5 months of age (P=0.002), but not at 4 months of age. There was 
a significant effect of age on glucose tolerance in WT mice (P=0.003). C) Corresponding 0-120 
minutes AUC for WT (open bars), AMHKO (grey bars) and MRKI (black bars) mice. Two-way 
ANOVA indicated a significant interaction between genotype and age (P=0.004). Data represent 
mean ± SEM (n = 8-9). **, P<0.01, significant differences from WT of same age; #, P<0.05, signifi-
cant difference between 4 and 5 months, by posthoc tests.
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1A). AMHKO and MRKI mice showed a similar gain in body weight with increasing 
age as WT mice. In addition, we determined the glucose tolerance of these mice. Sta-
tistical analysis indicated a significant interaction between genotype, age, and sample 
time point (P=0.006). Also for the 0-120 min AUC values a significant interaction 
between genotype and age was observed (P=0.004 by two-way ANOVA). Post-hoc 
analysis showed that at 4 months of age glucose levels during the IPGTT and the 0-120 
min AUC values did not differ between genotypes (Figure 1B and C). In contrast, at 5 
months of age AMHKO and MRKI mice had a significantly higher glucose clearance 
than WT mice (P<0.01 by post-hoc analysis, Figure 1B), reflected by significantly 
lower 0-120 min AUC values (P<0.01 by post-hoc analysis) (Figure 1C). Post-hoc 
analysis also indicated that WT mice displayed a significant worsening in glucose 
tolerance with increasing age (P=0.003), which is reflected by the increased 0-120 
min AUC values at 5 months of age compared to 4 months of age (P<0.01 by post-hoc 
analysis). In contrast, AMHKO and MRKI mice did not show this age-dependent 
worsening in glucose tolerance (Figure 1B and C). Fasting glucose and insulin levels 
did not differ between WT, AMHKO, and MRKI mice at both ages. C-peptide levels 
increased in WT mice with increasing age, while this did not occur in the AMHKO 
and MRKI mice (Table 2).
Table 2. Hormone and lipid levels in WT, AMHKO, and MRKI mice.
4 months 5 months
WT AMHKO MRKI WT AMHKO MRKI
Fasting glucose 
(mM)
3.38 ± 0.17 3.48 ± 0.31 4.37 ± 0.28 4.54 ± 0.42 3.57 ± 0.27 4.09 ± 0.23
Insulin (ng/ml) 0.67 ± 0.13 0.64 ± 0.08 0.43 ± 0.16 0.56 ± 0.07 0.83 ± 0.13 0.61 ± 0.14












Leptin (ng/ml) 3.66 ± 0.38 1.48 ± 0.30*** 0.74 ± 0.23*** 4.69 ± 1.20 2.96 ± 0.45 0.81 ± 0.13**
Adiponectin (μg/ml) 34.34 ± 2.03 36.17 ± 1.79 24.21 ± 
2.29**
34.29 ± 1.44 37.88 ± 1.19 25.31 ± 
3.02*
Triglycerides (mM) 0.83 ± 0.06 1.01 ± 0.09 0.69 ± 0.03 0.95 ± 0.06 0.70 ± 
0.03**, ##
0.66 ± 0.05**
Glycerol (mmol/L) 0.51 ± 0.03 0.50 ± 0.03 0.43 ± 0.02 0.52 ± 0.03 0.44 ± 0.03 0.39 ± 0.02*
NEFA (mmol/L) 1.02 ± 0.05 0.97 ± 0.06 0.92 ± 0.05 1.18 ± 0.05 1.11 ± 0.07 0.86 ± 0.09*
Serum samples were collected when mice were 4 months or 5 months old. Two-way ANOVA in-
dicated a significant effect of genotype on leptin, adiponectin, glycerol, and NEFA levels (2WA g: 
P<0.001, P<0.001, P=0.003, and P=0.006, respectively). For c-peptide and triglyceride levels there 
was a significant interaction between genotype and age (2WA g x a: P=0.007 and P=0.003, respec-
tively). Values represent mean ± SEM (n = 8-10 mice per group). *, P<0.05; **, P<0.01; ***, P<0.001, 
significant differences from WT of same age; ##, P<0.01, significant difference between 4 and 5 
months, by posthoc tests.
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Altered adipokine and lipid profile in mice lacking AMH signaling
To elucidate the improved glucose tolerance in AMHKO and MRKI mice during ag-
ing, we measured serum levels of adipokines and lipids. By two-way ANOVA, there 
was a significant effect of genotype on leptin levels (P<0.001) independent of age. 
Leptin levels were 2.5-fold lower in AMHKO mice and 5-fold lower in MRKI mice 
compared to WT mice at 4 months of age (P<0.001 by post-hoc analysis). Leptin 
levels remained decreased in 5- month-old AMHKO and MRKI mice by a comparable 
magnitude, although the difference with WT mice remained significant only for the 
MRKI mice (P<0.01 by post-hoc analysis) (Table 2). Also for adiponectin, a significant 
effect of genotype was observed. Although adiponectin levels did not differ between 
WT and AMHKO mice, levels were significantly lower in MRKI mice at both ages 
studied (P<0.01 and P<0.05, respectively, by post-hoc analysis) (Table 2). There was 
a significant interaction between genotype and age on triglyceride levels (P=0.003). 
Levels were markedly decreased in 5-month-old AMHKO and MRKI mice compared 
to WT mice (P<0.01 by post-hoc analysis). There was a significant effect of genotype on 
serum glycerol and NEFA levels (P=0.006), since levels were significantly decreased 
in 5-month-old MRKI mice (P<0.05 by post-hoc analysis) (Table 2).
Reduced adiposity in mice lacking AMH signaling
To further understand the improved glucose tolerance in AMHKO mice in the pres-
ence of a normal body weight, we analyzed several WAT depots (Figure 2). There was a 
significant effect of genotype on the relative weight of gonadal WAT (gWAT) and sub-
cutaneous WAT (sWAT) (P<0.001). Furthermore, there was a significant interaction 
Figure 2. Reduced adiposity in mice lacking AMH signaling.
A) Percentage adipose depot weight relative to body weight in WT (open bars), AMHKO (grey 
bars), and MRKI mice (black bars). Two-way ANOVA indicated a significant interaction between 
genotype and age for iWAT (2WA g x a: P=0.04). There was a significant effect of genotype on 
gWAT and sWAT (2WA g: P<0.001). Data represent mean ± SEM (n=8-17 except for vWAT: n = 5-8 
mice per group). *, P<0.05; **, P<0.01; ***, P<0.001, significant differences from WT of same age; 
##, P<0.01, significant difference between 4 and 5 months, by posthoc tests. B) Representative HE-
stained section of sWAT of WT, AMHKO, and MRKI mice of 4 and 5 months of age. Scale bar = 100 
μm. C) Adipocyte size distribution in WT (open circles), AMHKO (closed grey circles), and MRKI 
(closed black circles) mice. In each group the diameter of a total of 130 adipocytes was measured in 
three randomly selected sections per mouse. Three-way ANOVA indicated a significant interaction 
between genotype, age and size (P<0.001). RM ANOVA indicated a significant difference between 
genotypes at 4 and 5 months of age (P<0.001). There was a significant effect of age on adipocyte size 
distribution in WT mice (P<0.001). For clarity adipocyte size distribution graphs are presented per 
age. Data represent mean ± SEM (n=4 mice per group).
































































































































































































between genotype and age for the relative weight of inguinal WAT (iWAT) (P=0.04). 
The weight of these WAT depots did not differ between WT and AMHKO mice at 4 
months of age, but was significantly lower in MRKI mice (P<0.01 by post-hoc analysis) 
(Figure 2A). This difference in depot weight, between WT and MRKI mice remained 
present at 5 months of age (P<0.01 by post-hoc analysis). Also in 5-month-old AMHKO 
mice the weight of iWAT was significantly lower compared to WT mice (P<0.05 by 
post-hoc analysis). Interestingly, while iWAT of WT mice showed a significant increase 
in weight with increasing age (P<0.01 by post-hoc analysis), this increase did not occur 
for iWAT of AMHKO and MRKI mice (Figure 2A). No significant differences between 
genotypes were observed for the relative weight of visceral WAT (vWAT).
Histological analysis of sWAT revealed that at 4 months of age AMHKO and 
MRKI mice had smaller adipocytes compared to WT mice (Figure 2B). This differ-
ence in adipocyte size between WT mice and mice lacking AMH signaling was even 
more pronounced at 5 months of age (Figure 2B). Measurement of the cell diameter 
of the adipocytes confirmed that sWAT of AMHKO and MRKI mice contained 
significantly more smaller adipocytes compared to WT mice (P<0.001 by three-way 
ANOVA, genotype x age x size of the adipocytes), reflected by the left shift in the size 
distribution at both ages (Figure 2C). The decrease in subcutaneous adipocyte size 
was also reflected by the average cell diameter, for which there was a significant inter-
action between genotype and age (P<0.003). The average cell diameter significantly 
increased with age in WT mice (61.6 ± 2.2 µm vs. 81.8 ± 3.3 µm, at 4 and 5 months of 
age respectively, P<0.002 by post-hoc analysis). In contrast, the average diameter of 
subcutaneous adipocytes in AMHKO and MRKI mice did not significantly change 
with increasing age (AMHKO: 45.6 ± 1.4 μm vs. 53.2 ± 3.1 μm, respectively, P=0.06 
by post-hoc analysis; MRKI: 44.0 ± 2.8 µm vs. 40.3 ± 4.2 µm, respectively, P=0.49 by 
post-hoc analysis). Similar findings were obtained for gWAT (data not shown).
Increased browning of WAT and increased BAT activity in mice lacking AMH 
signaling
Analysis of the morphology of sWAT revealed that sWAT of AMHKO and MRKI 
mice contained islets of multilocular adipocytes interspersed within the larger uni-
Figure 3. Increased browning of sWAT in mice lacking AMH signaling.
Top panel: HE-stained sections of sWAT showing islets of multilocular beige adipocytes. sWAT of 
AMHKO and MRKI contained more dense islets compared to WT mice. Middle panel: Immuno-
histochemical analysis of UCP1 expression in sWAT using adjacent sections. UCP1-positive stain-
ing diminished in WT mice while a stronger staining was observed in AMHKO and MRKI mice 
with increasing age. Bottom panel: 2.5-fold magnification of the inset of the middle panel. Top and 
middle panel: scale bar = 1000 μm; bottom panel: scale bar = 100 μm.




































locular adipocytes (Figure 3), which is indicative for the presence of brown-like or 
beige adipocytes. Indeed, immunohistochemistry for the BAT-specific marker UCP1 
confirmed the presence of UCP1-positive cells in sWAT (Figure 3). UCP1 staining 
intensity did not differ between genotypes at 4 months of age. However, at 5 months 
of age, UCP1-positive staining was stronger in sWAT of AMHKO and MRKI mice 
compared to WT mice. Interestingly, at 5 months of age sWAT of AMHKO and MRKI 
mice contained more islets of beige adipocytes and more intense staining of UCP1 
than at 4 months of age, whereas in WT mice UCP1 staining intensity diminished 
(Figure 3).
Islets of beige adipocytes were also observed in iWAT. At 4 months of age, iWAT 
of all three genotypes contained islets of beige adipocytes (Supplemental Figure 2A 
and B). However, UCP1-positive staining was more intense in iWAT of AMHKO 
and MRKI mice compared to iWAT of WT mice. With increasing age, the presence 
of beige adipocyte islets disappeared in iWAT of WT and AMHKO mice but not in 
iWAT of MRKI mice (Supplemental Figure 2B).
Because AMHKO and MRKI mice have reduced adiposity and increased browning 
of their WAT depots, we also determined whether the function of the classical BAT 
depot was affected in AMHKO and MRKI mice. The weight of interscapular BAT 
was not affected between genotypes (data not shown), however histological analysis 
of BAT showed that at 4 months of age BAT of AMHKO mice had a more compact 
structure compared to BAT of WT mice, which was even more pronounced in MRKI 
mice (Figure 4A). Surprisingly, immunohistochemistry for UCP1 showed a weaker 
staining of UCP1 in BAT of 4-month-old AMHKO and MRKI mice compared to 
WT mice (Figure 4B). At 5 months of age, lipids had accumulated in BAT of WT 
mice resulting in the appearance of unilocular lipid droplets. This accumulation of 
lipids was reduced in BAT of AMHKO mice and appeared absent in BAT of MRKI 
mice (Figure 4A). At 5 months of age UCP1-positive staining was stronger in BAT of 
AMHKO and MRKI mice compared to WT mice (Figure 4B).
Increased lipolysis and decreased lipogenesis in BAT and sWAT of mice lacking 
AMH signaling
To elucidate whether an altered lipid metabolism could explain the reduced fat mass 
in AMHKO and MRKI mice, we determined the expression of the lipolytic genes 
hormone sensitive lipase (HSL) and adipose TG lipase (ATGL), and the lipogenetic 
genes lipoprotein lipase (LPL) and CD36, also known as fatty acid translocase. In 
BAT, analysis indicated a significant interaction between genotype and age for HSL 
(P=0.016) and ATGL (P=0.025). There was a highly significant effect of genotype 
on the expression of LPL and CD36 independent of age (P=0.001) (Figure 5A). 
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In BAT of AMHKO and MRKI mice the mRNA expression of HSL and ATGL was 
increased compared to WT mice at 5 months of age (P<0.05 and P=0.07, respec-
tively by post-hoc analysis). Interestingly, the expression of these genes tended to 
decrease in BAT of WT mice with increasing age (P=0.054 and P=0.06, respectively 
by post-hoc analysis), whereas a comparable or increased expression was observed in 
AMHKO and MRKI mice (Figure 5A). The mRNA expression of LPL and CD36 were 
significantly increased in BAT of MRKI mice compared to WT mice at both ages 
(LPL: P<0.01; CD36: P<0.05, by post-hoc analysis) (Figure 5A).
In sWAT, there was a significant interaction between genotype and age by two-
way ANOVA for the mRNA expression of HSL (P=0.005) (Figure 5B). HSL mRNA 
expression was decreased in sWAT of AMHKO and MRKI mice at 4 months of age 
(P<0.05 and P<0.001, respectively, by post-hoc analysis). Furthermore, while an 
age-dependent decrease in mRNA expression of HSL mRNA was observed in WT 
mice (P=0.009 by post-hoc analysis), HSL mRNA increased in sWAT of MRKI mice 
(P=0.019 by post-hoc analysis) (Figure 5B). Genotype had a significant effect on the 
expression of ATGL (P=0.04) and LPL (P=0.009) independent of age, since ATGL 
and LPL mRNA expression were decreased in sWAT of 4-month-old MRKI mice 
compared to WT mice (P<0.05 by posthoc analysis) (Figure 5B).
AMHRII mRNA is not expressed in metabolic tissues.
To assess whether the observed metabolic phenotype in AMHKO and MRKI 
mice could be the result of a direct effect of AMH on metabolic tissue, AMHRII 
mRNA expression was analyzed by real-time PCR in all adipose depots, muscle, 
pancreas, liver and hypothalamus. AMHRII mRNA could not be detected in any of 
the metabolic tissues, while expression could easily be detected in the ovary (results 
not shown).
Improved metabolic phenotype in AMHKO mice of advanced age
Next we examined whether the improved metabolic phenotype in AMHKO mice 
persisted at an older age. Unfortunately, MRKI mice were not available for this ag-
ing study. It is known that ovaries of AMHKO mice are depleted of their follicles 
at a younger age than WT mice (22). Indeed, the number of growing follicles was 
significantly reduced in 8-month-old AMHKO mice compared to WT mice 
(P=0.01). Compared to 4- and 5-months old mice, the number of growing follicles 
had decreased nearly 4-fold in the aged AMHKO mice, whereas in 8-month-old WT 
mice the number of growing follicles did not differ from 4- and 5-month old WT 
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Figure 6. Metabolic analyses of 8-month-old WT and AMHKO mice.
A) The ip glucose tolerance test was performed 5 days before sacrifice at 8 months of age (WT mice, 
open circles; AMHKO mice, closed circles). Two-way RM ANOVA indicated a borderline signifi-
cant effect of genotype (P=0.07). AMHKO mice have a better glucose clearance compared to WT 
mice (P<0.05 at 60 and 120 min) (n=6 mice per group). B) Percentage adipose depot weight relative 
to body weight in WT (open bars) and AMHKO (black bars) mice (n=6 mice per group). C) HE-
stained sections of sWAT of 8-month-old WT and AMHKO mice. Scale bar = 100 μm. D) Adipo-
cyte size distribution in WT (open circles) and AMHKO (closed circles) mice. In each group the 
diameter of a total of 130 adipocytes was measured in three randomly selected sections per mouse 
(n=3 mice per group). Data represent mean ± SEM. *, P<0.05; **, P<0.01, significant differences 
from WT mice. E) HE-stained section and section with immunohistochemical UCP1 expression of 
BAT of WT and AMHKO mice. A stronger UCP1 staining is present in BAT of AMHKO compared 
to BAT of WT mice. Scale bar = 100 μm.
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of primordial follicles, containing nearly 5-fold less primordial follicles compared to 
WT mice (P<0.001) (Supplemental Figure 1B).
At 8 months of age, body weight did not significantly differ between WT and 
AMHKO mice (27.88 ± 2.24 gr vs. 24.83 ± 0.84 gr, P=0.23). However, AMHKO 
mice tended to have a better glucose tolerance compared to their WT littermates 
(Figure 6A) (two-way RM ANOVA P=0.07). Particularly, AMHKO mice showed a 
significantly improved recovery phase of glucose levels upon IPGTT (P<0.05). In 
agreement with the observations at the younger ages, 8-month-old AMHKO mice 
had significantly decreased WAT depot weights compared to WT mice (Figure 
6B). Histological analysis of sWAT revealed that 8-months-old AMHKO mice had 
smaller adipocytes compared to WT mice (Figure 6C). Measurement of adipocyte 
cell diameter confirmed that sWAT of AMHKO mice contained significantly more 
small adipocytes compared to WT mice (P<0.001 by two-way ANOVA) (Figure 6D). 
Similar results were observed in gWAT (results not shown). At this age, sWAT of 
AMHKO mice still contained some beige adipocytes, but islets were less dense than 
at a younger age (results not shown). Although lipid accumulation had increased 
in BAT of 8-month-old AMHKO mice compared to 5-month-old AMHKO mice, 
lipid accumulation remained reduced compared to 8-month-old WT mice. Likewise, 
UCP1 staining remained stronger in AMHKO mice compared to WT mice (Figure 
6E).
Hormone measurements revealed that fasting insulin levels and C-peptide levels 
were significantly decreased in AMHKO mice compared to WT mice (P<0.01) (Table 
3). NEFA levels were significantly increased in AMHKO mice compared to WT mice 
(P<0.05). No significant differences were observed in leptin, adiponectin, triglycer-
ides and glycerol levels (Table 3).
Table 3. Hormone and lipid levels in 8-months-old WT and AMHKO mice.
8 months
WT AMHKO
Fasting glucose (mM) 5.27 ± 0.43 3.52 ± 0.32**
Insulin (ng/ml) 0.75 ± 0.05 0.45 ± 0.06**
C-Peptide (pM) 625.42 ± 26.01 460.59 ± 31.66**
Leptin (ng/ml) 5.58 ± 1.50 3.39 ± 0.79
Adiponectin (μg/ml) 43.89 ± 3.06 39.50 ± 2.52
Triglycerides (mM) 0.72 ± 0.09 0.86 ± 0.03
Glycerol (mmol/L) 0.48 ± 0.07 0.53 ± 0.03
NEFA (mmol/L) 0.15 ± 0.05 0.31 ± 0.04*
Serum samples were collected when mice were 8 months old. Values represent mean ± SEM (n = 6 
mice per group). *, P<0.05; **, P<0.01, significant differences from WT.
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Discussion
In this study, we show that female mice deficient in AMH signaling have an im-
proved metabolic phenotype with increasing age compared to WT mice. AMHKO 
and MRKI mice had an improved glucose tolerance, reduced adiposity and overall 
smaller adipocytes. This reduced adiposity was also reflected by decreased leptin 
levels, and lower reduced glucose and insulin levels in 8-month-old AMHKO mice.
Energy homeostasis is established by a balance between energy intake and energy 
expenditure. WAT is responsible for energy storage in the form of triglycerides, while 
BAT is responsible for non-shivering thermogenesis through oxidation of lipids, 
mediated by its energy burning capacity which is regulated by UCP1 activity (26, 
27). Aging is associated with an increase in obesity, reduced insulin sensitivity, and 
increased serum leptin levels (28, 29). This energy imbalance may, in part, be due to 
a diminished function of BAT leading to reduced UCP1 expression with increasing 
age (30-32). Indeed, in the present study, WT mice showed a worsening in glucose 
tolerance and an increase in WAT depot weight with enlarged adipocytes. These ef-
fects of metabolic aging were already evident at 5 months of age and are in agreement 
with a previous study in female mice in which an increase in body weight and leptin 
levels was observed between 3 and 6 months of age (33). Interestingly, this worsening 
in metabolism at a relatively young age did not occur in mice lacking AMH signaling. 
Furthermore, AMHKO mice remained a healthier metabolic phenotype than WT 
mice at an older age (8 months). During aging the percentage body fat increases 
while lean mass decreases (34). AMHKO and MRKI mice showed reduced adiposity 
with a normal body weight, suggesting that AMHKO and MRKI mice may have an 
increased lean body mass. Unfortunately, assessment of body composition was not 
available for this study, and will need to be performed in future studies.
The reduced weight of WAT depots in mice lacking AMH signaling suggests that 
energy expenditure may be increased in these mice. Increased BAT activity has been 
associated with increased energy expenditure and reduced adiposity (27). Indeed, 
we observed that BAT morphology differed between genotypes. BAT of AMHKO 
and particularly of MRKI mice showed an increased abundance of multilocular adi-
pocytes, giving it a denser appearance. Furthermore, the age-related decline in BAT 
activity in WT mice, illustrated by lipid accumulation and reduced UCP1 expression, 
was significantly reduced in mice lacking AMH signaling. The absence of the age-
dependent decrease in expression of the lipolytic genes HSL and ATGL in combina-
tion with increased UCP1 expression in AMHKO and MRKI mice suggest that these 
mice have an improved lipid metabolism and mitochondrial function compared to 
WT mice. Aging and the age-related decline in BAT activity can be delayed by caloric 
restriction (35, 36). Nevertheless, preliminary results suggest that food intake was not 
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reduced in 5-month-old mice lacking AMH signaling. Detailed energy expenditure 
analyses are therefore necessary to confirm that energy expenditure is increased in 
AMHKO and MRKI mice. However, the finding that the metabolic protection in these 
mice is accompanied by an increased number of beige adipocytes interspersed within 
WAT depots strongly supports such a conclusion. An increasing number of stud-
ies suggest that these beige adipocytes contribute to energy expenditure, since they 
phenotypically and functionally resemble classical BAT (37, 38). Particularly sWAT of 
AMHKO and MRKI mice exhibited an increased brown-like phenotype. Recently, it 
was shown that in male mice these beige adipocytes in sWAT disappear during ag-
ing, independently of adiposity, and that this brown-to-white transition was already 
initiated before 4 months of age (39). Also in our female WT mice we observed a near 
complete disappearance of beige adipocytes in sWAT at 5 months of age. In contrast, 
at this age, AMHKO and MRKI mice even showed increased browning of sWAT. 
These beige adipocytes in sWAT of AMHKO mice eventually also disappeared, since 
at 8 months of age only a few brown adipocyte islets could be observed.
AMH is a gonadal-specific member of the TGFβ superfamily, signaling through its 
specific AMH type II receptor and type I receptors which are shared by BMPs (40). In 
the ovary, AMH is expressed by granulosa cells of small growing follicles and regu-
lates folliculogenesis. Previously, we showed that in the absence of AMH, primordial 
follicle recruitment is enhanced resulting in an increased number of small growing 
follicles, and ultimately cessation of ovarian function at an earlier age (22). Here, we 
show that MRKI mice are an ovarian phenocopy of AMHKO mice, except that the 
primordial follicle pool was reduced at a faster rate. Also the metabolic phenotype 
appeared more pronounced in MRKI mice, with MRKI mice having smaller adipo-
cytes and more intense browning of sWAT than AMHKO mice. This suggests that 
AMHRII may have an AMH-independent role, and that the loss of this basal receptor 
activity in the MRKI mice causes a more pronounced phenotype. Alternatively, other 
ligands may signal through AMHRII since a high degree of crosstalk or promiscu-
ity exists for ligands and receptors of the TGFβ family. For instance, a receptor can 
interact with multiple ligands, as was illustrated by the different phenotypes in mice 
deficient for BMP2 and BMP4 or BMPR2 and BMPR1A (41-44). Since AMHRII 
interacts with BMP type I receptors, BMP ligands are potential candidate ligands 
for AMHRII. However, similar to AMH, AMHRII is solely expressed in reproduc-
tive organs (45), and we were unable to detect expression of AMHRII in metabolic 
tissues, such as WAT and liver, making a biological action beyond the reproductive 
system unlikely. This strongly suggests that the observed protection from metabolic 
aging in AMHKO and MRKI mice is not a direct effect of loss of AMH signaling, 
but instead may be driven by the altered follicle pool of these mice. The increased 
number of growing follicles could lead to altered levels of secreted ovarian growth 
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factors, as illustrated by increased inhibin B levels, which we showed previously (22). 
Members of the TGFβ family are potential candidates given their ovarian expression 
and their important role in brown and brown-like adipocyte differentiation. Several 
BMP ligands have been shown to stimulate brown adipogenesis. Overexpression of 
BMP7 or treatment with BMP7 induced brown fat mass, BAT activity and brown-
ing of WAT in mice (46, 47). BMP8b was reported to increase BAT activity in mice 
in vitro and in vivo studies (48). Furthermore, in a recent study, BMP6 was shown 
to induce brown adipocyte differentiation in murine C2C12 myoblast cells and hu-
man skeletal muscle precursor cells (49). Interestingly, loss of BMPR1A signaling in 
brown adipogenic precursor cells resulted in reduced interscapular BAT formation 
but increased recruitment of brown adipocytes in sWAT upon cold exposure (50), 
indicating the presence of compensating mechanisms in the regulation of thermo-
genesis. In contrast, TGFβ and activin signaling have inhibitory effects on brown 
adipogenesis. Inhibition of TGFβ signaling through genetic deletion of Smad3 (51, 
52), genetic deletion of myostatin/GDF8 (53, 54), or inhibition of activin signaling 
using a soluble decoy receptor ActRIIB-Fc or an ActRIIB neutralizing antibody (55, 
56), all led to browning of WAT, reduced obesity, and increased energy expenditure 
in mice. Given the plethora of effects and interaction with receptors by TGFβ super-
family members, it is currently difficult to identify the responsible factor secreted by 
ovaries deficient in AMH signaling. In addition, other growth factors such as VEGF 
and several FGF family members have also been implicated in brown and brown-
like adipocyte proliferation and differentiation (57-61), and are also expressed by the 
ovary. Future studies are aimed at the identification of the ovarian factor(s) that con-
tribute to the maintenance of a healthier metabolic phenotype in mice lacking AMH 
signaling. Interestingly, the metabolic protection persists at older ages, despite the 
fact that AMHKO mice cease ovarian function at an earlier age (this study and (22)). 
During reproductive life, estrogens are known to protect against lipid accumulation 
in adipose tissues. After menopause in women, this protective effect is lost due to 
sharp decline in estrogen levels (62). Thus we anticipated that AMHKO mice would 
show advanced adiposity with increasing age compared to WT mice. In contrast, 
exposure to the altered ovarian growth factor profile during reproductive life appar-
ently induces a favorable metabolic phenotype that can, at least partly, prevent the 
negative metabolic effects of estrogen loss.
In conclusion, our results suggest that changes in follicle dynamics affect metabo-
lism. In the presence of an increased pool of growing follicles, as present in mice 
lacking AMH signaling, this results in protection from metabolic aging through ef-
fects on both WAT and BAT. Identification of the ovarian growth factors responsible 
for the improved metabolic phenotype might provide novel targets in the treatment 
of obesity.
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Supplemental Fig. 1. Follicle numbers in mice lacking AMH signaling.
A) Number of primordial follicles, healthy growing follicles and atretic follicles in 4- and 5-month-
old mice. AMHKO and MRKI mice display enhanced primordial follicle recruitment leading 
to a decreased number of primordial follicles and increased number of growing follicles. Two-
way ANOVA indicated that genotype significantly affected primordial follicle number, number 
of healthy growing follicles, and number of atretic follicles independent of age (2WA g: P=0.002, 
P<0.001, and P<0.001, respectively). B) Follicle numbers in 8-month-old WT and AMHKO mice. 
The number of follicles was determined per ovary in WT (open bars), AMHKO (grey bars), and 
MRKI mice (black bars). Data represent mean ± SEM (n = 5-10). Significant differences from WT 
by posthoc tests: *, P<0.05; **, P<0.01; ***, P<0.001.
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Polycystic Ovary Syndrome (PCOS) is defined by two out of the following three 
criteria being met: oligo- or anovulation, hyperandrogenism, and polycystic ovaries. 
Affected women are often obese and insulin resistant. Although the etiology is still 
unknown, members of the Transforming Growth Factor β (TGFβ) family, including 
Bone Morphogenetic Proteins (BMPs) and anti-Müllerian hormone (AMH), have 
been implicated to play a role. In this pilot study we aimed to measure serum BMP 
levels in PCOS patients.
Methods
Twenty patients, fulfilling the definition of PCOS according to the Rotterdam Crite-
ria, were randomly selected. Serum BMP2, -4, -6 and -7 levels were measured using 
commercially available BMP2, BMP4, BMP6 and BMP7 immunoassays.
Results
Serum BMP2, serum BMP4 and serum BMP6 levels were undetectable. Three pa-
tients had detectable serum BMP7 levels, albeit at the lower limit of the standard 
curve.
Conclusions
BMP levels were undetectable in almost all patients. This suggests that with the cur-
rent sensitivity of the BMP assays, measurement of serum BMP levels is not suitable 
as a diagnostic tool for PCOS.
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Introduction
Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders 
in premenopausal women [1]. The diagnosis is based on two of the following three 
criteria being met: hyperandrogenism, oligo- or anovulation, and polycystic ovaries 
[2]. PCOS is the most frequent cause of infertility in women in their reproductive 
years, affecting 6-8% of women in the general population worldwide. Besides the 
reproductive phenotype, women with PCOS often display a metabolic phenotype: 
38-88% of women with PCOS are obese with a characteristic abdominal distribution 
of fat and up to 70% are insulin resistant and some are found to have type II Diabetes 
Mellitus [3-4]. Although the etiology is unknown, it is generally agreed that elevated 
androgens are the main culprit of the syndrome [5]. The increased ovarian androgen 
production may result from the increased GnRH pulsatility, which leads to increased 
LH secretion in favor of FSH [6]. Combined with the advanced LH responsiveness of 
small growing follicles, this causes increased androgen production, which is further 
enhanced by the elevated insulin levels. This abnormal endocrine environment has 
been suggested to suppress FSH action and causing follicular arrest [7]. In addition, 
intrinsic alterations in folliculogenesis have been proposed to contribute to the 
failure in dominant follicle selection in PCOS [7]. Ovarian growth factors, such as 
members of the transforming growth factor β (TGFβ) family, play important roles 
in follicle recruitment, follicle selection, and FSH responsiveness. Studies performed 
predominantly in rodents showed that the various Bone Morphogenetic Proteins 
(BMPs) are expressed in a cell-specific manner in the ovary, and display spatial and 
temporal changes in expression depending on the stage of follicular development 
[8-10]. BMP15 is specifically expressed by oocytes [11], also in ovine, bovine and 
human, whereas BMP6 has an oocyte/granulosa cell expression pattern in various 
species. BMP2 is expressed by granulosa cells in rodents and bovine, while BMP4 
and BMP7 are theca cells derived growth factors with mRNA expression detectable 
from the small preantral stage onwards in rats [8, 12]. However, in mouse, human 
and bovine ovaries also granulosa cell expression of BMP4 mRNA has been reported 
[13-15]. Anti-Müllerian hormone (AMH) is specifically expressed by the granulosa 
cells of small growing follicles in various species including human [16]. BMPs and 
AMH differently regulate FSH responsiveness and FSH-induced steroidogenesis, 
hence it has been suggested that these factors may contribute to the pathogenesis 
of PCOS.
Several studies have shown that serum AMH levels are elevated in women with 
PCOS. These elevated levels reflect the increased antral follicle count (AFC) in PCOS. 
In addition, AMH production per granulosa cell appears to be increased [17-19]. 
Whether serum BMP levels are altered in women with PCOS is unknown.
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Given the role of BMPs in FSH-responsiveness and FSH-induced steroidogenesis, 




Twenty normogonadotrophic normoestrogenic dysovulatory patients, fulfilling the 
definition of PCOS according to the Rotterdam Criteria [2], were selected from the 
Rotterdam PCOS cohort, which comprises of PCOS patients attending our fertility 
clinic between 1997 and 2011. Standardized initial screening (clinical investigation, 
transvaginal ultrasound, and fasting blood withdrawal) was performed on a random 
cycle day between 0900 and 1100 h, irrespective of the interval between blood sam-
pling and the preceding bleeding, as previously described [20]. Biochemically hyper-
androgenemia was defined as an elevated (>4.5) free androgen index (testosterone 
x 100/ SHBG) and clinical hyperandrogenemia was defined as a Ferriman Gallway 
score > 8. Polycystic ovaries were defined as 12 or more follicles (measuring 2-9 mm) 
per ovary, and/or an ovarian volume above 10 ml [21]. Endocrine screening included 
assessment of serum AMH, testosterone and SHBG levels and were determined pre-
viously [22-23]. Briefly, blood samples were stored at −20°C until further assessments 
were made. Serum hormone levels were assessed at the time patients were originally 
seen. Serum SHBG was measured by luminescence-based immunometric assays 
(Immulite 2000, Diagnostic Products Corp., Los Angeles, CA). Serum testosterone 
was measured using a RIA (Diagnostic Products Corp.). AMH levels were measured 
collectively in samples stored, using an in-house AMH ELISA assay (commercially 
available through Beckman Coulter, Woerden, The Netherlands). Approval by the lo-
cal medical ethics committee was obtained and all participants have given informed 
consent.
BMP measurements
Serum BMP2, -4 and -7 levels were measured using a Quantikine BMP2, BMP4 
and BMP7 Immunoassay (R&D Systems, Minneapolis, MN, USA). Serum BMP6 
levels were measured using a human BMP6 DuoSet ELISA Development kit (also 
R&D Systems). All samples were measured in single measurements according to the 
manufacturer’s instructions. For BMP2 the detection limit of the assay was between 
62.5 pg/mL and 4000 pg/mL. For BMP4 and -7 the detection limits of the assay were 
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between 31.2 pg/mL and 2000 pg/mL. For BMP6 the detection limit of the assay was 
between 78.13 pg/mL and 1000 pg/mL. Controls with low, medium and high concen-
trations for BMP2 (207-558 pg/mL, 759-1509 pg/mL, 1670-3061 pg/mL), BMP4 (89-
140 pg/mL, 512-780 pg/mL, 958-1468 pg/mL) and BMP7 (180-248 pg/mL, 502-698 
pg/mL, 1010-1442 pg/mL) were provided by R&D Systems. For BMP6 controls were 
not available. All samples where measured in one plate per assay.
Results
PCOS patient characteristics are given in Table 1. Serum BMP7 was detectable in only 
three of the 20 PCOS patients (Table 1), albeit at very low levels. Serum BMP2, -4 and 
-6 were undetectable in all PCOS patients (Table 1). Extending the standard curve 















1 28 1.63 21.6 42 13.2 – – – –
2 28 0.92 22 55 28.7 – – – –
3 30 1.68 20 47 15.8 – – – –
4 20 0.62 22.2 50 20 – – – –
5 30 1.03 19.6 59 31.9 – – – 57.60
6 30 7.93 24.6 40 30.9 – – – –
7 23 5.53 19.4 73 28.5 – – – –
8 22 5.70 21.1 54 n.d. – – – –
9 20 5.50 24.7 62 n.d. – – – 43.88
10 25 13.27 24.2 48 26.6 – – – –
11 25 1.50 30.4 32 6.5 – – – –
12 31 1.75 44.1 77 23.5 – – – –
13 31 1.42 30.1 41 8.8 – – – –
14 24 1.21 31.8 44 13.6 – – – –
15 26 13.50 30.1 160 n.d. – – – –
16 25 15.13 32.3 153 37 – – – 42.38
17 27 19.20 32.7 110 n.d. – – – –
18 27 9.20 32.0 103 17.8 – – – –
19 28 9.50 34.3 101 n.d. – – – –
20 23 26.57 43.2 91 26.6 – – – –
FAI: Free Androgen Index; BMI: Body Mass Index; AFC: Antral Follicle count.
n.d.: not determined
–: below detection limit of the assay
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with an extra dilution step, allowed the detection of serum BMP4 in only one patient, 
whereas BMP2 and -6 remained undetectable. In contrast, serum AMH levels were 
easily detectable at an average concentration of 20.9 ng/mL. For four patients AMH 
levels were unknown, because data and serum of these patients were collected before 
AMH measurements were routinely determined in the clinic.
Discussion
In this pilot study, BMP2, -4 and -6 were undetectable in all PCOS patients. BMP7 
was detectable in only three patients, but with levels close to the lower limit of the 
standard curve. The addition of an extra lowest point to the standard curve did not 
improve the measurement of BMPs. The patients with discernible serum BMP7 
values did not show a consistent pattern with respect to FAI, BMI or AFC. Since 
the BMPs studied were undetectable in nearly all of the twenty PCOS patients, and 
therefore could not be used to further distinguish the heterogeneous PCOS popula-
tion, we did not attempt to analyze a larger number of PCOS patients nor a cohort of 
normo-ovulatory women as controls.
In a recent study by Son et al [24], serum BMP4 levels were measured in male and 
female subjects and shown to be associated with adiposity, insulin resistance and 
the metabolic syndrome. BMP4 levels ranged between 0.63 ± 0.41 pg/mL and 9.91 
± 4.48 pg/mL and were determined with the same assay as in our study. Since the 
lowest point of the standard curve of the BMP4 assay is 31.2 pg/mL, these values are 
well below the standard curve, and therefore it is unclear whether the results of Son 
et al have any practical implications. Associations of BMP4 values that far below the 
detection range are weak at best.
Conflicting results have also been reported for BMP2 and BMP7. Using the same 
assay, one study showed that serum BMP2 levels were undetectable in patients with 
femoral fractures [25], whereas in another study, serum BMP2 and -7 levels [10, 26-
27] could be detected in patients with ankylosing spondylitis, arthritis and healthy 
subjects [28]. Also, in the latter study BMP levels were near or below the detection 
range of the assay. In agreement, other studies have also shown that serum BMP7 
levels are often below or close to the standard curve of the assay [29-30].
All women used in this study had polycystic ovaries and in accordance with these 
results increased AMH levels. An explanation for the undetectable serum BMP levels 
in this study could be that BMPs are not secreted by the human ovary, although it 
has been reported that BMP2, -4, -6 and 7 are expressed by the human ovary [9]. 
This explanation may not be likely since this would be in contrast to other ovarian 
expressed TGFβ family members that are secreted, such as AMH, Inhibin B and 
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Activin A [18, 31]. Alternatively, BMP immunoreactivity may not have been pre-
served. Prolonged storage and repeated freeze/thawing of the samples did not affect 
the immunoreactivity of AMH, a family member of BMPs, but an effect on BMP 
immunoreactivity cannot be ruled out. However, based on the studies mentioned 
above and our own study, we prefer to suggest an alternative reason, namely that 
the current available BMP assays are not sensitive enough to detect BMP ligands in 
the circulation of human subjects. Therefore, more sensitive assays are necessary to 
determine whether serum BMP levels could be used as an additional diagnostic tool 
in PCOS and other metabolic diseases.
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Context: Polycystic ovary syndrome (PCOS) is associated with an increased risk 
for the metabolic syndrome (MetS). Serum anti-Müllerian hormone (AMH) levels 
are increased in women with PCOS. Conflicting results are present regarding the 
relationship between serum AMH levels and metabolic risk factors.
Objective: To determine the association between serum AMH and MetS.
Design and setting: Cross-sectional study at a referral fertility clinic.
Patients: We evaluated 522 Caucasian women with PCOS, diagnosed by the Rotter-
dam criteria, for whom data on all MetS risk factors were available.
Results: Serum AMH levels were significantly lower in PCOS women with MetS 
than those without MetS (P=0.003). Multiple regression analyses revealed that, with 
HOMA-IR and FAI as covariates, serum AMH contributed to the prediction of waist 
circumference (β= −2.175, P<0.001), triglycerides (β= −0.054, P=0.029), and systolic 
(β= −1.410, P=0.002) and diastolic (β= −1.695, P=0.002) blood pressure, indepen-
dently of follicle count. In addition, serum AMH contributed to the prediction of the 
overall number of metabolic risk factors (β= −0.161, P=0.002). However, serum AMH 
did not remain an independent predictor for the presence of MetS. Furthermore, the 
observed associations between serum AMH and MetS risk factors were attenuated 
when BMI was included as a covariate.
Conclusions: Serum AMH levels are inversely correlated with the severity of MetS in 
women with PCOS, although this effect is largely driven by BMI. Our results therefore 
indicate that serum AMH levels should be interpreted with caution in overweight 
and obese PCOS women.
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Introduction
Polycystic Ovary Syndrome (PCOS) is one of the most common causes of infertility 
and affects approximately 6.5-8% of women worldwide (1). PCOS is clinically defined 
according to the Rotterdam Criteria by the presence of two out of the following three 
criteria: ovarian dysfunction characterized by oligo- or anovulation, hyperandrogen-
ism, and the presence of polycystic ovaries on ultrasound (2). In addition, PCOS 
is frequently associated with a metabolic phenotype: 38-88% of PCOS women are 
obese and 50-70% of women with PCOS are insulin resistant (3, 4). The metabolic 
derangements present in PCOS patients closely resemble the metabolic syndrome 
(MetS). MetS is a cluster of multiple risk factors for the development of cardiovas-
cular disease. According to the National Cholesterol Education Program’s Adult 
Treatment Panel III report (ATP III) these risk factors include abdominal adiposity, 
elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), 
elevated blood pressure, and high fasting glucose levels (5). This implies that PCOS 
not only is a reproductive disorder, but also has severe health implications beyond 
the reproductive system. Approximately 30-40% of the affected women will develop 
impaired glucose tolerance and 7.5-10% type 2 diabetes (6). Furthermore, women 
with PCOS might also have an increased risk for cardiovascular diseases (7).
A relationship between ovulatory function and metabolism in women with PCOS 
is evident since several studies have shown that even a modest weight reduction is 
translated into significant improvements in menstrual function, fertility and hyper-
androgenic features (8, 9). Furthermore, the use of insulin-sensitizing agents like 
metformin not only lead to weight reduction but also causes improvements of men-
strual frequency and fertility rate (10). These effects suggest that insulin resistance 
significantly contributes to the severity of the PCOS phenotype (11).
Anti-Müllerian hormone (AMH), a member of the TGFβ family, is expressed by 
granulosa cells of small growing follicles (12). Serum AMH levels decline gradually 
with increasing age, and this decline strongly correlates with the decreasing number 
of growing follicles (13, 14). Also in PCOS, serum AMH levels strongly correlate with 
follicle count (15, 16). Indeed, in women with PCOS, 2-3 fold increased serum AMH 
levels are observed (15, 16). Furthermore, analysis of granulosa cells of anovulatory 
PCOS women indicated that the mRNA expression of AMH is increased by nearly 
75-fold compared to control women (17), which is also reflected by increased fol-
licular fluid AMH levels (18). Thus, not only the increased follicle number but also 
the increased production per granulosa cell contributes to the elevated serum AMH 
levels in PCOS. Interestingly, serum AMH levels seem to reflect the severity of the 
ovarian phenotype in PCOS. Hyperandrogenic PCOS women with a polycystic ovary 
morphology (PCOM) have higher AMH levels compared to normo-androgenic 
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PCOS women with PCOM (19). Furthermore, serum AMH levels are highest in an-
ovulatory PCOS patients with prominent PCOM compared to those without PCOM 
but with an equal degree of hyperandrogenism (15, 20).
However, the relationship between serum AMH levels and metabolic parameters 
in PCOS is less clear. Conflicting results have been reported on the relationship be-
tween serum AMH and obesity and insulin resistance. Some studies mention a lack 
of association between AMH levels and BMI (21), whereas others report a negative 
association between AMH levels and BMI (20, 22, 23). Likewise, conflicting results 
were observed for the relationship between serum AMH levels and HOMA-IR in 
women with PCOS. Studies showed both positive, negative, or even non-existent as-
sociations (21-25). Relatively small PCOS cohorts, which varied in severity of PCOS-
related characteristics and consisted of different ethnicities, could possibly explain 
these contradictory results. Because metabolic complications in women with PCOS 
can result in long term health consequences (26), we investigated in a large cohort 
of Caucasian PCOS women whether serum AMH levels correlated with MetS risk 
factors and the presence of MetS.
Methods
Participants
Patients attending our fertility clinic between 1997 and 2011, who fulfilled the defini-
tion of PCOS according to the Rotterdam Criteria (2), were enrolled in this study. 
Informed consent was obtained from all participants and the study was approved by 
the Medical Ethics Review board of the Erasmus MC.
Standardized initial screening (clinical investigation, transvaginal ultrasound and 
fasting blood withdrawal) was performed on a random cycle day between 0900 and 
1100 h, irrespective of the interval between blood sampling and the preceding bleed-
ing, as previously described (27). Previously performed laboratory screening included 
assessment of serum gonadotrophins, estradiol, AMH, testosterone, fasting insulin, 
fasting glucose and lipid levels. Biochemical hyperandrogenemia was defined as an 
elevated (>4.5) free androgen index (FAI) (testosterone x 100/ SHBG) and clinical 
hyperandrogenemia was defined as a Ferriman Gallway score >8. Polycystic ovaries 
were defined as 12 or more follicles (measuring 2–9 mm) in one or both ovaries, and/
or an ovarian volume above 10 ml. Metabolic syndrome was diagnosed according to 
the ATP III definition (5) and was established when three or more of the following 
risk factors were present: (i) increased waist circumference (≥88 cm for Caucasian 
women), (ii) increased triglycerides (≥1.69 mmol/L), (iii) reduced levels of HDL-C 
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(<1.29 mmol/L), (iv) increased systolic blood pressure ≥130 mmHg or increased dia-
stolic blood pressure ≥85 mmHg, and (v) increased fasting glucose (≥5.6 mmol/L). 
For the present study, 522 Caucasian women with PCOS, in whom all characteristics 
of the metabolic syndrome were available, were included.
Assays
Endocrine screening was performed as described previously (28-30). Briefly, blood 
samples were stored at −20°C until further assessments were made. Serum hormone 
levels were assessed at the time patients were originally seen. Serum SHBG, LH, FSH 
and insulin were measured by a luminescence-based immunometric assay (Immulite 
2000, Siemens-DPC, Los Angeles, CA) (29, 30). Serum testosterone was measured 
using a RIA (Siemens-DPC) (29). Serum AMH levels were measured collectively 
in stored samples, using an in-house AMH ELISA assay (commercially available 
through DSL, now Beckman Coulter, Woerden, The Netherlands) (28). Total cho-
lesterol and triglycerides were analyzed using commercially available assays (Wako 
Diagnostics, Osaka, Japan) (30). HDL-C was analyzed using the direct HDL assay 
from Wako Diagnostics (30).
Statistical analysis
Continuous variables are presented as median and minimum and maximum value 
rates. Whenever appropriate, hormone levels were log transformed to normalize their 
distribution (AMH, FAI, glucose, insulin, HOMA-IR (fasting glucose (mmol/L) x 
fasting insulin mU/L) / 22.5) (31) and triglycerides). Differences between PCOS wom-
en with or without MetS were analyzed by one way analysis of variance (ANOVA). 
Correlations between serum AMH levels and hormonal and metabolic factors were 
assessed using Pearson’s correlation coefficients. Stepwise multiple linear regression 
analyses were performed to analyze the contribution of serum AMH to the individual 
risk factors of MetS. The variables AMH, follicle count, age, FAI, and HOMA-IR were 
considered for selection in the model. Probability-to-enter or to-remove of 0.05 and 
0.1, respectively, were used. In addition, stepwise multiple linear regression analysis 
was performed to determine the contribution of these covariates to the number of 
MetS risk factors. The number of risk factors of MetS was determined by the sum of 
the five risk factors (range 0-5), which were coded dichotomously according to above 
described ATP III definition cutoff values: (i) waist circumference (1 = ≥88 cm; 0 = 
<88 cm), (ii) triglycerides (1 = ≥1.69 mmol/L, 0 = <1.69 mmol/L), (iii) HDL-C (1 = 
<1.29 mmol/L, 0= ≥1.29 mmol/L), (iv) systolic blood pressure (1 = ≥130 mmHg or dia-
stolic blood pressure ≥85 mmHg, 0 = <130 mmHg systolic or <85 mmHg diastolic), 
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and (v) fasting glucose (1 = ≥5.6 mmol/L, 0 = <5.6 mmol/L). Binary multiple logistic 
regression analysis (enter method) was performed to examine the contribution of 
serum AMH levels to the presence of MetS. Areas under the receiver operating char-
acteristic (ROC) curve (AUCs) of the covariates for predicting MetS were calculated.
To assess the effect of obesity on the association between AMH levels and MetS, 
analyses were repeated including BMI as a covariate. For these analyses, waist cir-
cumference was excluded from the MetS risk factor summary score.
Analyses were performed using SPSS software (version 21.0, SPSS, Inc., Chicago, 
IL). P values <0.05 were considered significant.
Results
Effect of MetS on baseline characteristics of women with PCOS
The full study cohort consisted of 522 Caucasian women with PCOS, of whom 15% 
had MetS (n=77) based on the ATPIII definition. Descriptive information for the 
main characteristics of the full cohort and of those with or without MetS is presented 
in Table 1. The median age of the study cohort was 28 years. The median body mass 
index (BMI) of 24.9 kg/m2 was just within the normal range. However, BMI was 
significantly increased in women with PCOS with MetS compared to those without 
MetS (P<0.001). As expected, the risk factors of MetS (waist circumference, fast-
ing glucose, triglycerides, systolic and diastolic blood pressure, and HDL-C) were 
significantly different between PCOS women with or without MetS (fasting glucose 
P=0.014, others P<0.001). Furthermore, testosterone levels were significantly higher 
(P<0.001), while SHBG levels were significantly lower in PCOS women with MetS 
compared to those without MetS (P<0.001), explaining the significantly higher FAI 
in the women with MetS (P<0.001). The median serum AMH level was 8.7 ng/ml in 
the full cohort. Interestingly, serum AMH levels were significantly lower in women 
with PCOS with MetS compared to those without MetS (7.4 vs. 9.0 ng/ml, respec-
tively, P=0.003), while no difference in follicle count was observed.
Correlations between serum AMH and MetS risk factors
To gain more insight into the relationship between AMH and MetS, we analyzed 
whether AMH levels correlated with the risk factors of MetS. In addition, we analyzed 
the correlation between AMH and parameters of PCOS, such as follicle count and 
FAI (Table 2). As expected, serum AMH levels were strongly positively correlated 
with follicle count. A lower but significant positive correlation was observed between 
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AMH and FAI. A highly significant negative correlation was observed for AMH 
and age (Table 2). Highly significant negative correlations were observed for serum 
AMH levels and the metabolic risk factors waist circumference, blood pressure, and 
triglycerides in women with PCOS. A borderline significant positive correlation was 
observed between AMH and HDL-C levels, while AMH and fasting glucose levels did 
not correlate (Table 2). Furthermore, a significant negative correlation was observed 
between serum AMH and fasting insulin, HOMA-IR, and BMI (Table 2).
Contribution of serum AMH to prediction models for MetS risk factors
Because of the observed correlations between serum AMH and most risk factors 
of MetS, we performed forward stepwise multiple linear regression analyses to de-
Table 1. Main characteristics of Caucasian women with PCOS
Metabolic Syndrome
All PCOS patients No Yes P-value*
n 522 445 77 -
Age (yr) 28 (14-44) 28 (14-40) 27 (19-44) 0.09
BMI (kg/m2) 24.9 (16.0-45.3) 23.8 (16.0-43.3) 31.6 (22.1-45.3) <0.001
Waist circumference (cm) 80 (55-133) 77 (55-124) 98 (77-133) <0.001
Ferriman-Gallwey score 2 (0-25) 2 (0-25) 3 (0-20) 0.007
Systolic BP (mm Hg) 115 (90-175) 114 (90-175) 125 (96-160) <0.001
Diastolic BP (mm Hg) 75 (52-164) 74 (52-96) 85 (66-164) <0.001
Fasting glucose (mmol/L) 4.6 (1.7-10.5) 4.6 (1.7-7.7) 4.8 (3.3-10.5) 0.014
Fasting insulin (mU/L) 6.2 (0.3-197.6) 5.5 (0.3-197.6) 14.1 (2.0-59.8) <0.001
HOMA-IR 1.2 (0.6-40.4) 1.1 (0.1-40.4) 2.9 (0.7-14.0) <0.001
Cholesterol (nmol/L) 5.2 (2.2-12.2) 5.2 (2.2-12.2) 5.7 (3.6-9.2) 0.011
HDL-C (mmol/L) 1.5 (0.5-4.1) 1.6 (0.5-4.1) 1.1 (0.5-3.1) <0.001
Triglycerides (mmol/L) 1.0 (0.3-5.1) 0.9 (0.3-4.0) 1.7 (0.5-5.1) <0.001
LH (IU/L) 8.3 (0.4-105.0) 8.3 (0.4-105.0) 7.8 (1.2-62.8) 0.987
SHBG (nmol/L) 42.4 (7.6-192.0) 46.2 (7.6-192.0) 23.5 (7.9-148.0) <0.001
Testosterone (nmol/L) 1.7 (0.1-5.3) 1.6 (0.2-5.2) 2.0 (0.1-5.3) 0.004
FAI 4.4 (0.3-63.2) 3.9 (0.3-63.2) 8.9 (0.4-32.1) <0.001
Follicle count 37.5 (2-105) 37 (2-97) 38 (4-105) 0.958
AMH (ng/ml) 8.7 (0.1-66.8) 9.0 (0.1-66.8) 7.5 (0.2-52.3) 0.003
Values are expressed as median (minimum-maximum). BMI, body mass index; BP, blood pressure; 
HOMA-IR, homeostasis model assessment of insulin resistance; HDL-C, high-density lipoprotein 
cholesterol; LH, luteinizing hormone; SHBG, sex hormone-binding globulin; FAI, free androgen 
index; AMH, anti-Müllerian hormone. * P-values by ANOVA for the comparison of PCOS patients 
with or without the metabolic syndrome. Statistically significant P-values are shown in bold.
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termine whether serum AMH contributed in the prediction of the levels of these 
risk factors in women with PCOS (Table 3). Age and follicle count were included as 
covariates because of their known correlation with AMH, while FAI and HOMA-IR 
were included because of their relationship with MetS in PCOS and because of the 
observed correlations with serum AMH. Serum AMH levels did not significantly 
contribute to the final model predicting fasting glucose and HDL-C levels. However, 
serum AMH remained an independent predictor for waist circumference, triglycer-
ides, systolic and diastolic blood pressure, while follicle count did not contribute to 
the final models (Table 3). HOMA-IR and FAI yielded a positive coefficient for each 
risk factor, whereas AMH yielded a negative coefficient.
Next, we determined by forward stepwise multiple linear regression whether AMH 
also contributed to the prediction of the number of metabolic risk factors present 
(range 0-5). In the final model, 39.7% of the variation in the number of risk factors 
was explained by HOMA-IR, FAI, AMH and age (Table 4). Again, follicle count did 
not significantly contribute to the model. HOMA-IR (β = 0.592; P<0.001) and FAI 
(β = 0.466; P<0.001) were the strongest prediction factors, followed by AMH (β = 
−0.161; P = 0.002).
Table 2. Correlations between serum AMH and ovarian and metabolic parameters in women with 
PCOS.
r P-value
Age (yr) −0.234 <0.001
BMI −0.219 <0.001
Follicle count 0.526 <0.001
FAI 0.086 0.049
HOMA-IR −0.119 0.007
Fasting insulin (mU/L) −0.120 0.006
Fasting glucose (mmol/L) −0.024 0.588
Waist circumference (cm) −0.154 <0.001
Systolic BP (mm Hg) −0.146 0.001
Diastolic BP (mm Hg) −0.143 0.001
HDL-C (mmol/L) 0.08 0.066
Triglycerides (mmol/L) −0.140 0.001
Data are given as Pearson’s correlation coefficients. BMI, body mass index; FAI, free androgen in-
dex; HOMA-IR, homeostasis model assessment of insulin resistance; BP, blood pressure; HDL-C, 
high-density lipoprotein cholesterol. Statistically significant P-values are shown in bold.
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Table 3. Final stepwise multiple linear regression model of the Metabolic Syndrome risk factors 
for women with PCOS
MetS risk factor Variables b Coefficient S.E. P-value
Waist circumference ln(HOMA-IR) 7.664 0.654 <0.001
ln(FAI) 6.536 0.650 <0.001
ln(AMH) −2.175 0.606 <0.001
Age 0.214 0.104 0.041
Model R2=0.473
Triglycerides ln(HOMA-IR) 0.162 0.027 <0.001
Age 0.013 0.004 0.003
ln(FAI) 0.098 0.026 <0.001
ln(AMH) −0.054 0.025 0.029
Model R2=0.410
Systolic BP ln(HOMA-IR) 3.940 0.636 <0.001
Age 0.240 0.111 0.001
ln(AMH) −1.410 0.659 0.002
Model R2=0.092
Diastolic BP ln(HOMA-IR) 3.110 0.609 <0.001
ln(FAI) 1.984 0.590 0.001
ln(AMH) −1.695 0.552 0.002
Model R2=0.134
Fasting glucose ln(HOMA-IR) 0.081 0.009 <0.001
Age 0.004 0.002 0.012
Model R2=0.130
HDL-C ln(FAI) −0.203 0.033 <0.001
ln(HOMA-IR) −0.128 0.033 <0.001
Follicle count 0.004 0.001 0.001
Model R2=0.161
Covariates considered for selection in each model: AMH, age, follicle count, HOMA-IR and FAI.
Table 4. Final stepwise multiple linear regression model of the number of Metabolic Syndrome 
risk factors for women with PCOS
Variables b coefficient S.E. P-value
ln(HOMA-IR) 0.592 0.057 <0.001
ln(FAI) 0.466 0.057 <0.001
Age 0.035 0.009 <0.001
ln(AMH) −0.161 0.053 0.002
Model R2=0.397
Covariates considered for selection in each model: AMH, age, follicle count, HOMA-IR and FAI.
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Influence of serum AMH on the prediction of MetS
Since our results indicated that serum AMH influences the number of MetS risk 
factors, we next determined whether AMH also contributed to the prediction of 
MetS. By binary multiple logistic regression (enter method) serum AMH did not 
remain an independent predictor of MetS. In the final model, HOMA-IR, FAI and 
age significantly contributed to the presence of MetS (Table 5). Receiver operating 
characteristic curve (ROC) analysis showed that a model that included FAI and 
HOMA-IR had an AUC of 0.86, which was not improved by the addition of AMH 
to the model. Addition of age to the model resulted in a slightly improved AUC of 
0.87 (Figure 1A). The ROC curves of the univariate and corresponding multivariable 
models are shown in Figure 1B.
Table 5. Final multiple linear regression model (enter method) for the presence of Metabolic Syn-
drome in women with PCOS
Variables b coefficient S.E. P-value
ln(AMH) −0.286 0.204 0.161
Follicle count 0.004 0.009 0.628
Age 0.096 0.033 0.004
ln(FAI) 0.985 0.233 <0.001
ln(HOMA-IR) 1.450 0.232 <0.001
Variables AUC 95% CI P-value
ln(AMH) 0.408 0.338-0.477 0.001
Age 0.534 0.460-0.608 0.342
ln(FAI) 0.779 0.723-0.836 <0.001
ln(HOMA-IR) 0.839 0.795-0.883 <0.001
ln(FAI) + ln(HOMA-IR) 0.858 0.817-0.898 <0.001
ln(AMH) + ln(FAI) + ln(HOMA-IR) 0.863 0.822-0.905 <0.001
Age + ln(FAI) + ln(HOMA-IR) 0.870 0.830-0.910 <0.001
A B 
Variables AUC 95% CI P-value
ln(AMH) 0.4 8 0.338-0.477 0.0 1
Age 0.534 0.460-0.6 8 0.342
ln(FAI) 0.779 0.723-0.836 <0.0 1
ln(HOMA-IR) 0.839 0.795-0.883 <0.0 1
ln(FAI) + ln(HOMA-IR) 0.858 0.817-0.898 <0.0 1
ln(AMH) + ln(FAI) + ln(HOMA-IR) 0.863 0.822-0.9 5 <0.0 1
Age + ln(FAI) + ln(HOMA-IR) 0.870 0.830-0.910 <0.0 1
A B 
Figure 1. Areas under the curve (AUC) and receiver operating characteristics curves (ROCs) for 
selected variables for the prediction of MetS. A) AUCs of the univariable and multivariable models 
in the prediction of MetS are shown. In the univariable analysis it is shown that AMH has signifi-
cant predictive value, while HOMA-IR had the highest predictive value. In the multivariable mod-
els the added value of variables to HOMA-IR is shown. Addition of age to a model that included 
HOMA-IR and FAI resulted in a slightly better accuracy than addition of AMH to this model. B) 
ROC curves for the single and combined variables for the prediction of MetS.
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Effect of BMI on the association between serum AMH and MetS risk factors
Previous studies reported a significant negative relationship between BMI and AMH 
levels in women with PCOS (20, 22). Also in our cohort of Caucasian women with 
PCOS we observed a significant negative correlation between serum AMH levels and 
BMI (r = −0.219, P<0.001) (Table 2). Hence, we repeated the analyses for the contribu-
tion of AMH to the levels of individual MetS risk factors and the number of MetS risk 
factors present (range 0-4) by including BMI as an independent variable. Inclusion 
of BMI removed serum AMH as a predictive variable from all models (results not 
shown). With BMI included, HOMA-IR, FAI and age remained significant predictors 
of the number of parameters of MetS (all P<0.001), although their contribution to the 
model decreased (HOMA-IR: β = 0.274, P<0.001; FAI: β = 0.166, P=0.001; age: β = 
0.024, P=0.001; BMI: β = 0.038, P<0.001).
Discussion
In the present study, we observed that PCOS women with MetS had lower AMH 
levels than those without MetS. Furthermore, serum AMH was an independent 
negative predictor of the number of MetS risk factors present, suggesting that lower 
AMH levels are associated with an increased number of MetS risk factors in women 
with PCOS. Serum AMH was associated with waist circumference, TG, and hyper-
tension. In agreement with previous studies (15, 16), we observed a strong positive 
correlation between serum AMH and follicle count. However, in contrast to AMH, 
follicle count did not differ between PCOS women with or without MetS, and follicle 
count did not contribute to the prediction models of individual MetS risk factors or 
the overall number of MetS risk factors. Thus, our results suggest that in the pres-
ence of MetS AMH production is reduced while follicle number is not affected. This 
may suggest that the variance in AMH levels in PCOS is not only explained by the 
number of follicles, but also by intrinsic properties of the granulosa cell itself. Indeed, 
several studies have shown that AMH production per granulosa cell is increased in 
women with PCOS (17, 32). Furthermore, in a prediction model for AMH levels in 
women with PCOS, follicle number only explained 5.3% of the variance in AMH 
concentration (20). In the latter study, BMI was shown to be an independent negative 
predictor of AMH levels (20). A negative correlation between AMH and BMI has 
also been reported by other studies (22, 23). Our results support these findings, since 
the observed association between AMH and MetS risk factors was largely driven by 
BMI. In our cohort nearly 50% of the women had a BMI≥25 and these women had 
significantly lower AMH levels compared to those with a normal BMI (results not 
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shown). When BMI was included as a covariate in the regression model serum AMH 
no longer remained an independent predictor of the number of MetS risk factors. 
Also, the associations between AMH levels and the individual risk factors were com-
pletely attenuated when BMI was added to the model.
The negative association between AMH and BMI may not be limited to women 
with PCOS. In a large multiethnic cohort of regularly cycling women, low serum 
AMH was associated with more MetS risk factors (33). In agreement with our find-
ings, this association was driven by BMI. Likewise, in a small cohort of late repro-
ductive regularly cycling women, obese women had lower AMH levels compared 
to normal weight women, despite a similar follicle count (34, 35). Furthermore, we 
recently observed in a cohort of female survivors of childhood cancers that obese 
subjects had lower serum AMH levels (36). Combined these results strongly suggest 
that obesity may affect granulosa cell function, including AMH production.
Obesity contributes to infertility, leading to reduced fecundity and reduced ovarian 
response upon ovarian stimulation, and increased cycle cancellation rates in IVF (37-
39). Obesity induces insulin resistance, leading to compensatory hyperinsulinemia. 
Hence insulin has been proposed as a factor causing ovarian dysfunction in obese 
women (40). Insulin can directly stimulate steroidogenesis (41). Furthermore, in 
granulosa cells insulin can synergize with LH to induce premature LH receptor expres-
sion causing premature granulosa cell differentiation (42). Interestingly, in our study 
we observed a negative correlation between serum AMH and HOMA-IR. Indeed, 
serum AMH levels tended to be lower in women with hyperinsulinemia (results not 
shown). However, whether insulin can directly affect AMH expression levels remains 
to be determined. A direct effect of AMH on insulin levels seems unlikely given that 
the specific AMH type II receptor is not expressed beyond the reproductive system.
In addition to insulin resistance, obesity also affects adipocyte function leading 
to changes in adipokine levels, such as lower adiponectin and elevated leptin levels. 
Adipokines have been suggested to affect ovarian function (43). The central effect 
of leptin on GnRH secretion has been well studied (44). However, adipokines also 
have direct effects on the ovary. In rodents, leptin administration results in reduced 
follicular growth and reduced ovulation rates (45, 46). In cultured human granulosa 
and theca cells of regularly cycling women leptin was shown to antagonize the IGF1-
induced steriodogenesis (47). Importantly, it was shown recently that in cultured 
luteinized granulosa cells obtained from non-PCOS infertile women, leptin, but not 
adiponectin, reduced the expression of AMH (48). Although this finding requires 
confirmation preferably in non-luteinized granulosa cells, it suggests that obesity 
may directly affect AMH levels through increased leptin levels.
In our cohort of Caucasian women with PCOS, the prevalence of metabolic 
syndrome was 15%. This percentage is lower than the 33-47% range that has been 
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reported previously (49-51). The lower prevalence in our cohort seems mainly due to 
the lower percentage of women having an increased waist circumference compared 
to other studies (33.5% vs. 73-79%, respectively) (49, 51). This may suggest that our 
cohort represents women with PCOS with a relatively mild degree of obesity. Given 
the observed association of serum AMH with waist circumference, the observed dif-
ferences in serum AMH levels between women with or without MetS may be even 
more pronounced in a more obese cohort.
There have been several studies showing that serum AMH reflects the severity 
of PCOS. Indeed, higher serum AMH levels are observed in hyperandrogenic and 
anovulatory women (15, 19, 20). In contrast, when referring to the metabolic status, 
our data suggest that lower AMH levels reflect the worst metabolic profile. A pos-
sible direct effect of obesity on AMH expression, may also explain why weight loss 
did not change AMH levels but did increase ovulatory cycles in those women with 
a lower baseline AMH levels (52, 53). Although speculative, one might argue that 
upon weight loss, leptin levels decline leading to improved granulosa cell function 
and subsequently to increased AMH expression. Since serum AMH reflects the total 
follicular output, the relative increase in AMH production per follicle may be masked 
by the normalization of follicle number upon weight loss. Likewise, this may explain 
why in women with PCOS upon treatment with the insulin sensitizer metformin, 
serum AMH levels initially do not decline while follicle number does (54). Another 
plausible explanation might be that upon weight loss the number of non-AMH pro-
ducing atretic follicles declines, leading to relatively more healthy follicles.
In conclusion, our study shows that serum AMH levels are negatively associated 
with MetS risk factors in Caucasian women with PCOS, and that these associations 
were driven by BMI. Obesity therefore may affect serum AMH levels; although a 
causal relationship remains to be established. Given the importance of serum AMH 
as a marker of ovarian function in the clinic, understanding of the regulation of 
AMH in normal and pathological conditions is needed. Our results also suggest that 
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Polycystic ovary syndrome (PCOS) is a disorder of fertility but also has metabolic 
pathophysiologies. The co-morbidities may include obesity and insulin resistance 
or even type 2 diabetes. As such, PCOS is associated with the metabolic syndrome 
(MetS), which among other factors includes hypertension and cardiovascular disease 
(CVD). The exact mechanisms behind this association between PCOS and MetS are 
unknown, but the consensus in the field is that androgens are the main culprit (1). 
Indeed, most women with PCOS suffer from hyperandrogenism and high androgen 
levels correlate with a more severe metabolic phenotype, such as abdominal adiposity, 
insulin resistance and a disturbed lipid metabolism (2). Androgens are produced both 
by the ovary and adrenal cortex, although in PCOS mainly the ovary is responsible 
for the androgen excess. Nevertheless, also normo-androgenic women with PCOS 
have metabolic pathophysiologies (3), implying that androgens are not the sole cause 
for the metabolic disturbances. Besides oligo-amenorrhea and hyperandrogenism, a 
polycystic ovarian morphology, i.e., an increase in the number of growing follicles, is 
one of the other criteria for the diagnosis of PCOS. This increase could also change 
the profile of secreted ovarian products. An example is AMH, a member of the TGFβ 
family of growth and differentiation factors, which is increased in patients with 
PCOS (4-7). Therefore, we hypothesize that, in addition to androgens, other secreted 
ovarian products, in particular ovarian growth factors, contribute to the metabolic 
phenotype of women with PCOS.
The objective of this thesis is to study the role of the ovary in the regulation of 
metabolism.
In this general discussion we will focus on the metabolic disturbances associated with 
PCOS. In the next section the role sex steroid hormones play in MetS will be discussed 
(7.2). Subsequently, we will discuss several mouse models that may aid in deciphering 
the effect of the ovary on metabolism (7.3). Next, we will focus on the effect of the 
ovary on metabolism, either directly or indirectly through regulation of the central 
nervous system (7.4). We will conclude this chapter with some final remarks (7.5).
7.2  Sex steroid hormones and the metabolic 
syndrome
Men and women in their reproductive years suffer from different metabolic patholo-
gies, especially with respect to the different risk factors of MetS. MetS is a cluster of 
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multiple risk factors for the development of cardiovascular disease, i.e., 1) abdominal 
adiposity, 2) elevated triglycerides, 3) low levels of HDL-C, 4) elevated blood pressure 
and 5) high fasting glucose levels (8). The incidence of MetS is much higher in the 
male population compared to pre-menopausal women (9). By comparing each of 
these risk factors in men and women this difference becomes clearer.
1) Abdominal adiposity. Body fat distribution differs between men and pre-meno-
pausal women. In general, women develop peripheral obesity by subcutaneous fat 
accumulation, while men are more prone to central or android obesity. Central body 
fat distribution is characterized by fat accumulation mainly in abdominal depots and 
is a known risk factor for the development of insulin resistance and type 2 diabetes 
(10).
2 & 3) Elevated triglycerides and low levels of HDL-C. Abdominal obesity is as-
sociated with high plasma triglycerides, reduced plasma HDL-C and elevated plasma 
LDL cholesterol. A study performed in a Dutch cohort between the age of 35 and 
60 years, showed that Caucasian men have increased LDL cholesterol and plasma 
triglyceride concentrations compared to BMI-matched Caucasian women (9). This 
study also showed that Caucasian Dutch women have reduced levels of HDL-C 
compared to Caucasian Dutch men. However, the combination of high levels of LDL 
cholesterol and elevated triglycerides can contribute to the higher prevalence of the 
MetS in men compared to premenopausal women.
4) Elevated blood pressure. Pre-menopausal women have a lower tendency to 
develop hypertension than do age-matched men. Furthermore, it was shown that 
obesity is associated with hypertension and that central obesity is an independent 
risk factor for the development of hypertension (11).
5) High fasting glucose levels. As mentioned earlier, central obesity is a known risk 
factor for the development of insulin resistance and type 2 diabetes. As such, elevated 
fasting blood glucose levels were found more frequently in men compared to women. 
However, impaired glucose tolerance was found more frequently in women (12).
As a result of the higher incidence of these risk factors men develop CVD at a 
younger age than women and in addition have a worse prognosis for CVD (13). 
An obvious explanation for the differences in MetS risk factors between men and 
premenopausal women may be found in the difference in sex steroid hormone levels 
in men and women. Whereas both sexes have circulating levels of androgens and 
estrogens, men have much higher androgen levels, while estrogens dominate in 
premenopausal women. Based on the levels of sex steroid hormones found in men 
and women, it may be suggested that either androgens increase the incidence of MetS 
risk factors, or that estrogens have an ameliorating, protective effect. It appears that 
the effects of androgens and estrogens are sexually dimorphic, as illustrated by the 
following findings:
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Elevating serum estrogen levels in men, as seen in the treatment of male to female 
transsexuals, causes insulin resistance, suggesting that high estrogen levels in men 
are not positive. Interestingly, also in women high estrogens levels are associated with 
insulin resistance, as often seen during pregnancy (14, 15) and women using oral con-
traceptives also show an increase in insulin resistance (16-18). Similarly, treatment 
of males with estrogen led to an increase in the risk of thromboembolisms (19), also 
seen after oral contraceptive use in women (20). Thus, it appears that high estrogen 
levels have a negative effect on metabolic parameters in both sexes. The effects of 
androgens are clearly different between men and women. Testosterone therapy has 
been demonstrated to reduce total body fat and abdominal adiposity in hypogonadal 
young men, obese middle-aged and older men with low baseline testosterone levels 
and also in healthy weight middle-aged men with already normal testosterone levels 
(21). However, in women and especially in women with PCOS, hyperandrogenism is 
associated with obesity and hyperinsulinemia.
The effects of sex steroid hormones on different tissues in both sexes, such as vis-
ceral or peripheral adipocytes are also not identical. Human adipose tissues express 
the androgen and estrogen receptors (22). Estrogen sensitivity as indicated by the 
number of estrogen receptor binding sites is the same for visceral and subcutaneous 
adipose tissue in women, whereas in men subcutaneous adipose tissue appears to be 
more sensitive to estrogens than the visceral adipose tissue (23). In addition, higher 
expression levels of the androgen receptor were detected more often in visceral than 
in subcutaneous pre-adipocytes of both sexes (24). The differences in sensitivity to 
estrogens and androgens in combination with the widely different serum concen-
trations of the steroid hormones between the different sexes may well explain the 
observed differences in body fat distribution. In addition, the relatively high levels of 
estrogens in premenopausal women may explain the lower rates of lipolysis found in 
women, compared to men (25-28). Hence, combining these observations it appears 
that during their reproductive years, women have a healthier metabolic phenotype 
compared to men, which could be explained by the difference in sex steroid hormone 
levels.
However, it is not a specific sex steroid hormone, which has a specific action on 
different tissues, but rather a shift in ratios between androgens to estrogens (29). 
One way of interpreting the different effects of androgens and estrogens in men and 
women is to invoke the ratio between the levels of the two sex steroid hormones. 
Thus, in men a low estrogen over androgen ratio is seen, whereas in women the 
opposite is found. Especially during menopause there is a strong drop in estrogen 
production, whereas the androgen production by the adrenals is less affected, leading 
to a decrease in the estrogen/androgen ratio and subsequently giving rise to the risk 
factors of the MetS in menopausal women, as also seen in women with PCOS.
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Indeed in women with PCOS, who are normo-estrogenic but have elevated 
androgen levels and therefore a decreased estrogen/androgen ratio, metabolic 
pathophysiologies are very common. A large proportion of PCOS women are obese 
(38-88%, depending on the study (30, 31)), with predominantly abdominal adiposity, 
which is considered a risk factor for MetS (32, 33). 50-70% of women with PCOS 
are insulin resistant which may lead to type 2 Diabetes Mellitus (8-10). In addition, 
their leptin levels are elevated, whereas adiponectin levels are low (34). Indeed, in our 
PCOS-like mouse model (further referred to as PCOS model) (Chapter II), leptin 
levels are elevated and adiponectin levels are decreased. Furthermore, these mice 
had increased adiposity and were glucose intolerant. The more male-like estrogen to 
androgen ratios found in PCOS women may also contribute to the male-like pattern 
of adipokine levels in women with PCOS, especially since sex steroid hormones are 
known to have a large influence on leptin production (35).
An altered estrogen to androgen ratio may also be involved in the observed in-
creased blood pressure in women with PCOS (36). Changing this ratio in female 
rats by treating them chronically with DHT or testosterone caused elevated blood 
pressure (37, 38). Although we did not determine blood pressure per se, the PCOS 
model exhibited decreased endothelium dependent vasorelaxation (39). In this study, 
mice were also treated with DHT for a shorter period (60 days) which did not induce 
a metabolic phenotype, but did cause a decrease in vasorelaxation, indicating that 
elevated blood pressure most likely is a direct effect of androgens and not second-
ary to obesity (39). As also often seen in women with PCOS, the PCOS model had 
significantly higher nonesterified fatty acids (NEFA) levels which are associated 
with the risk of cardiovascular disease (40, 41). Treatment with DHT also caused an 
adverse change in the expression of genes related to obesity in visceral adipose tissue. 
Increased mRNA expression of the lipogenic genes aP2 and LPL were found, which is 
in agreement with previous studies that observed altered expression of both genes in 
relation to obesity and MetS (42, 43). In addition, a trend for decreased ATGL mRNA 
expression was observed, consistent with the decrease observed in obese and insulin 
resistant mice (44).
The incidence of MetS increases with age in both men and women. However, 
whereas in men this increase is gradual, in women a sharp increase in the incidence 
of MetS accompanies menopause and therefore most probably is associated with the 
large alterations in the levels of sex steroid hormones seen at the time of menopause. 
In perimenopausal women, basal levels of FSH increase throughout the menstrual 
cycle especially in the early follicular stage as a result of the decreased levels of 
ovarian inhibin B (45), caused by a decrease in the size of the ovarian follicle pool, 
accompanied with a shorter follicular phase, shorter overall menstrual cycle length 
and decreased estrogen levels (46, 47). The remaining estrogens in post-menopausal 
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women are mainly produced by WAT where the enzyme aromatase converts ovarian 
and adrenal androgens to estrogens. However, the increase in aromatization by the 
adipose tissue does not compensate for the decrease in estrogen plasma levels caused 
by the lack of follicular growth seen in postmenopausal women. The stroma of the 
post-menopausal ovary continues to express LH receptors and most of the steroido-
genic enzymes, but lacks aromatase (48). Thus, in post-menopausal women the ovary 
produces little estrogens but continues to produce androgens. Combined with the 
decreased SHBG levels this results in increased free testosterone levels and a com-
pletely changed estrogen-androgen ratio (49, 50). This most probably explains the 
increased incidence of MetS in post-menopausal women (51). Indeed, the increase in 
the rate of hypertension is higher in post-menopausal women compared to men after 
60 years of age (52). Furthermore, the weight gain seen in post-menopausal women 
is associated with an increase in visceral adipose tissue, leading to the development 
of an android pattern.
Also in women with PCOS, the estrogen/androgen ratio changes after the meno-
pause. Since ovarian function normalizes when PCOS women approach menopause, 
the PCOS characteristics, including the increased androgen levels, ameliorate (53, 54). 
However, postmenopausal PCOS women remain to be exposed to higher androgen 
levels, of both adrenal and ovarian stroma origin, than postmenopausal non-PCOS 
women (55). Since PCOS women have already been exposed to increased androgens 
before menopause, a further gain in body weight and increase in blood pressure does 
not occur, in contrast to postmenopausal non-PCOS women (56-58). Thus, at 60 
years or older the differences in body weight and blood pressure between PCOS and 
non-PCOS women have disappeared (56-58).
In conclusion, a large part of the differences in the prevalence of MetS between 
sexes can be explained by a shift in the ratio of estrogens and androgens.
7.3  Metabolism and ovarian function in mouse 
models
To study the relationship between ovarian function and metabolism we have used 
AMHKO and MRKI mice, two mouse models without AMH signaling that show 
a specific ovarian phenotype, i.e., a large increase in the number of growing fol-
licles (chapter IV). We found that this increase in the number of growing follicles 
is associated with a protection against the adverse metabolic changes that occur in 
aging mice. AMHKO and MRKI mice have an improved glucose tolerance, display 
reduced adiposity with WAT depots containing smaller adipocytes and a concomi-
tant reduction in serum leptin and triglyceride levels. A direct effect of the absence 
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of AMH signaling on metabolic tissues can most probably be excluded since, to 
our knowledge, AMH and its type 2 receptor are exclusively expressed in ovaries 
of women and female mice (however, see also section 7.4). In addition, both the 
AMHKO and MRKI models display a similar metabolic phenotype, excluding AMH 
as a direct actor, in view of the absence of the ligand in AMHKO mice. Therefore, the 
observed metabolic phenotype in AMHKO and MRKI mice is probably the result 
of the increased number of growing follicles in the ovary, which leads to an altered 
profile of secreted humoral factors. Reduced insulin signaling has been shown to 
delay metabolic aging and improve longevity (59, 60). Interestingly, aging AMHKO 
mice have decreased insulin and C-peptide levels (Chapter IV), thus the protection 
against metabolic aging in these mice may be secondary to an effect of the ovarian 
factors on insulin signaling, although we cannot rule out that the reduced adiposity 
in AMHKO and MRKI mice drives the reduced insulin levels. Also the results from 
our studies of the PCOS mouse model (Chapter 3) indicate a pivotal role of the ovary, 
since ovariectomy prevented some of the metabolic effects resulting from the DHT 
treatment. The next important question is the identification of these factors and their 
further development into biomarkers and targets for intervention in patients with 
PCOS or with other metabolic disturbances.
Of course, many products are secreted by the ovarian follicles, many of which are 
unknown. Interestingly, members of the TGFβ family, most notably BMP subfamily 
members play essential roles in the function of the ovarian follicles and may very 
well be secreted into the circulation. Moreover, several BMP family members have 
been demonstrated to be involved in the regulation of metabolism. In rat L6 myotube 
cells, BMP9 signaling through Smad5 improves insulin sensitivity by increasing Akt2 
expression, a step-limiting effector involved in insulin-induced GLUT4 translocation 
and glucose uptake (61). BMP2 and BMP4 stimulate the differentiation of mesenchy-
mal stem cells into lipid-storing white adipocytes, although these effects are depen-
dent on the stem cell model and also appear to be affected by the BMP-dosage used 
(62). Interestingly, another BMP family member, BMP7 changes the differentiation 
of these cells into a brown adipocyte direction, resulting in cells that express UPC1 
and can oxidize lipids to produce heat (62). BMP4 and its receptor BMPR1A are 
expressed in pancreatic β cells. When BMPR1A function is attenuated in a transgenic 
mouse model, the mice were found to be glucose-intolerant. Many β cell genes in-
volved in glucose-induced insulin secretion were expressed at lower levels, showing 
that BMPR1A signaling in β cells is critical for glucose homeostasis (63). In addition, 
systemic administration of BMP4 to intact mice improved their glucose tolerance 
(63). These observations suggest a possible involvement of BMPs in the link between 
ovarian function and metabolic state and, therefore, identification of the BMP family 
members involved may be a worthy target for more detailed investigation.
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A less candidate protein-driven approach would be to identify secreted proteins 
by using proteomics to compare follicular fluids from control and PCOS women 
in parallel with a similar comparison in the PCOS mouse model. Although techni-
cally challenging, this approach may be feasible if the right material can be obtained 
(especially the human follicular fluid may be a challenge). Alternatively, whole tran-
scriptome RNA sequencing could be performed. One of the challenges that hampers 
this approach is the heterogeneity of the ovarian follicle population, i.e., at the same 
time follicles of all sizes are present, including healthy and atretic follicles and recent 
and older corpora lutea. Therefore, analysis of carefully microdissected ovarian tissue 
should not be omitted.
Another possibility would be to use mouse models in which follicle development 
is arrested at a specific stage. Female FSHβ knockout mice are infertile due to a block 
in folliculogenesis at the pre-antral secondary stage, rendering ovaries isolated from 
these mice an excellent source of products of follicles at an early stage of growth and 
differentiation (64). A mouse model with an even earlier arrest of follicle growth and 
differentiation are GDF9 null mice (65). Since follicles larger than the primary stage 
with one layer of granulosa cells are not observed, ovaries from these mice will only 
contain products from the earliest growing follicles. Obviously, these models harbor 
the risk of an altered expression pattern of the follicles present due to the absence 
of FSH or GDF9 itself. Nevertheless, these mouse models, including the AMHKO 
mice, could be used to identify the factors present in the altered profile of secreted 
ovarian factors. By comparing the profiles of several mouse models, one may identify 
the most important factors, which could then be validated in studies in which levels 
of these factors are correlated with metabolic parameters. Such studies may include 
cohorts of women with PCOS, but also obese women without cycle disturbances. 
Interestingly, our studies showed that AMHKO mice, despite having an early cessa-
tion of ovarian function, are protected against metabolic aging (Chapter IV). This 
would suggest that exposure to ovarian growth factors early in life has a protective 
effect on the age-related metabolic decline. Several studies have shown that a large 
variation in number of growing follicles, reflected by AMH levels, is present in the 
human general female population of reproductive age (66, 67). The identified factors 
therefore may prove to be markers to identify women of reproductive age at risk for 
MetS after menopause. Furthermore, these factors might be used as drug targets for 
the treatment of MetS.
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7.4  A possible link between the ovary, 
metabolic tissues, and the central 
nervous system?
The classical feedback loop of the hypothalamic-pituitary-gonadal (ovarian) (HPG) 
axis is established by gonadotropins, estradiol and the inhibins A and B. However, it 
is well known that the metabolic status has a major impact on the HPG axis. Both 
under- and overnutrition lead to ovarian dysfunction. The adipokine leptin has 
been identified as a major player integrating metabolic and reproductive function 
(reviewed by (68-70)). Serum leptin levels are positively correlated with fat mass (71). 
Leptin has an anorectic effect via the arcuate nucleus of the hypothalamus, which 
contains NPY/agouti related peptide (AgRP) and POMC neurons. These neurons 
are important in the regulation of appetite, i.e., NPY and AgRP stimulate, whereas 
melanocortins, products of the POMC gene, inhibit appetite. Leptin activates POMC 
neurons and inhibits NPY/AgRP neurons, thereby inhibiting food intake (72). 
Indeed, leptin deficient ob/ob mice are severely obese (73) but strikingly are also 
infertile. Ovarian lipotoxicity leading to advanced follicular atresia contributes to 
this infertility, but importantly, ob/ob mice also are defective in hypothalamic GnRH 
release, resulting in significantly reduced gonadotrophin secretion (74). Pituitary go-
nadotropin secretion is regulated by the pulsatile secretion of hypothalamic GnRH, 
under control of the GnRH pulse generator, which is driving sexual development. 
Before puberty, the GnRH pulse generator is in a quiescent state. At the onset of 
puberty, the GnRH pulse generator is activated leading to enhanced gonadotropin 
secretion (75). Although leptin is not the trigger for puberty, its levels need to reach a 
certain threshold for pubertal development to proceed (76). Humans with congenital 
leptin deficiency show pubertal failure and infertility, while women suffering from 
anorexia nervosa, leading to reduced circulating leptin levels, show a suppression of 
gonadotropin release (77). Thus, leptin is a critical factor stimulating GnRH release.
The effects of increased leptin levels as occurs in obesity on GnRH release have 
been less well studied. Interestingly, although obese subjects have elevated leptin 
levels, food intake is not suppressed (72). The development of hypothalamic leptin 
resistance, similar to insulin resistance, has been suggested as an explanation for this 
contradictory finding (78, 79). Thus, both under- and overnutrition may lead to simi-
lar effects on GnRH release. Since leptin receptors are not present in GnRH neurons 
(80), the effects of leptin on GnRH secretion are indirect. Several studies have nicely 
shown that Kiss1 neurons form the afferent pathway by which leptin mediates its 
effect (81, 82).
Kiss1 neurons in the arcuate nucleus produce kisspeptins, which can directly 
stimulate GnRH neurons to secrete GnRH (83-85). Interestingly, a recent study 
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showed that kisspeptin levels are elevated in both obese and normal weight women 
with PCOS compared to control women (86). Therefore, it would be interesting to 
explore the role of kisspeptin in the connection between metabolism and ovarian 
function in the various mouse models described in this thesis to further dissect the 
relationship between the ovary, metabolic tissues, and the neuroendocrine system.
Although it is evident that the hypothalamic-pituitary axis plays a crucial role 
in the regulation of endocrine glands, recent studies using retrograde viral tracing 
techniques have clearly demonstrated that also pituita a role through neural path-
ways (87-89). For instance, adrenal innervation controls catecholamine release, the 
circadian rhythm of cortisol secretion, and plays a role in the compensatory adrenal 
hypertrophy after unilateral adrenalectomy (90-92). Furthermore, several studies 
have indicated that bidirectional communication between brain and WAT exists 
through the sympathetic nervous system (reviewed by (93, 94)). WAT is innervated 
by sympathetic endings of the autonomic nervous system which stimulate lipolysis, 
leading to the release of glycerol and free fatty acids (reviewed by (93, 95)). Further-
more, WAT innervation also controls adipocyte proliferation since the number of 
adipocytes increased upon surgical denervation of rat WAT (96).
Studies, originally described by Gerendai et al (97), have shown that also the ovary 
is innervated by sympathetic and parasympathetic fibers. The nerves to and from the 
ovary, i.e., the superior ovarian nerve, the ovarian plexus, and the vagus nerve, play 
a role in the regulation of several ovarian functions. Denervation of the ovary in rats 
delayed puberty onset, reduced ovulations, decreased steroid secretion, and resulted 
in acyclicity (98). Similar to the adrenal, innervation of the ovary is asymmetrical 
since the left ovary is denser innervated (89, 99). Interestingly, women with left-sided 
epileptic seizures more frequently develop PCOS, while women with right-sided sei-
zures may develop hypogonadotropic hypogonadism (100). These findings suggest 
that alterations of the sympathetic tone may contribute to ovarian pathologies.
The association of an altered ovarian sympathetic input and development of PCOS 
has been suggested by several studies (101-104). In ovaries of PCOS patients an in-
creased density of catecholaminergic nerves has been reported and nerve growth fac-
tor (NGF) levels are elevated in follicular fluid of PCOS patients (102, 103, 105). NGF 
belongs to the neurotrophin family, which also includes brain-derived neurotrophic 
factor (BDNF) and neurotrophin 3 and 4 (NT3 and NT4) (106). Neurotrophins are 
important for the survival and differentiation of neuronal cells, and indeed recovery 
of ovarian sympathetic innervation after transplantation is driven by increased ex-
pression of NGF in the ovary (107, 108). In the ovary, neurotrophins are expressed by 
oocytes and granulosa cells of growing follicles (109, 110). Analysis of knockout mice 
and in vitro studies demonstrated that, in addition to neuronal control, neurotroph-
ins contribute to the formation of the primordial follicle pool and the regulation 
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of its recruitment (110, 111). Stimulation of neonatal rat ovaries with NT4, and high 
levels of BDNF, enhanced recruitment of primordial follicles (110). NGF has been 
shown to stimulate ovulation (112). However, overexpression of NGF in mice has an 
opposite effect. In transgenic mice in which NGF expression is driven by the 17-hy-
droxylase promoter, allowing selective overexpression of NGF in steroidogenic cells, 
ovaries become hyperinnervated. These mice also display antral follicle accumula-
tion and increased apoptosis. Furthermore, androgen production is increased upon 
PMSG stimulation and LH exposure leads to cyst formation (105). These findings 
suggest that increased sympathetic innervation of the ovary might be involved in 
the development of a polycystic ovarian (PCO) morphology. In agreement, in a rat 
model, in which PCO was induced by a single injection of estradiol valerate, ovaries 
displayed an increased sympathetic tone reflected by increased immunoreactivity 
of tyrosine hydroxylase, increased norepinephrine (NE) production, and increased 
NGF production (113-115). Interestingly, denervation of the ovary, through transec-
tion of the superior ovarian nerve, restores cyclicity in this model (113). Similarly, 
inhibition of NGF action by neutralizing antibodies and antisense oligonucleotides 
against its receptor also restored ovarian function (114), implicating an important 
role for NGF in the development of the phenotype. Whether hyperinnervation 
contributes to both the reproductive and metabolic phenotype in PCOS remains to 
be established. Tracing studies of dual labeled viruses showed that overlap exists in 
the innervations of different organs. For instance, when both the adrenal and the 
ovary were injected, double labeled neurons were detected in brain regions, such as 
the hypothalamic paraventricular nucleus and the lateral hypothalamus, suggestion a 
common nervous regulation of the ovary and the adrenal (116). Given that PCOS has 
often been suggested to be driven by both ovarian and adrenal disturbances, a role 
of hyperinnervation in the etiology of PCOS is tantalizing. Whether overlap exists 
in the nervous regulation of ovarian and adipose tissue remains to be established. 
However, in the DHT-induced rat PCOS model, which displays both the cystic ovar-
ian phenotype and a metabolic phenotype, NGF expression is increased in WAT (117, 
118). Furthermore, exercise and electro-acupuncture, which have a beneficial effect 
on sympathetic innervation, reduce NGF expression in WAT and improve insulin 
sensitivity without affecting obesity (119).
Based on these findings, it would be interesting to investigate the contribution of 
the sympathetic nervous system in our mouse models. We would expect that also 
in our DHT-induced mouse PCOS model ovarian and adipose tissue innervation is 
increased. Although we suggest that ovarian growth factors directly modulate meta-
bolic function, we cannot rule out that these effects are in part mediated through the 
nervous system. Given that ovariectomy not only results in loss of ovarian growth 
factors but also in ablation of the nervous communication between the ovaries and 
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the brain, we cannot rule out an effect of an improved sympathetic tone of metabolic 
tissues in the partial improvement of the metabolic phenotype in DHT-treated mice 
upon OVX. In an elegant study by Lazzarini et al (120), in which the retroperitoneal 
white adipose tissue was unilaterally denervated in OVX mice, it was shown that 
intact fat pads lost more weight than the denervated fat pads upon subcutaneous es-
trogen replacement. These results demonstrate that the sympathetic nervous system 
plays a role in the protective effects of estrogens on adiposity. A similar link may exist 
between the sympathetic nervous system and ovarian growth factors. Therefore, it 
would be interesting to study the expression of neurotrophins and immunoreactivity 
in ovaries and adipose tissues of our mouse models.
7.5 Conclusion and final remarks
In this thesis we have used several perspectives to investigate the relationship be-
tween ovarian function and metabolism in women. The known association of several 
characteristics of the MetS with PCOS prompted us to develop a mouse PCOS model 
enabling the study of metabolic features of the model in mice that would allow experi-
mental interventions in the future. The model, DHT treatment, indeed shows many 
adverse metabolic changes that can be partially ameliorated by removing the ovaries 
from the DHT-treated animals; thus showing that the ovary is directly involved in 
the physiological regulation of lipid and glucose metabolism. Similarly, manipulating 
the follicular makeup of the ovaries by introducing null alleles of AMH (AMHKO) 
and its AMH type 2 receptor (AMHR2) (MRKI) again elegantly shows that changes 
in ovarian function have direct effects on the metabolic phenotype. Finally, returning 
to the PCOS patients we could show that the levels of the ovarian-specific hormone 
AMH are inversely associated with the severity of MetS, although this association is 
largely driven by BMI.
Overall the observations as outlined in this thesis clearly show an important role 
of the ovary in the regulation of metabolic homeostasis in women. Our results war-
rant the identification of the mechanisms by which this relationship is established 
and such studies should include a more thorough investigation of the involvement 
of the CNS in addition to the identification of ovarian secreted factors. The results 
of such studies will identify targets amenable to pharmacological intervention in 
women with severe aberrations of their metabolic state.
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Obesity, insulin resistance and hypertension are risk factors which are part of the 
metabolic syndrome (MetS). Unfortunately, these risk factors comprise a major 
health problem of epidemic proportions. During the reproductive years, the inci-
dence of the MetS is higher in the male population compared to women. However 
after menopause, the incidence of the MetS is significantly increased in women. In 
women with the polycystic ovary syndrome (PCOS), metabolic disturbances are very 
common. PCOS is the most common endocrine disorder in women in their repro-
ductive age, with a prevalence of up to 15% in the general population. The clinical 
expression includes oligo- or anovulation, hyperandrogenism and the presence of 
polycystic ovaries.
In Chapter I, the general introduction, the background of the reproductive and 
the metabolic phenotype observed in women with PCOS is provided. In addition, the 
currently used androgen-induced and transgenic mouse models for PCOS are de-
scribed. Furthermore, the role of the transforming growth factor β family members, 
particularly anti-Müllerian hormone (AMH), in the development of follicles in the 
ovary (folliculogenesis) and in PCOS is discussed. Finally, the aim and scope of this 
thesis are introduced: to study the role of ovarian growth factors in the regulation of 
metabolism.
To learn more about the etiology of PCOS, the use of animal models is inevitable. 
Chapter II describes the development of a mouse model of PCOS. By treating prepu-
bertal female mice for 90 days with a continuous release pellet containing dihydrotes-
tosterone (DHT), we developed a mouse model that displays both the reproductive 
and the metabolic phenotype as observed in women with PCOS. DHT-treated mice 
were acyclic and had an increased number of atretic follicles which had a cyst-like 
structure. Furthermore, these mice were glucose intolerant and showed an increase 
in adiposity. This model allows us to understand more of the factors involved in the 
pathophysiology of PCOS.
In Chapter III we investigated whether, besides androgens, also other factors 
secreted by the ovary contribute to the metabolic dysregulation in PCOS. We showed 
that removal of the ovaries of our DHT-induced PCOS mice normalized the glucose 
tolerance and reduced lipid accumulation in brown adipose tissue (BAT). This in-
dicates that indeed, in addition to androgens, ovarian factors may contribute to the 
metabolic phenotype of PCOS.
Next we investigated the relationship between ovarian function and metabolism 
in a mouse model with an increased number of growing follicles. In Chapter IV we 
studied the metabolic phenotype of mice lacking AMH signaling. AMH is secreted by 
small growing follicles in the ovary and inhibits the recruitment of follicles from the 
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primordial follicle pool. Therefore, female mice deficient in AMH signaling display 
an enhanced recruitment of primordial follicles resulting in an increased number 
of growing follicles and therefore an increase in ovarian growth factors. Interest-
ingly, we showed that with increasing age female mice with an increase in number of 
growing follicles had a better metabolic phenotype compared to wild type mice, such 
as reduced adiposity, improved glucose tolerance and increased browning of white 
adipose depots. This indicates that an increased number of growing follicles, and 
therefore altered profile in secreted ovarian growth factors, affects metabolic aging.
Bone Morphogenetic Proteins (BMPs), members of the TGFβ family, are crucial 
for follicular development and also play an important role in metabolism. Therefore, 
BMPs are promising candidates to study in women with PCOS and their serum levels 
might be used as a possible diagnostic tool, which we investigated in Chapter V. 
Twenty PCOS patients with a normal or elevated BMI and normal or elevated free 
androgen index levels were randomly selected, providing a heterogeneous patient 
group. Unfortunately, BMP2, 4, 6, and 7 levels were undetectable in almost all pa-
tients. Since it is known that BMPs are secreted by the human ovary, we concluded 
that the currently available BMP ELISAs are not sensitive enough to detect BMPs in 
the circulation.
In Chapter VI we investigated the association of serum AMH levels with risk fac-
tors of the MetS in women with PCOS. Serum AMH levels are increased in women 
with PCOS, however conflicting results regarding the relationship between AMH 
levels and metabolic risk factors have been reported. We found that PCOS women 
with MetS had lower AMH levels than those without MetS. In addition, lower AMH 
levels are associated with an increased number of metabolic risk factors in women 
with PCOS. However, serum AMH was not an independent predictor for the pres-
ence of MetS. Interestingly, the negative association between serum AMH and MetS 
risk factors was largely driven by BMI. This may indicate that obesity affects AMH 
production and therefore AMH levels should be interpreted with caution in over-
weight and obese PCOS women.
In the general discussion, Chapter VII, the role of sex steroid hormones in the 
development of the MetS in men, women and women with PCOS throughout their 
adult years is discussed. In addition, the effect of an altered ovarian function, as ob-
served in our and other mouse models, on metabolism is evaluated and suggestions 
for further research are made. Finally, a potential role of the central nervous system 
linking ovarian and metabolic function is proposed.
Samenvatting
Overgewicht, insulineresistentie en hoge bloeddruk zijn belangrijke risicofactoren 
van het metabool syndroom (MetS). Helaas vormen deze risicofactoren een gezond-
heidsprobleem van epidemische omvang. Tijdens de vruchtbare jaren is de incidentie 
van MetS hoger in mannen dan in vrouwen. Maar na de menopauze neemt de in-
cidentie van MetS significant toe bij vrouwen. Metabole verstoringen komen vaak 
voor bij vrouwen met het polycysteus ovarium syndroom (PCOS). PCOS is de meest 
voorkomende hormonale ziekte bij vrouwen in de vruchtbare levensfase, met een 
prevalentie in de algemene bevolking oplopend tot 15%. De ziekte wordt gekenmerkt 
door oligo- of anovulatie, hyperandrogenisme en de aanwezigheid van polycysteuze 
ovaria.
In Hoofdstuk I, de algemene inleiding, wordt de achtergrond van het reproduc-
tieve en metabole fenotype van vrouwen met PCOS besproken. Daarnaast worden 
ook de huidige androgeen geïnduceerde en transgene muismodellen voor PCOS 
beschreven. Ook de rol van transforming growth factor β familieleden, vooral het 
anti-Müllers hormoon (AMH), in de regulatie van follikelgroei in het ovarium (fol-
liculogenese) en in PCOS wordt bediscussieerd. Het doel van dit proefschrift was het 
bestuderen van de rol van ovariële groeifactoren in de regulatie van de stofwisseling.
Om meer inzicht te krijgen in de oorzaak van PCOS is het gebruik van diermodel-
len onvermijdelijk. Hoofdstuk II beschrijft de ontwikkeling van een muismodel voor 
PCOS. Door prepuberale vrouwelijke muizen te behandelen met een pellet dat 90 
dagen lang dihydrotestosteron (DHT) afgeeft, hebben we een muismodel ontwikkeld 
dat zowel het reproductieve als het metabole fenotype laat zien dat ook voorkomt 
bij vrouwen met PCOS. DHT behandelde muizen waren acyclisch en hadden een 
toename van atretische follikels met een cyste-achtige structuur. Daarnaast waren 
deze muizen glucose-intolerant en hadden zij meer vet (obesitas). Dit model geeft 
ons inzicht in de factoren die een rol kunnen spelen in de pathofysiologie van PCOS.
In Hoofdstuk III wordt onderzocht of er naast androgenen ook andere factoren 
door het ovarium worden uitgescheiden die bijdragen aan de metabole verande-
ringen in PCOS. Het verwijderen van de ovaria in ons DHT geïnduceerde PCOS 
muismodel leidde tot een genormaliseerde glucosetolerantie en een afname van de 
ophoping van vetdruppels in bruin vetweefsel. Dit houdt in dat, naast androgenen, 
ovariële factoren inderdaad bijdragen aan het metabole fenotype van PCOS.
Vervolgens hebben wij de relatie tussen de ovariële functie en metabolisme 
onderzocht in een muismodel met een toename in het aantal groeiende follikels. 
Hoofdstuk IV beschrijft het metabole fenotype van vrouwelijke muizen waar AMH 
werking ontbreekt. AMH wordt uitgescheiden door de kleine groeiende follikels in 
het ovarium en het remt de rekrutering van follikels uit de primordiale follikel voor-
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raad. Daardoor hebben muizen zonder AMH werking een toename in de rekrutering 
van primordiale follikels, wat leidt tot meer groeiende follikels en daarom tot een toe-
name in ovariële groeifactoren. Opmerkelijk was dat met veroudering deze muizen 
met meer groeiende follikels een betere stofwisseling hadden dan wild type muizen, 
namelijk een afname in vetzucht, een verbeterde glucosetolerantie en een toename in 
de “bruining” van de witte vetweefsels. Dit suggereert dat een toename van het aantal 
groeiende follikels en daarmee samengaand een veranderd profiel van uitgescheiden 
ovariële groeifactoren een effect heeft op metabole veroudering.
De bot-morfogenetische proteïnen (BMPs) zijn leden van de TGFβ familie. Zij 
zijn cruciaal voor de ontwikkeling van follikels en spelen ook een belangrijke rol 
in de stofwisseling. Daarom zijn BMPs veelbelovende kandidaten om te bestuderen 
in vrouwen met PCOS en kunnen hun serumspiegels mogelijk gebruikt worden als 
een diagnostisch hulpmiddel. Dit hebben wij onderzocht in Hoofdstuk V. Twintig 
PCOS patiënten met een normale of verhoogde BMI en normale of verhoogde vrije 
androgeenspiegels werden willekeurig geselecteerd, wat leidde tot een heterogene 
studiegroep. Helaas waren BMP2, -4, -6 en -7 spiegels niet meetbaar in bijna alle 
patiënten. Aangezien het bekend is dat BMPs uitgescheiden worden door het ova-
rium, concludeerden wij dat de huidige bepalingsmethoden voor BMPs niet gevoelig 
genoeg waren om BMPs in de circulatie te meten.
In Hoofdstuk VI hebben wij de associatie van serum AMH spiegels met risico-
factoren van MetS bij vrouwen met PCOS onderzocht. Serum AMH spiegels zijn 
verhoogd bij vrouwen met PCOS, maar tegenstrijdige resultaten zijn gemeld over de 
verhouding tussen AMH spiegels en metabole risicofactoren. In onze studie bleek dat 
PCOS vrouwen met MetS lagere AMH spiegels hadden dan PCOS vrouwen zonder 
MetS. Daarnaast waren lagere AMH spiegels geassocieerd met een toename in het 
aantal metabole risicofactoren bij vrouwen met PCOS. De AMH spiegels waren 
echter geen onafhankelijke voorspeller voor de aanwezigheid van MetS. Opmerkelijk 
was dat de negatieve associatie tussen serum AMH spiegels en de risicofactoren voor 
MetS grotendeels gedreven werd door de BMI. Dit kan betekenen dat obesitas een 
effect heeft op de AMH productie. Daarom dient men voorzichtig te zijn met de 
interpretatie van AMH spiegels bij PCOS vrouwen met overgewicht en obesitas.
In de algemene discussie, Hoofdstuk VII, wordt de rol van de geslachtshormonen 
in de ontwikkeling van MetS bij mannen en vrouwen met en zonder PCOS bediscus-
sieerd. Daarnaast wordt het effect van een veranderde ovariële functie, zoals gezien in 
onze maar ook in andere muismodellen, op de stofwisseling geëvalueerd en worden 
er suggesties voor toekomstig onderzoek gedaan. Ten slotte wordt een mogelijke rol 
van het centrale zenuwstelsel als schakel tussen ovariële en metabole functie voorge-
steld.
Dankwoord
En dan nu waarschijnlijk het meest populaire deel van dit proefschrift. Mijn 
dankwoord.
In de afgelopen 5 jaar hebben veel mensen mij met raad en daad terzijde gestaan en 
een steentje of meer bijgedragen aan de totstandkoming van dit proefschrift. Zonder 
die ondersteuning zou dit proefschrift niet tot stand zijn gekomen. Ik waardeer hun 
bijdragen zeer.
In het bijzonder en met name gaat mijn dank uit naar mijn co-promotor Dr. Ir. J.A 
Visser, beste Jenny. Jij verdient je eigen hoofdstuk. Je hebt mij uitstekend begeleid. 
Jouw adviezen en raadgevingen verstrekte je zowel binnen het EMC met een kop 
koffie als daar buiten met een goed glas wijn. Zie hier het resultaat. Je enthousiasme 
bij bijzondere onverwachte resultaten die zich tijdens het onderzoek manifesteerden 
was altijd aanstekelijk en motiverend. Uiteraard zat het soms ook tegen, maar dan 
was je de eerste om even “rond de tafel” te gaan zitten om samen te brainstormen. Ik 
wil je bedanken voor je geduld en daarnaast je vertrouwen in mij. Ik kwam binnen na 
een afstudeeronderzoek en jij wilde dit pad met mij bewandelen.
Uiteraard Prof. Dr. Ir. A.P.N Themmen, beste Axel. Ik wil jou bedanken voor je kriti-
sche vragen en je heldere kijk vanuit verschillende invalshoeken. Jij dwong mij tijdens 
besprekingen om weer even terug te gaan naar het begin, afstand te nemen van die 
ene grafiek waar het resultaat toch echt significant was en weer een logische opbouw 
te creëren. Ondanks dat het onderwijs, junior medschool en decentrale selectie veel 
van je aandacht op eisen, kon ik altijd bij je binnenlopen. Vooral in de afrondende 
fase van dit proefschrift heb je me erg geholpen.
Prof. Dr. J.S.E. Laven, beste Joop. Soms loopt het net even heel anders. Tijdens mijn 
promotietraject ontstond er twijfel bij mij over de richting die ik op zou gaan binnen 
de geneeskunde. Bij ons eerste gesprek in Florence pikte jij die aarzeling feilloos op. 
Ik ben je dankbaar voor de met mij gedeelde inzichten en de keuze die ik op grond 
daarvan heb kunnen maken. Ook al ben ik misschien je adoptie promovendus en 
hebben wij tijdens mijn traject voornamelijk aan het einde daarvan intensief samen-
gewerkt, het resultaat en het onderzoeksbelang is er niet minder om.
Ook wil ik graag de leden van mijn leescommissie bedanken. Dr. Maassen van den 
Brink, beste Antoinette. Door jou kwam er een extra dimensie in mijn onderzoek: 
de vasculaire kant. Dit heeft mijn inzicht verbreed met een mooie paper als resultaat. 
185
186 Dankwoord
Bedankt voor de prettige samenwerking. Dr. E. Stener-Victorin, dear Elisabet. Thank 
you for the meetings during conferences where we could talk about our animal 
models. Your research has had a big influence on mine and could be used to perfect 
our PCOS mouse model. Thank you for our pleasant collaboration. Prof. Dr. F.H. de 
Jong, beste Frank. Bedankt voor je input tijdens de labbabbels en je kritische vragen. 
Jij dwong me dieper op de stof in te gaan en leerde mij ook kritische vragen te beant-
woorden, ook jou wil ik bedanken voor de prettige samenwerking.
Uiteraard de leden van de grote commissie: Prof. Dr. E.A.P. Steegers, Dr. E.F.C. van 
Rossum, Prof. Dr. A. Kalsbeek en Prof. Dr. B.C.J.M Fauser, bedankt voor het plaats-
nemen in mijn commissie.
Mijn collega’s op het lab! Piet, wat hebben we gelachen met die gekke muizen, het 
heeft mij zelfs mijn laatste stelling opgeleverd, het is wat het is… Die beesten deden 
nooit wat ze moesten doen. Ik wil je bedanken voor je keiharde inzet als we weer 
eens op zaterdagochtend muizen moesten implanteren, als we 7 dagen achter elkaar 
uitstrijkjes moesten afnemen of op vaste dagen moesten wegen wat dan ook altijd 
in het weekeinde bleek te vallen. Daarnaast de eindeloze coupes die jij hebt gesne-
den, de immuno’s en alle tellingen, ik vind het geweldig dat jij mijn paranimf bent. 
Martin: “I’ve got a feeling, oehoe….” Stiekem zat jij natuurlijk helemaal niet in onze 
onderzoeksgroep, maar wat heb je me geholpen zeg! Jij was er altijd als luisterend 
oor als ik even moest spuien en als mijn wiskunde knobbel me in de steek liet, kon 
ik altijd bij jou terecht. Naast het lab hebben we een goede vriendschap opgebouwd 
en daarom vind ik het extra leuk dat jij mijn paranimf bent. Anke, jij hebt mij van 
a tot z alles op het lab geleerd. Ik wil je bedanken voor de eindeloze assays die we 
samen gepipeteerd hebben en dat dat ook nog eens gezellig was. Bas, bedankt voor je 
precisie in het snijden van de coupes. Dank ook voor je altijd welgemeende interesse 
in de ontwikkeling van het onderzoek. Coby, bedankt voor je gezelligheid op het lab 
en je hulp bij het maken van primers. Patrick, lekker in het Nederlands: bedankt voor 
je tips bij de besprekingen en je droge humor. Aldo, bedankt voor je inzicht in onze 
muis experimenten en de gezellige sfeer die jij bij ons op de kamer bracht. Anneke, 
volgens mij zagen wij elkaar vaker in het weekend op het lab dan doordeweeks, ik wil 
jou bedanken voor de gezelligheid en jouw hulp bij onze EYES avonturen, zonder jou 
was er nooit een eerste EYES meeting in Rotterdam geweest! Jeffrey, in mijn laatste 
jaar kwam jij als master student binnen en heb je veel werk verricht voor onze aging 
studie. Het resultaat daarvan is ook terug te vinden in dit proefschrift. Hartstikke 
bedankt voor je harde werk en de leuke sfeer die jij bracht. Ik wens je veel succes in 
je verdere carrière en hoop in de toekomst weer je collega te mogen zijn. Chen, de 
vrolijkste student die ik ken, ook jou wens ik veel succes in de toekomst. Marlies, ook 
Dankwoord 187
al ben je al een tijd weg van het lab, je hoort er nog wel bij. Bedankt voor al je hulp 
met SPSS in onze klinische studie. Ik heb veel van je geleerd.
Van de afdeling gynaecologie, Yvonne. Bedankt voor al je hulp met de patiënten 
gegevens. Zonder jou hadden onze twee studies nooit tot stand kunnen komen. We 
zullen elkaar vast nog wel tegenkomen in de toekomst.
Natuurlijk de vijfde verdieping, helaas te groot om iedereen met name te noemen. 
Iris en Anke van Kerkwijk, ook al zijn jullie overgelopen naar een ander lab en zijn 
wij maar kort collega’s geweest het was altijd super gezellig. Simone, je hebt me wer-
kelijk naar het spinnen toe gesleept maar ik heb ervan genoten. Het gaf ons de tijd 
om lekker bij te kletsen. Demmers en Mirjam “de kleine” bedankt voor de lekkere 
biertjes na het werk.
Mijn collega’s van het Ikazia ziekenhuis, bedankt voor het warme onthaal van de 
“labrat”. Jullie hebben mij weer wegwijs gemaakt in de kliniek.
Lieve Em, mijn paarse poppetje. Je bent een topvriendin en de eerste die met een kop 
koffie klaar stond in de koffiebar als het tegenzat. Je hebt me er doorheen gesleept bij 
de diepte punten en met me gejuicht bij de hoogtepunten.
Mijn lieve jaarclub, bedankt voor alle ontlading na het werk, de hilarische grappen 
over mijn muizen en alle gezellige borrelmomenten. Lieve Mar, jij in het bijzonder. 
Bedankt voor je niet aflatende belangstelling voor de ontwikkelingen in mijn onder-
zoek. Altijd de eerste die vroeg hoe het was gegaan. Al onze filmavonden! Je bent een 
grote steun voor me geweest.
Al mijn andere vriendinnetjes: lieve Lou, ondanks dat jij helemaal in Spanje zit stond 
jij ook altijd voor me klaar. Lieve Cat, een top oud huisgenoot en vriendin. Loes, 
Cyn, Yvon en Jean, mijn oude studiegroepje maar nog steeds goede vriendinnen. 
Lieve Bianc, bedankt voor de jarenlange vriendschap. Naast mijn vriendinnetjes, ook 
Marnix: bedankt voor alle gezellige etentjes en interesse.
Dan wil ik graag eindigen met mijn familie. Mijn fantastische ouders: lieve papa, 
jij bent de stem in mijn achterhoofd, de wilskracht om door te zetten en de reden 
waarom ik het al zover geschopt heb. Lieve mama, jij kreeg alles op je bordje, goede 
dagen maar ook slechte dagen. Je hebt altijd voor me klaargestaan, de eindeloze tele-
foon gesprekken en je altijd positieve instelling, jullie zijn geweldig. Mijn allerliefste 
broertje, bedankt voor al je steun en altijd opbeurende telefoontjes. Lieve Sigrid, 
188 Dankwoord
bedankt voor alle gezelligheid tijdens het sporten! Mijn lieve schoonmama en schoo-
nopa, bedankt voor alle Brabantse gezelligheid! Het voelt altijd als thuiskomen.
Lieve Roy, mijn alles. Geen woorden kunnen beschrijven wat je voor mij betekent, 
ik hou van je.
Rotterdam, september 2014
Curriculum Vitae
Leonie van Houten werd op 15 juni 1982 geboren in Leiden. Zij volgde het gymnasium 
aan het Comenius College te Capelle aan den IJssel, alwaar zij in 2001 haar diploma 
haalde. In 2001 volgde zij de studie Kunstgeschiedenis aan de Rijksuniversiteit in 
Utrecht. In 2002 werd zij decentraal toegelaten voor de studie geneeskunde aan de 
Erasmus Universiteit in Rotterdam. In 2005 volgde zij een 8-weekse keuze stage op 
de afdeling chirurgie in het Horatio E. Oduber ziekenhuis op Aruba. In 2008 startte 
Leonie met haar afstudeeronderzoek, onder begeleiding van Dr. A. Umar en Prof. Dr. 
P.M.J.J. Berns, waarbij ze 6 maanden onderzoek deed op het oncologisch laboratorium 
van de afdeling Interne Oncologie, Erasmus MC, Rotterdam. Dit resulteerde in het 
verslag “Kinase activity profiling in breast cancer” en het behalen van haar doctoraal 
Geneeskunde. In 2009 haalde ze haar arts-diploma en startte Leonie vervolgens met 
haar promotie onderzoek op de afdeling Endocrinologie, Inwendige Geneeskunde, 
Erasmus MC, onder supervisie van Dr. Ir. J.A. Visser, Prof. Dr. Ir. A.P.N. Themmen en 
Prof. Dr. J.S.E. Laven, waarvan het onderzoek beschreven in dit boek het resultaat is. 
Gedurende haar promotietraject was zij ambassadeur van Nederland voor de YARE 
(Young Active Researchers in Endocrinology), commissie lid van de EYES (Euro-
pean Young Endocrine Scientists), was zij bestuurslid van de redactie van ESE news 
(European Society of Endocrinology) en commissie lid van de Wetenschapsdagen. 
Daarnaast heeft zij deelgenomen aan de organisatie van de eerste EYES meeting in 
Rotterdam. In juni 2013 startte zij als arts-assistent gynaecologie en obstetrie in het 




Name PhD student: Leonie van Houten
Erasmus MC Department: Internal Medicine
Research School: Molecular Medicine
PhD period: april 2009 – May 2013
Promotor: Prof. Dr. Ir. A.P.N. Themmen, Prof. Dr. J.S.E. Laven





Omgaan met groepen, Desiderius School, Workshop Tutoren Erasmus 2009 1
Cursus Proefdierkunde (Artikel 9) 2009 2
Course Biomedical Research Techniques 2009 1
Cursus Management voor Promovendi en Postdocs, NIBI, Utrecht 2010 2
Research Management for PhD students & Postdocs 2010 1
Statistiek cursus Classical Methods for Data Analysis, Netherlands Institute for 
Health Sciences (NIHES)
2010 2
Course on Basic and Translational Endocrinology 2011 1
English Biomedical Writing and Communication 2011 2
Endocrine Trainee Day, Boston, Verenigde Staten 2011 1
Endocrine Trainee Day, Houston, Verenigde Staten 2011 1
Oral presentations
Wetenschapsdagen Inwendige Geneeskunde, Antwerpen, België – Development 
of a PCOS-like mouse model
2011 1
13th European Congress of Endocrinology, Rotterdam, Nederland – 
Development of a PCOS-like mouse model
2011 2
Endo Retreat, Parijs, Frankrijk – Metabolic function in a mouse model for PCOS 2011 2
13th Annual YARE meeting, Stockholm, Zweden – Development of a PCOS-like 
mouse model
2011 1
Dutch Endocrine Meeting, Noordwijkerhout, Nederland – DHT treatment in 
mice induces a persistent PCOS phenotype
2012 1
14th European Congress of Endocrinology, Florence, Italië – DHT treatment in 
mice induces a persistent PCOS phenotype
2012 2
94th Annual Meeting of the Endocrine society, Houston, Verenigde Staten – 
Mice lacking Anti-Müllerian hormone are protected against increased adiposity 
and glucose intolerance with increasing age
2012 2
14th Annual YARE meeting, Dresden, Duitsland – Mice lacking Anti-Müllerian 





Wetenschapsdagen Inwendige geneeskunde, Antwerpen, België – Mice 
lacking anti-Müllerian hormone are protected against the age-related decline in 
metabolism
2013 1
Molmed dag, Rotterdam, Nederland – Mice lacking anti-Müllerian hormone are 
protected against the age-related decline in metabolism
2013 1
Poster Presentations
Summer School on Endocrinology, Bregenz, Oostenrijk – Development of a 
mouse PCOS model
2009 1
Molmed dag, Rotterdam, Nederland – Development of a mouse PCOS model 2011 1
13th European Congress of Endocrinology, Rotterdam, Nederland – 
Development of a mouse PCOS model
2011 1
93th Annual Meeting of the Endocrine Society, Boston, Verenigde Staten – 
Development of a mouse PCOS model
2011 1
Wetenschapsdagen, Inwendige Geneeskunde, Antwerpen, België – DHT 
treatment in mice induces a persistent PCOS phenotype
2012 1
Molmed Dag, Rotterdam, Nederland DHT treatment in mice induces a persistent 
PCOS phenotype
2012 1
94th Annual Meeting of the Endocrine society, Houston, Verenigde Staten – 
DHT treatment in mice induces a persistent PCOS phenotype
2012 1
Other (inter)national conferences
Endo Retreat, Rotterdam 2009 2
Novel Insights in Adipose Cell Functions, Fondation Ipsen colloquium, Parijs 2009 2
Nederlandse Endocrinologie Dagen, Noordwijkerhout 2010 2
Wetenschapsdagen Inwendige Geneeskunde, Antwerpen, België 2010 1
Rotterdamse Internistendag, Rotterdam, Nederland 2010 1
Nederlandse Endocrinologie Dagen, Noordwijkerhout, Nederland 2010 1
Supervising practical and excursion, tutoring
Tutoring first year medical students 2009-2011 2
Endocrinology practical lectures for medical students 2010-2011 2
Supervising Master’s Theses
Mirjam ’t Mannetje, Medical student 2010-2011 2
Rianne Rodenburg, Medical student 2011 2
Christian von Kriegenbergh, Medical student 2012 2
Awards
Women in endocrinology young investigator award, Boston, USA 2011
Goodlife Healthcare travel award of the Dutch Endocrine Society of 
Endocrinology, Rotterdam, the Netherlands
2011
Endocrine Society Outstanding abstract award, Houston, USA 2012
Endrocrine Society Trainee Day travel award, Houston, USA 2012
PhD portfolio 193
Science Meeting Grant of the European Society of Endocrinology, Florence, Italy 2012





van Houten EL, Themmen AP, Visser JA. Anti-Müllerian hormone (AMH): regula-
tor and marker of ovarian function. Annales d’Endocrinologie 3:191-7, 2010
van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Repro-
ductive and metabolic phenotype of a mouse model of PCOS. Endocrinology153(6): 
2861-9, 2012
van Houten EL, Laven JS, Louwers YV, McLuskey A, Themmen AP, Visser JA. Bone 
morphogenetic proteins and the polycystic ovary syndrome. Journal of ovarian 
research 6: 32, 2013
Labruijere S, van Houten EL, de Vries R, Musterd-Bagghoe UM, Garrelds IM, 
Kramer P, Danser AH, Villalón CM, Visser JA, Van Den Brink AM. Analysis of 
the vascular responses in a murine model of polycystic ovary syndrome. Journal of 
Endocrinology 218: 205-213, 2013
Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van 
Houten EL, Visser JA, Morgan SA, Lavery GG, Oprescu A, Hübscher SG, Newsome 
PN, Tomlinson JW. Loss of 5α-reductase type 1 accelerates the development of hepatic 
steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology 
154(12): 4536-47, 2013
van Houten EL, Visser JA. Mouse models to study polycystic ovary syndrome: a 
possible link between metabolism and ovarian function? Reproductive Biology 14: 
32-43, 2014
Grefhorst A, van den Beukel JC, van Houten EL, Steenbergen J, Visser JA, Themmen 
APN. Estrogens regulate expression of bone morphogenetic protein 8b in brown 
adipose tissue. Journal of Endocrinology, accepted
van Houten EL, Kevenaar ME, Louwers YV, van Dorp W, Themmen APN, Laven 
JSE, Visser JA. Anti-Müllerian hormone serum levels are negatively associated with 
risk factors of the metabolic syndrome in women with polycystic ovary syndrome, 
submitted for publication
195
196 List of publications
van Houten EL, Kramer P, McLuskey A, Karels B, Themmen APN, Visser JA. Ovar-
ian growth factors contribute to the metabolic dysregulation in a mouse model of 
Polycystic Ovary Syndrome, To be submitted
van Houten EL, Hoek J, Kramer P, McLuskey A, Karels B, Themmen APN, Visser 
JA. Improved metabolic phenotype with increasing age in female mice lacking anti-
Müllerian hormone signaling, To be submitted
